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Abstract 
The RET receptor tyrosine kinase plays a major role in embryonic and adult vertebrate 
development. Deregulation of RET signalling leads directly to multiple human diseases. 
Like many receptor tyrosine kinases, the intracellular tyrosine kinase domain of RET is 
activated by binding of ligand/co-receptor to its ectodomain (ECD). RET is unique 
among receptor tyrosine kinases, possessing cadherin-like domains (CLD1–4) within its 
ECD. This thesis describes the architecture of the RET-ECD elucidated using small-
angle X-ray scattering (SAXS). These data reveal the interdomain angles and non-
linearity of the four CLDs, as well as the location of the membrane-proximal cysteine 
rich domain (CRD) packed against CLD4. I use this SAXS-derived model of the RET-
ECD together with published crystal structures of a RET ligand and co-receptor, to fit 
into a negative stain electron microscopy 3D reconstruction of a mammalian ligand/co-
receptor/RET-ECD ternary complex. The resulting preliminary pseudo-atomic model 
contains a two-fold symmetrical RET ternary complex with two RET-ECDs wrapped 
around a core ligand/co-receptor, making extensive contacts from both the N-terminal 
CLD1–3 region and the membrane-proximal CRD consistent with previous biochemical 
data and our antibody-epitope mapping. This thesis describes the first view of the RET-
ECD and the ligand/co-receptor/RET ternary complex architecture, with important 
implications for Hirschsprung’s disease and for understanding how ligand-independent 
RET activation occurs in type 2 multiple endocrine neoplasias. 
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Chapter 1. Introduction to the RET receptor tyrosine 
kinase 
1.1 Receptor tyrosine kinases structure and function 
Receptor tyrosine kinases (RTKs) are cell surface receptors for many soluble and 
membrane-anchored polypeptide growth factors and cytokines (Gschwind et al., 2004). 
RTKs couple extracellular signals to intracellular signalling pathways. They allow cells 
to respond to changes in their environment and to form complex tissues and make cell-
to-cell contacts. RTKs activate intracellular signalling pathways that control cellular 
processes such as proliferation, differentiation and apoptosis. They also have a critical 
role in the development and progression of many types of cancer (Lemmon and 
Schlessinger, 2010). RTKs have evolved with multi-cellular organisms. The 
intracellular signalling pathways they link to are found in unicellular organisms such as 
yeast, but the RTKs only appear in evolution from the invertebrate lineages (Manning et 
al., 2002a). 
There are 58 known RTKs in the human genome, which fall into 20 subfamilies. Well 
known examples include the epidermal growth factor receptor (EGFR) and the insulin 
receptor. The majority of RTKs are single pass transmembrane receptors and have a 
common overall architecture, consisting of a highly variable ligand-binding ectodomain 
(ECD), a transmembrane domain (TM), and an intracellular domain (ICD) containing a 
highly conserved tyrosine kinase that is frequently flanked by the more divergent 
juxtamembrane domain (JM) and C-terminal tail (C-tail) (Lemmon and Schlessinger, 
2010).  
RTK-ECDs are diverse in both structure and sequence, but are enriched for globular 
protein interaction modules such as immunoglobulin C2-like domains and fibronectin 
type III domains (Lemmon and Schlessinger, 2010). These domains can be organised 
repetitively or in different combinations to generate ligand-binding sites for their 
cognate ligands (examples of the diverse RTK ECD architecture are shown in Figure 
1.1). How RTK-ECDs couple with and stimulate the catalytic activity of associated 
intracellular tyrosine kinase function is a crucial question and likely to be distinct for 
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each type of RTK as the ligands are quite unrelated in many cases. Commonalities for 
RTK activation and auto-inhibition are however expected and are indeed observed. For 
example: control of RTK oligomeric state, allosteric activation and the removal of auto-
inhibitory elements in response to ligand-binding (Hubbard and Miller, 2007).  
The ICDs of RTKS are more structurally similar, possessing tyrosine kinase domains 
(KDs), which share their overall fold with all tyrosine and serine/threonine kinases 
(Cowan-Jacob, 2006). The KDs are flanked by a JM and C-tail, which are commonly 
flexible and are important for kinase regulation and downstream signalling. 
RTKs respond to their cognate ligands by activation of their intracellular kinase activity, 
which is commonly associated with dimerisation of the receptor (Hubbard and Miller, 
2007). This results in autophosphorylation in trans of a number of tyrosine residues 
within RTK ICDs, with phosphorylation of the different sites occurring in a precise 
sequential order (Furdui et al., 2006). These phosphotyrosines contribute to increased 
kinase activity and/or act as recruitment sites for signalling molecules containing SH2 
(Src homology-2) and phosphotyrosine-binding (PTB) domains. Recruitment of these 
signalling molecules results in the activation of interconnected downstream signalling 
pathways, leading to a coordinated response by a diverse range of cellular processes, 
involving for example changes in gene expression and cellular metabolism (Lemmon 
and Schlessinger, 2010).  
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Figure 1.1 RTK architecture and dimerisation mechanisms 
Ribbon representation of known crystal structures of RTK-ECDs in their ligand-bound 
dimeric form. Three different RTK superfamily members are highlighted, indicating the 
structural diversity of the ligand-binding extracellular regions of RTKs and some of the 
distinct mechanisms of RTK dimerisation that have been observed. The highly similar 
intracellular regions are shown as schematic lollipops for simplicity. Dotted lines 
represent the commonly flexible JMs and C-tails. The insulin receptor ECD is a 
disulphide-linked dimer of αβ heterodimers, consisting of three fibronectin type III 
domains, two leucine-rich domains and a cysteine rich domain. One αβ heterodimer is 
coloured slate and the other green. The epidermal growth factor receptor (EGFR)-ECD 
dimer (green and dark green) bound to its monomeric ligand EGF (slate and purple), 
exemplifies ligand-induced receptor-mediated dimerisation (Lemmon, 2009). Each 
EGFR monomer consists of two leucine-rich domains and two cysteine rich domains. 
The second cysteine rich domain is not observed in the crystal structure and is 
represented schematically as a triangle. The KIT-ECD/stem cell factor (SCF) complex 
exemplifies dimeric-ligand-mediated RTK dimerisation. The KIT-ECDs each consist of 
five immunoglobulin domains and are coloured green and dark green. The SCF 
monomers are coloured slate and purple. (Crystal structure references: insulin receptor 
PDB 2DTG (McKern et al., 2006); EGFR/EGF PDB 1IVO (Ogiso et al., 2002); 
KIT/SCF PDB 2E9W (Yuzawa et al., 2007)). 
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1.1.1 Protein kinase structure and active conformation 
Tyrosine kinases are phosphoryl transfer reaction catalysts. Upon binding of ATP and a 
tyrosine-containing substrate to a catalytically productive conformation of the kinase, 
they mediate the transfer of the ATP γ phosphate to the hydroxyl group of a substrate 
tyrosine residue (Figure 1.2a). The tyrosine kinase catalytic base (D1132 in the insulin 
receptor kinase) deprotonates the substrate tyrosine, catalysing nucleophilic attack by 
the tyrosine oxygen onto the electrophilic γ phosphate phosphorous. The reaction 
proceeds through a pentavalent transition state, resulting in a phosphorylated tyrosine 
and ADP. These products then dissociate from the kinase allowing a further ATP and 
substrate to bind and a subsequent round of catalysis to proceed (Lassila et al., 2011).   
The RTK-KDs like other tyrosine (and serine-threonine) kinases possess a bilobal fold, 
with a smaller predominantly β-strand N-lobe and a larger α-helical C-lobe (Figure 1.2) 
(Cowan-Jacob, 2006).  The strict conformational requirements within the RTK-KD fold 
for a catalytically productive kinase are shared with most other eukaryotic kinases. The 
structural elements crucial for catalytic activity are illustrated in Figure 1.2. The 
requirements for catalysis include: (1) the αC helix positioned close to the catalytic 
centre, which allows formation of the structurally and catalytically important K1030-
E1074 salt bridge (insulin receptor numbering); (2) an open and ordered activation loop 
conformation, allowing substrate binding; (3) the magnesium-binding DFG motif in the 
‘DFG-in’ arrangement, allowing proper magnesium coordination by the DFG aspartate; 
(4) the correct relative position of the N and C-lobes, bringing catalytic residues from 
both lobes together (Huse and Kuriyan, 2002). Disruption of the active arrangement of 
any of these elements will result in the inhibition of protein kinase activity. 
Chapter 1 Introduction 
 25 
 
Figure 1.2 Protein tyrosine kinase domain active conformation 
(a) Catalytic mechanism proposed for the phosphoryl transfer reaction of a tyrosine 
kinase. (b) & (c) The crystal structure of the insulin receptor KD (pale blue ribbon), 
with an ATP-analogue (purple sticks), substrate peptide (purple ribbon) and two 
magnesium ions (purple spheres) bound (PDB 1IR3; Hubbard, 1997). The key structural 
elements in an active kinase conformation are coloured as follows: αC helix, green; 
glycine-rich loop, cyan; catalytic loop, yellow; activation loop including the substrate-
binding P+1 loop, pink. Side chains of conserved residues important for catalysis are 
shown as sticks and dashed black lines highlight key interactions. D1132 is the catalytic 
base, which interacts with the attacking nucleophilic hydroxyl on the substrate peptide 
tyrosine. N1137 positions D1132 for catalysis and is involved in magnesium 
coordination. Other key residues are discussed in the text.  
1.2 Regulation of RTK activity 
In the simplest view of RTK function, their role in growth factor signalling pathways is 
as a growth factor responsive switch. In the absence of growth factor their intracellular 
tyrosine kinase activity is inhibited, then upon binding of the growth factor to their ECD 
the kinase is activated in a reversible manner. Structural biology has played a key role 
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in understanding how different RTKs ensure that kinase activity is linked to growth 
factor binding, although no RTK is fully understood. The precise details of regulatory 
mechanisms differ between individual RTKs, although there are a number of common 
themes that have emerged from the RTKs studied to date. These themes include 
allostery, dimerisation and autophosphorylation in trans (Hubbard and Miller, 2007).  
1.2.1 Allostery and RTK activation 
Within a broad definition of allostery, as adopted by Kuriyan and Eisenberg (Kuriyan 
and Eisenberg, 2007), allosteric regulation may become a common theme in 
understanding RTK regulation (Jura et al., 2011). They define allostery as where the 
activity of a protein is regulated by communication between the active site and a distant 
site of modification or binding. Upon modification/binding at this allosteric site, a 
structural change affecting tertiary and/or quaternary structure or a change in the 
flexibility of the protein occurs, leading to modulation of the activity of the protein at 
the active site (Kuriyan and Eisenberg, 2007).  
EGFR has emerged as the archetypal example of this type of regulation in a RTK. 
Autophosphorylation of EGFR does not result in kinase activation, rather an allosteric 
mechanism, similar to that observed in activation of CDKs by cyclins activates EGFR 
kinase activity following ligand-induced dimerisation (Zhang et al., 2006). This 
involves the formation of an asymmetric dimer of the EGFR-KDs, where one KD 
allosterically activates the other KD by binding and altering the position of its αC helix. 
This asymmetric KD dimer is stabilised by interactions between the two JMs (Jura et al., 
2009), which may also be coupled to a particular arrangement of the TMs (Bocharov et 
al., 2008; Endres et al., 2011).    
1.2.2 The role of dimerisation in RTK activation 
RTKs are activated in ligand/receptor complexes containing at least a receptor dimer, if 
not a higher oligomer (Heldin, 1995; Ullrich and Schlessinger, 1990). The precise role 
of ligand-driven dimerisation in the activation of RTKs varies amongst the superfamily 
(Lemmon and Schlessinger, 2010). For example, some receptors adopt pre-formed 
dimers in the absence of ligands and undergo allosteric changes in response to ligand 
rather than a change in receptor oligomeric state. Dimerisation appears to be a pre-
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requisite for RTK activation, facilitating both allosteric and trans-autophosphorylation 
mechanisms of kinase activation (Chen et al., 2008; Zhang et al., 2006). Furthermore 
activation of downstream signalling pathways is dependent on trans-
autophosphorylation of tyrosine residues within the RTK ICD requiring close receptor 
proximity to allow phosphorylation in trans to occur. The method of RTK dimerisation 
adopted by individual RTKs varies amongst the superfamily as described below. 
1.2.2.1 Ligand-independent RTK dimerisation 
At one end of the spectrum the insulin receptor family members are constitutive 
disulphide-linked dimers, with dimerisation therefore not part of the activation 
mechanism (McKern et al., 2006). Ligand-induced non-covalent dimerisation of RTKs 
is proposed to be a more widespread feature of RTK regulation (Lemmon and 
Schlessinger, 2010), although evidence is accumulating for pre-formed dimers of some 
RTKs in the absence of ligand (Whitty and Riera, 2008), as observed in microscopy 
studies of EGFR, where ligand then appears to induce tetramerisation (Clayton et al., 
2005; Kastner et al., 2009; Webb et al., 2008).  
Where ligand-independent dimerisation occurs, whether constitutive or transient, auto-
inhibitory mechanisms are needed to prevent stochastic misfiring of the kinase in the 
dimer in the absence of ligand. In the case of the constitutively dimeric insulin receptor, 
binding of a dimeric pseudosubstrate inhibitory partner protein to both KDs in the 
receptor dimer inhibits kinase activity (Depetris et al., 2005). Activation of the kinase 
activity of RTK’s in pre-formed dimers/oligomers is allosteric, with the ligand inducing 
a conformation change in the RTK dimer, which leads to kinase activation (Hubbard 
and Miller, 2007). In the case of the insulin receptor this would include the dissociation 
of the inhibitory partner protein. 
1.2.2.2 Ligand-dependent RTK dimerisation 
Observations from many RTKs suggest that ligand-induced RTK dimerisation is a 
widespread mode of RTK dimerisation but with many variations on the theme 
(Lemmon and Schlessinger, 2010). Four examples of these variations include: (1) 
dimeric-ligand-mediated dimerisation, where the dimeric-ligand exclusively mediates 
receptor dimerisation (e.g. TrkA/NGF (nerve growth factor); Wehrman et al., 2007); (2) 
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dimeric-ligand and receptor-mediated dimerisation, where the dimeric-ligand along with 
direct receptor:receptor interactions mediate dimerisation (e.g. KIT/stem cell factor 
(SCF); Yuzawa et al., 2007); (3) monomeric-ligand and receptor-mediated dimerisation, 
where the two monomeric ligands both contact both receptors in the dimer and 
receptor:receptor contacts are also involved (e.g. FGFR (fibroblast growth factor 
receptor)/FGF; Schlessinger et al., 2000); (4) receptor-mediated dimerisation, where the 
dimer is exclusively formed from receptor:receptor contacts (e.g. EGFR/EGF; Ogiso et 
al., 2002). Even where dimerisation is not ligand dependent, the ligand still binds and 
stabilises a particular kinase-active dimeric/oligomeric receptor arrangement and 
therefore these ligand-engagement mechanisms are still relevant (Lemmon and 
Schlessinger, 2010). 
Where receptor dimerisation is a key part of the RTK activation process, inhibitory 
mechanisms need to be in place to prevent ‘active’ dimer formation in the absence of 
ligand. Such mechanisms would then be overridden upon ligand binding. A structurally 
characterised example of the class 2 mode of dimerisation, described above, is KIT, a 
member of the PDGFR family. The KIT-ECD consists of five immunoglobulin (Ig)-like 
domains, which are arranged end-to-end creating an overall quasi-linear architecture. 
SCF, its dimeric-ligand, binds KIT’s three N-terminal membrane-distal Ig-like domains, 
cross-linking two receptors (Figure 1.1). This binding and dimerisation event leads to a 
rearrangement of the two membrane-proximal Ig-like domains, resulting in 
receptor:receptor interactions between these domains near the cell surface. It is thought 
that charge repulsion prevents these low-affinity receptor:receptor interactions 
occurring in the absence of ligand. This is overcome by ligand binding, which increases 
the local concentration of these two domains and positions them poised for productive 
interaction. It is the interaction of these membrane-proximal domains that is thought to 
lead to kinase activation, since it brings the TMs together, and therefore likely the 
tyrosine kinase domains (Yuzawa et al., 2007).   
In the case of EGFR (and family members ErbB3 and ErbB4), prevention of ligand-
independent ‘active’ dimer formation is achieved by the inaccessibility of the EGFR 
‘dimerisation arm’ in the absence of the EGF ligand binding. EGFR dimerisation upon 
EGF binding follows an extensive ligand-induced conformational change within the 
EGFR-ECD, which exposes the previously buried ‘dimerisation arm’ (Bouyain et al., 
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2005; Cho and Leahy, 2002; Ferguson et al., 2003; Ogiso et al., 2002) (Figure 1.1). 
Alongside the global rearrangement of the EGFR-ECD, EGF binding also results in the 
bending of the domain primarily involved in dimerisation (domain 2) (Alvarado et al., 
2009). This bend is required in at least one of the EGFR molecules in the dimer for 
kinase activation, since it allows the receptor dimer to adopt a conformation that 
positions the TMs (and therefore the ICDs) productively (Liu et al., 2012). This is 
thought to be the basis for the regulation of EGFR family member ErbB2, which has no 
known ligand and has a constitutively exposed dimerisation arm (Garrett et al., 2003). 
ErbB2 does not have a bent domain 2 and therefore ErbB2 homodimers are unable to 
form an active dimeric conformation (Alvarado et al., 2009). They must rather 
heterodimerise with a ligand-bound member of the EGFR family (Liu et al., 2012). 
1.2.3 Regulation by autophosphorylation 
Protein structures are dynamic and the tyrosine kinase domain is likely to sample a 
range of conformations in solution. In the low activity (auto-inhibited) form of tyrosine 
kinase domains, a broad range of mostly inactive conformers are thought to be sampled 
(Chen et al., 2007). Upon phosphorylation, flexible regions with phosphorylation sites 
become tethered to phospho-binding pockets restricting the range of conformers in 
solution towards the single active conformation (Chen et al., 2007).  Static inhibitory 
conformations have been defined for some tyrosine kinases, such as the insulin receptor 
described below, but for others there is little evidence for discrete inhibited forms. 
Autophosphorylation follows ligand engagement, which is thought to arrange the KDs 
in an RTK dimer/oligomer such that autophosphorylation in trans can occur despite low 
basal kinase activity (Furdui et al., 2006).  
There are three elements within the ICDs of RTKs that can regulate kinase activity in 
this phosphorylation dependent way: the KD activation loop, the JM and the C-tail 
(Hubbard and Miller, 2007; Lemmon and Schlessinger, 2010). These are discussed 
below. 
1.2.3.1 Activation loop phosphorylation 
The activation loop of protein kinases lines the base of the kinase cleft, between the N 
and C-lobes. It is located between C-lobe helices αE and αF and is generally 20–30 
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amino acids long. The activation loop begins with the conserved DFG motif and ends 
with a conserved APE motif. The central region is less well conserved between kinases, 
although tyrosine kinases commonly have between 1 and 3 tyrosines, which are 
autophosphorylation sites (Nolen et al., 2004).  
Crystal structures of non-phosphorylated KDs commonly display activation loop 
conformations that are incompatible with kinase activity (e.g. EphB2 (Wiesner et al., 
2006); FGFR (Chen et al., 2007); insulin receptor (Hubbard et al., 1994)). The non-
phosphorylated insulin receptor KD structure shows the activation loop blocking both 
the ATP binding pocket and the active site (Figure 1.3) (Hubbard et al., 1994). This 
non-productive activation loop arrangement is also linked to the non-productive 
position of the αC helix, which is rotated away from the active site. This arrangement is 
stabilised by activation loop Y1162 binding in the active site as if it were a substrate. 
However since the ATP pocket is blocked, and the αC helix is improperly positioned, 
Y1162 is not phosphorylated in cis (Hubbard et al., 1994). 
The insulin receptor activation loop contains three tyrosine residues that are 
autophosphorylation sites and phosphorylation increases kinase activity 200×. The 
crystal structure of the insulin receptor KD phosphorylated on all three of these sites 
and in complex with an ATP-analogue and substrate peptide, revealed how 
phosphorylation of these activation loop tyrosines stabilise the kinase in an active 
conformation (Hubbard, 1997). Phosphorylation of Y1162 inhibits binding in its own 
active site. Phosphorylation of Y1163 stabilises the active, open, conformation of the 
activation loop by forming hydrogen bonds with two other residues in the activation 
loop, R1155 and G1166. Phosphorylation of Y1158 does not appear to be important for 
the activation loop conformation: Its role is probably simply as a recruitment site for 
downstream signalling molecules (Hubbard, 1997).  
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Figure 1.3 Activation loop conformations of non-phosphorylated and phosphorylated 
insulin receptor KD 
(a) The crystal structure of the non-phosphorylated insulin receptor KD (pale green 
ribbon; PDB 1IRK; Hubbard et al., 1994), with the glycine-rich loop, αC helix and 
activation loop highlighted (green). The side chains of the activation loop tyrosines are 
shown as sticks. (c) The crystal structure of the tri-phosphorylated insulin receptor KD 
(pale blue ribbon), with an ATP-analogue (purple sticks), substrate peptide (purple 
ribbon) and two magnesium ions (purple spheres) bound (as Figure 1.2; PDB 1IR3; 
Hubbard, 1997). The glycine-rich loop, αC helix and activation loop are highlighted 
(cyan) and the side chains of the phosphorylated tyrosines are shown as sticks. (b) 
Superposition of the non-phosphorylated and tri-phosphorylated insulin receptor KD 
structures. (d) Close up of the kinase cleft. 
1.2.3.2 Juxtamembrane domain and C-terminal tail inhibition and 
phosphorylation 
Often alongside regulation of kinase activity by activation loop phosphorylation, the 
commonly flexible JM and C-tail of RTKs can also regulate kinase activity in a 
phosphorylation dependent manner. For example the JM of the EphB2 receptor binds 
the KD in cis and stabilises the αC helix in a distorted non-productive conformation. 
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Dissociation of the JM allows the αC helix to adopt an active conformation, and JM 
dissociation is promoted by phosphorylation of two JM tyrosine residues (Wiesner et al., 
2006; Wybenga-Groot et al., 2001). Tie2 is an example of C-tail inhibition. Its C-tail 
binds to the KD blocking substrate binding, which is likely relieved upon 
phosphorylation of tyrosines within the C-tail (Niu et al., 2002).  
1.3 The RET receptor tyrosine kinase 
RET (rearranged during transfection) was originally discovered as a proto-oncogene 
that could be activated by DNA rearrangement. This rearrangement resulted in the 
production of a fusion protein, which could transform NIH-3T3 cells (Takahashi et al., 
1985). The C-terminal portion of this gene fusion product was later shown to express a 
transmembrane and a tyrosine kinase domain (Takahashi and Cooper, 1987). This 
portion came from a gene encoding a receptor tyrosine kinase (RTK), which inherited 
the name RET.   
RET is the sole member of its RTK subfamily, and uniquely contains cadherin-like 
domains (CLDs) in its ECD (Anders et al., 2001), as well as a cysteine rich domain 
(CRD). Whilst the RET-ECD is unique, the RET-KD is highly similar, in sequence and 
structure, to other RTK-KDs. 
The intracellular region of RET is most closely related by sequence homology, to the 
FGFRs, vascular endothelial growth factor receptors (VEGFRs) and PDGFs (Manning 
et al., 2002b). These RTKs are all dubbed ‘split-kinase’ RTKs since their KDs contain a 
hydrophilic ‘kinase insert’, an embellishment on the common KD fold and a potential 
source of further regulation (Ullrich and Schlessinger, 1990). There are three 
alternatively spliced forms of RET, which differ in their C-terminal sequences. They are 
called RET9, RET43 and RET51 based on the number of splice variant specific residues 
found at their C-termini (9, 43 and 51 respectively) (Plaza-Menacho et al., 2006). 
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Figure 1.4 RET canonical signalling pathway 
Cartoon schematic showing the canonical RET signalling pathway. The disulphide-
linked homodimeric GDNF family ligands, with their respective GPI-linked GFRα co-
receptors, bind RET and activate its intracellular tyrosine kinase activity. This leads to 
autophosphorylation on a number of phosphotyrosine sites within the RET-ICD, as 
depicted (Kawamoto et al., 2004; Salvatore et al., 2000). These serve as docking sites 
for intracellular signalling/scaffold proteins. Recruitment of these proteins to RET leads 
to the activation of downstream intracellular signalling pathways (Ichihara et al., 2004; 
Kodama et al., 2005; Morandi et al., 2011; Plaza-Menacho et al., 2006; Santoro et al., 
2004). DOK = downstream of tyrosine kinase; FRS = fibroblast growth factor receptor 
substrate 2; GRB = growth factor receptor bound protein; IRS = insulin receptor 
substrate; PLC = phospholipase C (other acronyms defined in text). 
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1.3.1 RET ligands and co-receptors 
RET remained an orphan receptor for many years, lacking a known activating ligand. In 
1996 it was shown to be activated by and mediate downstream signalling from GDNF 
(glial cell line derived neurotrophic factor), a distant member of the TGF-β superfamily 
(Durbec et al., 1996; Trupp et al., 1996). RET is now known to act as a receptor for the 
four GDNF family ligands (GFLs): GDNF, Neurturin, Artemin and Persephin; which 
bind RET in complex with a ligand-specific co-receptor: GFRα1, 2, 3 and 4 (GDNF 
family receptor α 1–4) (Figure 1.4) (Airaksinen and Saarma, 2002; Klein et al., 1997; 
Treanor et al., 1996). Only one other RTK requires a co-receptor for ligand-binding: 
MuSK (muscle specific kinase) responds to its ligand, agrin, via agrin binding to Lrp4 
(LDL receptor-related protein 4) (Kim et al., 2008; Zhang et al., 2008). However there 
are a number of differences between the ligand/co-receptors for MuSK and RET, and 
therefore the mechanism of receptor activation is likely very different (Parkash et al., 
2008; Wang et al., 2006; Zong et al., 2012).  
The current model for an active RET signalling complex consists of a disulphide-linked 
ligand homodimer, two membrane-associated GPI (glycosylphosphatidylinositol)-
linked co-receptors and two RET molecules. Co-receptor can stably bind ligand in the 
absence of RET and work carried out on the RET/Artemin/GFRα3 complex determined 
the order of assembly to be: 1 GFRα3 + Artemin dimer + 1 RET + 1 GFRα3 + 1 RET 
(Schlee et al., 2006).  
However this is apparently not the only RET signalling competent complex. Soluble 
GFRα4, a splice variant of GFRα4, which lacks the GPI-link and contains an 
alternative second (D3) domain, has been shown to bind and activate RET in the 
absence of its ligand Persephin. This may be due to the formation of disulphide-linked 
homodimers of soluble GFRα4, utilising cysteine residues from the alternative D3 
domain, thereby negating the need for ligand mediated dimerisation of the co-receptor 
(Yang et al., 2007). A further alternative RET signalling complex has recently been 
proposed, linking RET to a new set of ligand/co-receptors. Ephrin-A has been proposed 
to be a novel co-receptor for RET, with RET binding GPI-linked Ephrin-A, in 
competition with GFRα1, and mediating reverse Eph-A receptor:Ephrin-A signalling in 
motor axons (Bonanomi et al., 2012). RET can also be activated through crosstalk with 
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other growth factor signalling pathways. The long isoform of RET (RET51) is activated 
in response to nerve growth factor (NGF) in sympathetic neurons through an apparently 
indirect, GFL/GFRα independent, mechanism (Arighi et al., 2005). 
Within the canonical GFL/GFRα RET signalling the location of the co-receptor can 
vary, leading to three models of GFL/GFRα RET signalling (Ibanez, 2010). The first of 
these is where GFRα and RET are co-expressed in the same cell. GFRα is commonly 
located in lipid rafts due to its GPI-link. Lipid rafts are signalling compartments within 
the cell membrane, characterised by high-levels of cholesterol and sphingolipids, and 
allow compartmentalisation of signalling molecules associated with the cell membrane 
(Hancock, 2006; Lingwood and Simons, 2010). Upon GFL binding, GFRα recruits 
RET to these rafts leading to RET activation in cis (Sariola and Saarma, 2003). A 
second model of GFL/GFRα RET signalling is where GFRα and RET are expressed by 
adjacent cells. In this scenario it has been shown that the GDNF/GFRα1 complex can 
bind and activate RET in trans (Paratcha et al., 2001). Finally GFRα1 is constitutively 
released from the cell membrane by membrane-associated phospholipases. The 
resulting soluble GFRα1 can still bind GDNF and subsequently bind and activate RET, 
removing the constraint of the requisite coincidence of GFRα and RET expression in 
the same cell or adjacent cells for GPI-linked GFRα (Ibanez, 2010; Paratcha et al., 
2001). 
1.3.1.1 GFL’s structure and function 
In the canonical RET signalling pathway, RET is activated upon binding to a GFL in 
complex with a GFRα co-receptor. There are four GFLs, which are conserved amongst 
vertebrates: GDNF, Neurturin, Artemin and Persephin (Hatinen et al., 2007). These 
have distinct but overlapping functions. For example GDNF is the principal GFL 
involved in early enteric nervous system (ENS) development, whereas Neurturin is 
required for the later development and maintenance of enteric and parasympathetic 
neurons (Airaksinen et al., 2006). Curiously Neurturin has been lost during evolution 
from the frog (Xenopus tropicalis) genome and Persephin from the chicken (Gallus 
gallus) genome, with other GFLs apparently binding GFRα2 and GFRα4 in these 
species. The zebrafish (Danio rerio) genome, along with the genomes of other fish, 
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encodes two GDNF and two Neurturin orthologs (Hatinen et al., 2007). Despite the 
presence of a RET ortholog in the arthropod genome no GFL ortholog has been 
identified in the Drosophila melanogaster genome (Hatinen et al., 2007).   
GFLs, with their GFRα co-receptors, signal through RET and also a non-RTK cell-
surface receptor, neural cell adhesion molecule (NCAM) (Paratcha et al., 2003). More 
recently GFLs GDNF, Neurturin and Artemin, have been shown to signal through the 
heparin sulphate proteoglycan Syndecan-3 in GABAnergic cortical neurons. This 
requires the GFLs to be immobilised on the extracellular matrix and is a RET and 
NCAM-independent signalling pathway (Bespalov et al., 2011).    
GFLs are distant relatives of TGF-β and are disulphide-linked homodimers. The crystal 
structures of GDNF and Artemin have been solved revealing each monomer has a 
cystine knot fold, with two β-sheet ‘fingers’ at one end and an α-helix ‘heel’ at the 
other (Eigenbrot and Gerber, 1997; Silvian et al., 2006). Formation of the dimer results 
in a two-fold symmetric structure with overlapping ‘heels’ and projecting ‘fingers’ 
(Figure 1.5).  
1.3.1.2 GFRα’s structure and function 
The GFLs signal through RET via interaction with GPI-linked GFRαs. Each GFL 
signals through a specific GFRα—GDNF/GFRα1, Neurturin/GFRα2, Artemin/GFRα3, 
Persephin/GFRα4 (Figure 1.4)—although there is some crosstalk, with GDNF able to 
bind and signal through GFRα2 for example (Airaksinen et al., 1999). The GFRαs are 
conserved amongst vertebrates, like the GFLs, and the fish genomes encode duplicates 
of some of the GFRαs with the zebrafish genome containing two GFRα1 and two 
GFRα2 genes (Hatinen et al., 2007).  
GFRαs contain three related domains designated D1–D3 (domain 1–domain 3), except 
GFRα4, which only has D2–D3 (Hatinen et al., 2007). The crystal structure of D2 and 
D3 from GFRα1 and GFRα3 revealed each domain possesses a triangular five-helix 
bundle fold, constrained by five disulphide bonds, which are formed by cysteine 
residues conserved amongst all GFRαs (Figure 1.5) (Leppanen et al., 2004; Parkash et 
al., 2008; Wang et al., 2006). D2 and D3 form a compact module, with a conserved 
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hydrophobic interface between the two domains (Wang et al., 2006). Consistent with 
the absence of D1 from GFRα4, GFRα-D2D3 contains the primary GFL and RET 
binding sites (Wang et al., 2006). D1 contains eight of the ten cysteines present in D2 
and D3, and is predicted to share the same overall helical fold (Leppanen et al., 2004). 
D1 is not required for GFL and RET binding (Scott and Ibanez, 2001), but does stabilise 
the complex and modulate RET signalling although it remains unclear how (Virtanen et 
al., 2005).  
Alongside the GFRαs there are some other distant members of the GFR superfamily, 
which contain domains sharing the cysteine pattern of GFRα D1–D3. These are GFAL 
(GFRα-like), GFRL (GFR-like) and Gas1 (growth arrest specific 1). They are of 
particular interest since, unlike the GFRαs, putative Gas1 and GFRL orthologs have 
been identified in arthropods as well as vertebrates, and therefore could hold the answer 
to the enigma of arthropod RET’s ligand. Gas1, GFAL and GFRL are orphan receptors 
however, appearing to be unable to bind GFLs (Hatinen et al., 2007). Gas1 has been 
reported to bind RET and has been shown to influence RET signalling, but as a negative 
regulator (Cabrera et al., 2006; Lopez-Ramirez et al., 2008).  
1.3.1.3 GFL/GFRα complex structure and putative RET binding site 
The crystal structures of GFL/GFRα complexes GDNF/GFRα1-D2D3 and 
Artemin/GFRα3-D2D3 revealed a two fold symmetric structure with a GFRα-D2D3 
bound to the finger region of the GFL at either end of the GFL dimer (Figure 1.5) 
(Parkash et al., 2008; Wang et al., 2006). The GFL finger inserts into the centre of the 
D2 triangular helical bundle, with D3 on the outside of the complex apparently 
stabilising D2 (Wang et al., 2006). A putative RET binding site on the GFRα-D2D3 
surface was identified by analysis of conservation amongst GFRαs of surface exposed 
residues (Wang et al., 2006). Mutation of nine of these conserved residues on GFRα1, 
either individually or in pairs, led to a three-fold or better reduction in RET activation, 
measured by RET autophosphorylation. These residues were R190, K194, R197, Q198 
and K202 from D2 and R257, E323 and D324 from D3, and create a highly charged 
putative RET interface spanning D2 and D3 (Figure 1.5a) (Parkash et al., 2008).  
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Figure 1.5 Ligand/co-receptor crystal structures 
(a) Crystal structure of the GDNF/GFRα1-D2D3 complex shown in ribbon 
representation, with residues involved in RET binding highlighted in red (Parkash et al., 
2008). (b) Crystal structure of the Artemin/GFRα3-D2D3 complex shown in ribbon 
representation (Wang et al., 2006). Comparison between the two structures reveals the 
Artemin complex is more elongated than the GDNF complex, due to the different 
intermonomer bend angle in the Artemin and GDNF dimers. 
Comparison between the GDNF/GFRα1-D2D3 and Artemin/GFRα3-D2D3 crystal 
structures revealed a possible structural basis for the ability of these ligands to stimulate 
different downstream signalling pathways, despite signalling through the same receptor, 
namely RET (Parkash et al., 2008). The binding of GFRα to the fingers of the GFL 
makes the overall shape of the complex sensitive to the bend angle of the GFL dimer. 
The Artemin dimer is more linear than the GDNF dimer in all of the crystal structures 
of both GFLs (Parkash and Goldman, 2009). This means that the Artemin/GFRα3-
D2D3 complex is more linear and therefore longer than the GDNF/GFRα1-D2D3 
complex (Figure 1.5), placing the putative RET binding sites on each GFRα in the 
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Artemin/GFRα3-D2D3 complex further apart. The arrangement of the two RET 
molecules in the GFL/GFRα/RET complex might therefore differ dependent on the 
ligand, which may lead to a different conformation of RET in its ICD as well. This 
could hypothetically influence downstream signalling, perhaps through accessibility of 
particular phosphotyrosine sites on RET (Parkash and Goldman, 2009; Parkash et al., 
2008).  
1.3.2 RET’s activation of intracellular signalling pathways 
RET stimulates the activation of similar downstream pathways to many other RTKs, but 
due to its unique ligand/co-receptor, unique timing of ligand/co-receptor availability, 
potentially unique activation kinetics, cell type specificity and combined activation with 
other RTKs, cells and organs show a physiologically unique response to RET 
activation. The best defined hallmark of RET activation is the phosphorylation of 
specific and invariant tyrosine residues within the RET-ICD. Mass spectrometry 
analysis identified eight (Y806, Y809, Y900, Y905, Y981, Y1062, Y1090, 1096) 
tyrosine residues in the RET-ICD, which were phosphorylated in response to ligand/co-
receptor binding (Kawamoto et al., 2004). Additionally Y687, Y752, Y928, Y1015, 
Y1029 have been observed by others as autophosphorylation sites (Liu et al., 1996; 
Salvatore et al., 2000; Schuringa et al., 2001). Y1090 and Y1096 are only present in the 
RET51 splice variant: the other 11 sites are present in all three splice variants. 
Phosphorylation of these sites leads to activation of mitogen-activated protein kinase 
(MAPK) pathways: rat sarcoma oncogene/extracellular signal-related kinase 
(RAS/ERK), p38 MAPK and ERK5; the janus kinase/signal transducer and activator of 
transcription (JAK/STAT) pathway; the phosphatidylinositol-3-kinase (PI3K)/AKT 
pathway; a protein kinase C (PKC) pathway; and the c-Jun N-terminal kinase (JNK) 
pathway (Figure 1.4) (Ichihara et al., 2004; Kodama et al., 2005; Morandi et al., 2011; 
Plaza-Menacho et al., 2006; Santoro et al., 2004). The pathways activated and the 
overall cellular response differs between the different RET ligands (Parkash and 
Goldman, 2009) and the different RET splice variants (Tsui-Pierchala et al., 2002). 
Oncogenic mutations also alter the downstream signalling from RET (Liu et al., 1996; 
Salvatore et al., 2001).  
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1.4 RET biological function 
Of the three RET splice variants RET9 and RET51 are the best characterised, are 
conserved amongst vertebrates, and have distinct but overlapping roles (Carter et al., 
2001). RET9 null mice show major developmental defects, primarily in the kidney and 
ENS, and generally die shortly after birth. RET51 null mice however are essentially 
normal (de Graaff et al., 2001). Mice that express no functional RET isoform show even 
more severe developmental defects than the RET9 null mice, commonly showing 
kidney agenesis and a complete absence of enteric ganglia from the colon (Schuchardt 
et al., 1994). RET, and particularly RET9, is therefore essential for proper development 
of the kidney and enteric nervous system in embryonic mice and this has also been 
shown to be the case in humans (Costantini and Shakya, 2006; Sasselli et al., 2012).  
More recently RET, along with GFRα3, has also been shown to be essential for the 
proper development of Peyer’s patches, which are a major component of the lymphoid 
tissue associated with the gut (Veiga-Fernandes et al., 2007). RET is also required for 
spermatogenesis. Impairment of RET signalling by mutation of phosphorylation site 
Y1062F (and L985P, a KD mutation of unknown impact) in RET9 in mice prevents 
spermatogonial differentiation and leads to apoptosis of spermatid precursor cells (Jain 
et al., 2004).  
As well as in the ENS and the excretory system, RET is also expressed in all other 
lineages of the peripheral nervous system and the motor and catecholaminergic neurons 
of the central nervous system (CNS) during early development. In adults RET 
expression is maintained in sympathetic and sensory neurons, the ENS, and the CNS 
motor, dopaminergic and noradrenergic neurons (Arighi et al., 2005; Tsuzuki et al., 
1995). In adult dopaminergic neurons RET’s ligand GDNF is an important survival 
factor, which is of particular interest since degeneration of these neurons is associated 
with Parkinson’s disease. However GDNF treatment of Parkinson’s disease clinically 
has so far produced inconclusive results (Hoffer and Harvey, 2011).  
1.4.1 Conservation of RET function in evolution  
A single RET gene is present in the mammalian, lower vertebrate and arthropod 
lineages of the animal kingdom (Shiu and Li, 2004). Uniquely the amphioxus genome 
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contains >100 RET pseudogenes, alongside a single canonical RET gene (D'Aniello et 
al., 2008). RET is absent from all other animal kingdom phyla, seemingly lost in the 
course of evolution from the Echinoderms and Ascidians (Shiu and Li, 2004).  
The model organisms zebrafish (Danio rerio), a lower vertebrate, and fruit fly 
(Drosophila melanogaster), an arthropod, have both been used to study RET. It has 
been shown in the zebrafish system that RET and GFL/GFRα function in the 
development of the ENS is conserved (Heanue and Pachnis, 2008; Marcos-Gutierrez et 
al., 1997; Shepherd et al., 2001; Shepherd et al., 2004). It is therefore thought RET’s 
biological function is conserved amongst vertebrates. In Drosophila, RET is expressed 
in an analogous range of tissue types as in the mammalian system (Hahn and Bishop, 
2001) and therefore likely has an analogous function. Furthermore a Drosophila model 
of the RET-associated cancer syndrome multiple endocrine neoplasia type 2 (MEN2) 
has been developed, which, due to the conservation of signalling pathways (Abrescia et 
al., 2005), has allowed kinome-wide drug profiling in the context of MEN2 oncogenic 
mutations, as well as direct studies of RET inhibitors (Dar et al., 2012; Das and Cagan, 
2010). However no GFL has been identified in Drosophila and therefore Drosophila 
RET remains an orphan receptor (Hatinen et al., 2007). 
1.5 RET and disease 
RET has been associated with a number of diseases. Loss-of-function mutations in RET 
result in developmental disorders, such as Hirschsprung’s disease and kidney agenesis, 
and gain-of-function mutations, aberrant expression or gene fusions/translocations can 
cause or promote tumorigenesis (Plaza-Menacho et al., 2006).  
1.5.1 Loss-of-function RET mutations and Hirschsprung’s disease 
Hirschsprung’s disease is a developmental disorder of the ENS characterised by the 
enteric ganglia failing to colonise the entire length of the colon (Amiel et al., 2008). 
This leads to a non-functional portion of the colon, which tonically contracts, resulting 
in intestinal obstruction. There are three different clinical subtypes of Hirschsprung’s 
disease classified by the degree of aganglionosis: short-segment Hirschsprung’s, where 
the rectum and a short portion of the colon are affected; long-segment Hirschsprung’s, 
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where aganglionosis occurs in a longer stretch of the colon; and the rarer and more 
severe total colonic aganglionosis, where the entire colon is affected (Heanue and 
Pachnis, 2007). A number of genes have been linked to Hirschsprung’s disease, with 
RET being the most common (Plaza-Menacho et al., 2006; So et al., 2011). 
Heterozygous mutations in RET have been observed in 50% of familial and 15–35% of 
sporadic Hirschsprung’s patients (Heanue and Pachnis, 2007). A large number of 
Hirschsprung’s-related loss-of-function RET mutations have been identified. These can 
be classified into five different classes based on the mechanism by which they confer 
loss-of-function (Error! Reference source not found.Plaza-Menacho et al., 2006) 
(Pelet et al., 1998; Plaza-Menacho et al., 2006).   
Class 1 mutations are found in the RET-ECD and result in decreased surface expression 
of RET by impairing proper folding of the protein and processing by the endoplasmic 
reticulum (ER) (Kjaer et al., 2010; Kjaer and Ibanez, 2003b). Some of these affect 
calcium-binding or N-linked glycosylation sites (Kjaer and Ibanez, 2003b; Pelet et al., 
1998).  
Class 2 mutations are a specialised group of class 1 mutations. They are all mutations of 
cysteine residues within the cysteine rich domain (CRD), leading to loss of an 
intramolecular disulphide bond, and leaving an unpaired cysteine. This results in 
increased misfolding, and decreased surface expression like the class 1 mutations. 
However these mutations also result in formation of disulphide-linked RET 
homodimers (Pelet et al., 1998), which constitutively activates RET. These mutations 
are therefore both loss-of-function and gain-of-function mutations, and often result in a 
combined Hirschsprung’s disease and MEN2A (multiple endocrine neoplasia type 2A, a 
cancer syndrome) syndrome, discussed in section 1.5.3 (Kjaer and Ibanez, 2003b). 
Class 3 mutations are found in the KD, and confer loss-of-function by impairing 
catalytic activity (discussed in Knowles et al., 2006). Class 4 mutations also affect the 
function, rather than cell surface expression of the receptor. These mutations affect the 
binding of downstream signalling molecules to phosphotyrosines in RET, leading to 
impairment of signalling downstream of RET (Geneste et al., 1999). 
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1.5.2 Loss-of-function RET mutations and kidney agenesis 
Commensurate with the well-studied role of RET in kidney development, RET 
mutations have been observed in some studies in up to 20–37% stillborn fetuses with 
uni- or bi-lateral kidney agenesis (Costantini and Shakya, 2006; Skinner et al., 2008). 
However the importance/frequency of RET mutations in severe human kidney 
developmental defects has been questioned by a more recent study on a larger number 
of fetuses with bilateral defects. In this study RET mutations were only observed in 7% 
of cases, and largely did not appear to be causal, since they were shared with healthy 
parents (Jeanpierre et al., 2011). 
1.5.3 RET point mutations in the hereditary cancer syndrome MEN2 
Germline gain-of-function point mutations in RET cause MEN2, of which there are 
three subtypes: MEN2A, MEN2B and familial medullary thyroid carcinoma (FMTC) 
(Arighi et al., 2005; Donis-Keller et al., 1993; Hofstra et al., 1994; Mulligan et al., 
1993). MEN2 is characterised by medullary thyroid carcinoma (MTC), a malignant 
cancer, which develops from the calcitonin-secreting C-cells of the thyroid gland 
(Santoro et al., 2004). MTC is the only pathology associated with FMTC, whereas 
MEN2A and MEN2B are associated with other cancers and pathologies, such as 
pheochromocytoma, a cancer of the adrenal gland. MEN2B is the most aggressive 
subtype, with widespread associated affects. These include ganglioneuromatosis of the 
gastrointestinal tract, medullated corneal nerves and marfanoid habitus (Ichihara et al., 
2004). The common RET mutations seen in MEN2 patients are detailed in Figure 1.6. 
Many of these have also been observed in sporadic MTC, with RET mutations found in 
around 50% of sporadic MTC cases (Arighi et al., 2005).  
The C634R mutation is the most common MEN2A mutation, observed in 50% of 
patients, with other C634 mutations accounting for a further 40% of MEN2A cases 
(Ichihara et al., 2004). C634 mutations, as well as the other CRD cysteine mutations, 
results in the formation of constitutively active disulphide-linked homodimers of RET 
(Asai et al., 1995; Santoro et al., 1995).  The proclivity of these cysteine mutants to 
produce RET homodimers has been shown to be linked to the self-association of the 
RET-TM. Dimerisation of RET via the TM brings the juxtamembrane regions of the 
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CRD, where all the MEN2A cysteine mutations are located, close together allowing 
intermolecular disulphide formation between the unpaired cysteines (Kjaer et al., 2006).  
Mutations in C634 and C630 do not affect RET folding and surface expression, and are 
therefore not linked to Hirschsprung’s disease (Kjaer et al., 2006). However mutations 
in C609, C611, C618 and C620 are class 2 Hirschsprung’s mutations (see section 1.5.1), 
and can result in a joint MEN2A and Hirschsprung’s disease syndrome (Plaza-Menacho 
et al., 2006).  
More rarely mutations within the RET-KD are observed in MEN2A, whereas the more 
severe MEN2B is primarily caused by KD mutations. The molecular basis for RET 
activation as a result of these KD oncogenic mutations is not well understood. M918T is 
associated with 95% of MEN2B cases, with a further 3–4% caused by A883F (Ichihara 
et al., 2004; Smith et al., 1997). The M918T mutation is highly activating, resulting in 
receptor autophosphorylation in the absence of ligand/co-receptor, and has been shown 
to be capable of mediating downstream signalling from the ER (Runeberg-Roos et al., 
2007). The mechanism underlying the activation of RET kinase activity by M918T is 
unclear. M918 resides in the substrate binding P + 1 loop of the RET-KD, and an 
analogous oncogenic mutation is also observed in MET RTK (M1250T). Based on the 
assumption that in vivo RET-KD adopts an inactive auto-inhibited conformation like 
that observed in non-phosphorylated crystal structures of its closest evolutionary 
relative, FGFR-KD, computational modelling showed the M918T mutation reduces the 
stability of this conformation (Dixit et al., 2009). This inactive conformation of RET-
KD has yet to be observed in a RET crystal structure however (Knowles et al., 2006). 
The M918T mutation in the context of recombinant RET-ICD results in a 10× increase 
in ATP affinity, which is curious given the distance of M918 from the ATP binding 
pocket (Gujral et al., 2006). M918T has also been proposed to confer activity by 
destabilising a trans-inhibitory interaction between RET-KDs (discussed further in 
section 1.7.2) (Knowles et al., 2006). A further hypothesis for M918T’s mechanism of 
action is that it promotes the detachment of the activation loop, which is required for 
trans-autophosphorylation of activation loop tyrosines by a partner KD. This activation 
loop detachment and engagement with a dimeric partner KD active site has been 
observed in crystal structures of a number of serine-threonine kinases (Oliver et al., 
2007) 
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1.5.4 RET fusion proteins in thyroid cancer, lung cancer and leukaemia 
As well as point mutations, RET can also be activated by the production of fusion 
proteins, as observed in papillary thyroid cancer (PTC). PTC is the most common form 
of thyroid cancer (80–90% of thyroid cancers), and RET fusion proteins are associated 
with both sporadic and radiation induced PTCs (Santoro et al., 2004). RET expression 
is not normally observed in normal thyroid follicular cells, and therefore these 
rearrangements result in the activation of RET expression as well as activity (Grieco et 
al., 1990; Lam et al., 1998). The first RET/PTC fusion protein was identified in 1990 
(Grieco et al., 1990), and there are now 11 known RET/PTC fusions (Figure 1.6) 
(Santoro et al., 2006).  These fusions link the RET-KD and C-tail to a constitutively 
dimeric fusion partner. This results in a cytoplasmic and constitutively active RET 
(Santoro et al., 2006).  
More recently similar RET fusions have been identified and proposed to be driver 
mutations in some lung adenocarcinomas (Kohno et al., 2012; Lipson et al., 2012; 
Takeuchi et al., 2012) and in chronic myelomonocytic leukaemia (Ballerini et al., 2012).  
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Figure 1.6 Cancer-associated RET mutations and gene fusions 
Schematic showing some of the clinically observed oncogenic RET mutations based on 
the following citations: MEN2/FMTC (Kodama et al., 2005; Plaza-Menacho et al., 
2006); PTC (Santoro et al., 2006); Lung adenocarcinomas (Kohno et al., 2012; Lipson 
et al., 2012; Takeuchi et al., 2012); CMML (Ballerini et al., 2012). 
1.5.5 Aberrant RET expression in breast, colorectal and other cancers 
RET over-expression has been reported in many different cancers including breast, 
prostate, pancreatic, lung, bile duct, neural-crest derived cancers and melanoma 
(Morandi et al., 2011). In many of these tissues RET is not normally expressed. More 
detailed analysis has been carried out on the role of RET in breast cancer, where over-
expression has been observed specifically in oestrogen receptor (ER)-positive invasive 
breast cancers (Boulay et al., 2008; Esseghir et al., 2007; Plaza-Menacho et al., 2010).  
Recently RET has been proposed to play a tumour suppressor role in colorectal cancer. 
Aberrant RET gene methylation, which has been shown to result in decreased RET 
expression, has been observed in 27% of colon adenomas and 63% of colorectal cancers. 
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Furthermore restoration of RET expression in colorectal cell lines led to apoptosis (Luo 
et al., 2012). 
1.6 RET ectodomain structure 
1.6.1 Cadherin-like domains predicted domain arrangement 
The RET-ECD contains four cadherin-like domains (CLDs), originally identified by 
sequence alignment to members of the classical cadherin family, which revealed their 
distant similarity to extracellular cadherin (EC) domains (Figure 1.7) (Anders et al., 
2001; Schneider, 1992). RET is therefore an atypical cadherin superfamily member 
(Nollet et al., 2000). 
Cadherins are single-pass transmembrane proteins, involved in calcium-dependent cell 
adhesion. They are characterised by the presence of EC domain repeats in their ECDs. 
EC domains adopt a seven-stranded β-barrel fold (βA-βG), which RET CLDs share 
(Figure 1.7). 
EC domains in vertebrate classical cadherins are arranged end to end, with their 
junctions rigidified by three bound calcium ions (Boggon et al., 2002a; Harrison et al., 
2011; Shapiro et al., 1995). The calcium-binding residues at EC–EC junctions are 
conserved. They are generally acidic residues and are found in five different motifs. 
Three motifs are from the preceding EC domain: E at the end of βA, DRE between βE 
and βF; and DXNDN in the EC–EC linker. And two motifs are from the succeeding EC 
domain: DXD after βB; and D at the end of βF (see Jin et al., 2012 and Figure 1.7). 
Sequence analysis of the RET-ECD revealed that the CLD2–CLD3 junction contains 
almost the full complement of calcium-binding residues, which are conserved from 
human to Drosophila RET, lacking only the D at the end of βF in CLD3. RET is 
therefore predicted to bind calcium and display an end-to-end CLD2–CLD3 
arrangement (Figure 1.7) (Anders et al., 2001).  
The RET CLD1–CLD2 and CLD3–CLD4 junctions contain only some of the conserved 
calcium-binding residues. CLD2 lacks both motifs (DXD and D) that would form the 
CLD1–CLD2 junction calcium-binding sites. CLD3 and CLD4 both contain some but 
not all of the calcium-binding residues that would form the CLD3–CLD4 junction 
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(Figure 1.7). The CLD1–CLD2 and CLD3–CLD4 junctions also contain longer linkers 
than the EC–EC junctions in classical cadherin and the CLD2–CLD3 junction. The lack 
of calcium-binding residues and the presence of longer linkers suggested that the 
arrangement of CLD1–CLD2 and CLD3–CLD4 is different to the calcium-bound EC 
domain arrangement of classical cadherin. This was found to be true for CLD1–CLD2, 
as discussed below (section 1.6.4) (Kjaer et al., 2010).  The arrangement of the CLD3–
CLD4 junction was unknown, and is presented in this thesis.  
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Figure 1.7 Alignment of RET CLDs to cadherin consensus sequences 
Alignment of vertebrate RET CLDs with human C-cadherin EC domains. The 
alignment is based predominantly on Anders et al., 2001 and Jin et al., 2012. Emphasis 
was placed on aligning cadherin consensus sequences, calcium-binding residues, and 
conserved hydrophobics, which define cadherin domain structure. C-cad = human 
(Homo sapien) C-cadherin; hRET = human RET; mRET = mouse (Mus muscularis) 
RET; rRET = rat (Rattus norvegicus) RET; cRET = chicken (Gallus gallus) RET; xRET 
= Xenopus laevis RET; zRET = zebrafish (Danio rerio) RET  
1.6.2 The role of calcium in RET structure and function 
RET has been shown to bind calcium directly (Anders et al., 2001). And, as described 
above, the CLD2–CLD3 junction contains the cadherin consensus calcium-binding 
residues and is therefore predicted to be the calcium-binding site (Anders et al., 2001). 
These calcium-binding residues are conserved from Drosophila to human RET.  
Calcium is crucial for RET folding and intracellular processing as well as RET-
mediated signalling. In the absence of extracellular calcium, or in the presence of a drug 
that causes the release of calcium from internal stores, RET fails to reach the cell 
surface but remains in the ER, presumably due to misfolding (van Weering et al., 1998). 
Commensurate with this, mutations in the RET ‘DRE’, ‘DEDD’ and ‘DXD’ (R231H, 
D267N, D300N) calcium-binding motifs have been observed in Hirschsprung’s disease, 
and lead to an impairment in RET intracellular trafficking (Pelet et al., 1998).   
Calcium is required for RET binding to GDNF, both in vitro and in vivo (Anders et al., 
2001; Nozaki et al., 1998). In line with this RET autophosphorylation and activation of 
MAPK downstream signalling pathway in response to GDNF or Neurturin is calcium-
dependent (Nozaki et al., 1998).  
These data suggest that the proposed calcium-conferred rigidity of the CLD2–CLD3 
junction, analogous to the classical cadherin EC junctions, is vital for the proper folding 
and ligand-binding function of RET. 
1.6.3 RET lacks an accessible adhesion motif present in cadherins 
The presence of CLDs in the RET-ECD, which is unique for a RTK, led to speculation 
as to whether RET could mediate cell adhesion (Runeberg-Roos and Saarma, 2007). 
However this does not appear to be the case, except through binding GFL/GFRα’s in 
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trans, since the elements involved in cadherins adhesive function are not conserved 
(Kjaer et al., 2010; Nollet et al., 2000). 
Classical cadherins mediate cell adhesion by formation of a trans dimer between 
cadherin molecules from opposing cells. The N-terminal EC (EC1) domains from each 
monomer intimately interact, symmetrically swapping their N-terminal β-strands and 
burying the conserved tryptophan residue (W2) side chain in a conserved hydrophobic 
pocket in their partners EC1 domain (Figure 1.8a) (Harrison et al., 2010). W2 is not 
conserved with RET, which instead has a phenylalanine. The non-classical T-cadherin 
also mediates cell adhesion by formation of a trans dimer, but this dimer is not formed 
by a strand-swap between EC1 domains. Rather the dimerisation interface spans both 
the EC1 and EC2 domains resulting in the formation of an X-shaped dimer, with the 
calcium-binding sites at the EC1–EC2 junctions juxtaposed at the centre of the X-shape 
(Figure 1.8b) (Ciatto et al., 2010). The mechanisms by which other non-classical 
cadherins mediate cell adhesion have not yet been elucidated and may be different to 
those detailed above (Jin et al., 2012).  
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Figure 1.8 Cadherins mediate cell adhesion via formation of trans dimers 
(a) Ribbon representation of the EC1 domains from a C-cadherin dimer (PDB 1L3W). 
EC1 domains from C-cadherin mediate symmetric trans dimerisation by a strand swap 
mechanism. The first β-strand (βA, coloured red) from each EC1 domain buries itself in 
its partner, an arrangement that is stabilised by the conserved W2 (side chain shown). 
(b) Ribbon representation of EC1–EC2 domains from a T-cadherin dimer (PDB 3K5S): 
one monomer is coloured yellow and orange with red calciums and the second is 
coloured green and dark green with green calciums. T-cadherin forms an X-shaped 
dimer, with the interface focussed around the EC1–EC2 calcium-binding junctions.  
1.6.4 The crystal structure of human RET-CLD(1–2)  
1.6.4.1 A clamshell CLD1–CLD2 arrangement 
The crystal structure of human RET-CLD(1–2) (hRET-CLD(1–2)) was solved by Dr. 
Svend Kjær in the Structural Biology Laboratory (Kjaer et al., 2010). This revealed that 
CLD1–CLD2 adopts a clamshell arrangement similar to the calcium-free T-cadherin 
EC1–EC2 structure (Figure 1.9a) (Ciatto et al., 2010). However unlike the calcium-free 
T-cadherin structure, this arrangement is not the result of the chelation of calcium from 
a normally linear calcium-rigidified junction, but rather is the constitutive hRET-
CLD(1–2) arrangement. A disulphide bond formed between a cysteine in the CLD1–
CLD2 linker and a cysteine in CLD2 (C157–C197) rigidifies the CLD1–CLD2 
clamshell, and these cysteines are conserved from Drosophila to human. The interface 
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between CLD1 and CLD2 is predominantly hydrophobic and buries a surface area of 
~1250 Å2 (Kjaer et al., 2010). The N-terminal β-strand of CLD1 is buried in the centre 
of this structure, packed into CLD1 (Figure 1.9a), thereby preventing the formation of 
strand-swapped trans-dimers as seen in classical cadherins (Figure 1.8a).   
1.6.4.2 Mammalian-specific CLD1 structural elements 
Both CLD1 and CLD2 have seven-stranded β-barrel folds, confirming their cadherin-
like nature. The hRET-CLD(1–2) crystal structure also revealed that CLD1 contains 
three additional structural elements that are not shared with cadherins (Figure 1.9b). 
These are a short anti-parallel β-strand (βC’–βC”), an 11-residue α-helix (α1), and a 
six-residue loop containing a cis-proline and constrained by a disulphide bond (cis-Pro 
loop). These elements had already been implicated in RET/ligand/co-receptor complex 
formation (discussed further in section 1.6.5) (Kjaer and Ibanez, 2003a), and curiously 
are only conserved amongst mammalian RETs and not with lower vertebrate or 
arthropod RETs (Kjaer et al., 2010). The βC’–βC” strand appears to be absent in non-
mammalian RETs, which generally have a shorter loop between βC and βD. The α1 
helix sequence is not conserved between mammalian and non-mammalian RETs. 
Finally the cis-Pro loop is absent from non-mammalian RETs, since one of the cysteines 
is not present in lower vertebrate RETs, and both are absent in arthropod RETs. In the 
lower vertebrate case an alternative disulphide appears to be present, formed between 
the remaining ‘cis-Pro’ cysteine, and a lower vertebrate specific cysteine in the βC–βD 
loop, leading to an alternative structural arrangement at this CLD1 surface (Figure 1.9c) 
(Kjaer et al., 2010).  
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Figure 1.9 The human RET-CLD(1–2) crystal structure revealed mammal-specific 
structural elements and disulphide arrangements 
(a) The hRET-CLD(1–2) crystal structure (PDB 2X2U), shown in ribbon 
representation, reveals a clamshell arrangement with CLD1 (teal) folded back against 
CLD2 (blue). The N-terminal βA strand of CLD1 (red) is buried in CLD1. The 
disulphide bonds are shown as yellow sticks, and the C-tail, which in the absence of 
CLD3 is folded back onto CLD2, is coloured pink. (b) CLD1 contains additional 
mammal-specific structural elements not seen in classical cadherin structures, which are 
highlighted in green. (c) A schematic showing the different disulphide patterns observed 
in mammalian, lower vertebrate and arthropod/amphioxus RET-CLD(1–2). (d) hRET-
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CLD(1–2) crystal structure with regions important for hGDNF/rGFRα1 binding, 
identified by homologue scanning mutagenesis, coloured magenta (Kjaer and Ibanez, 
2003a). (e) The table details the reduction in hGDNF/rGFRα1 binding by hRET-ECD 
upon mutation of the identified regions to the corresponding Xenopus RET sequence. 
1.6.4.3 The hRET-CLD(1–2) dimer 
These mammalian-specific CLD1 structural elements, and particularly the loop between 
βC’ and βC” and the cis-Pro loop, are principally involved in a dimeric interface 
observed in the hRET-CLD(1–2) crystal lattice (Figure 1.9d). These observations led to 
the proposal that the hRET-CLD(1–2) dimer may have some physiological relevance 
given its extent and the unusual interdigitation of mammal-specific arginine side chains 
at the interface. Whether the dimer is relevant to a ligand-free RET dimer or a 
ligand/co-receptor bound form remains to be shown. Data in Kjaer et al. suggests 
mutation of the interface interdigitating arginines can impede the formation of the RET 
ternary complex (Kjaer et al., 2010).  
1.6.5 Mapping ligand/co-receptor interactions onto RET 
There have been two studies directly looking for the binding site for GFL/GFRα 
complexes on RET, which reached very different conclusions. The first, based on the 
observation that human RET cannot bind lower vertebrate (Xenopus) GDNF/GFRα1 
and vice versa, used homologue scanning mutagenesis to identify the regions of human 
RET that were required for human/Xenopus RET chimeras to recognise 
hGDNF/rGFRα1 (Kjaer and Ibanez, 2003a). They concluded that human RET-CLD1, 
CLD2 and CLD3 were required. In further analysis they showed that certain predicted 
surface exposed regions of CLD1 and CLD2 were important for the GDNF/GFRα1 
interaction, since mutation of these stretches in human RET to the equivalent Xenopus 
sequence significantly reduced binding to hGDNF/rGFRα1 (Kjaer and Ibanez, 2003a). 
The regions they identified are shown on the subsequently solved hRET-CLD(1–2) 
crystal structure in Figure 1.9d&e (Kjaer et al., 2010). Three of these regions are found 
at the hRET-CLD(1–2) crystallographic dimer interface, which is consistent with the 
conclusion of (Kjaer et al., 2010); that this CLD(1–2):CLD(1–2) interaction occurs in 
the context of GFL/GFRα binding and stabilises the complex (see section 1.6.4.3).  
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The second study looking at the RET GFL/GFRα binding interface, was a cross-
linking-based study (Amoresano et al., 2005). This group identified three interactions, 
based on cross-linked peptides, between RET, GFRα1 and GDNF that were not 
observed in the GDNF/GFRα1 complex alone. These were all focused on the same 
region of GFRα1-D1, which cross-linked to RET-CRD, the base of RET-CLD4 and the 
N-terminal tail of GDNF. They did not identify an interaction between RET and 
GFRα1-D2 or D3, which is the primary RET binding surface (Scott and Ibanez, 2001). 
The caveat to these results is that the cross-linked residues they identified between 
GDNF and GFRα1 in the absence of RET, are on the same side of the GDNF/GFRα1 
crystal structure, but are not directly interacting. In this study they also show in cell-
based assays that RET-CLD(1–3) cannot compete with RET for GDNF/GFRα1 binding, 
showing that RET-CLD4CRD is important in RET’s interaction with GDNF/GFRα1 
(Amoresano et al., 2005).  
 
Figure 1.10 Formation of the RET/ligand/co-receptor ternary complex 
Schematic showing what is currently known about the interactions between RET and 
ligand/co-receptor (Amoresano et al., 2005; Kjaer and Ibanez, 2003a; Parkash et al., 
2008). For simplicity the primary interaction between GDNF and GFRα1-D2, which 
occurs in the presence and absence of RET, is not shown. 
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1.7 Regulation of RET’s tyrosine kinase activity 
Binding of GFL/GFRαs to the RET-ECD results in the activation of RET’s intracellular 
tyrosine KD and autophosphorylation, which leads to the activation of downstream 
signalling. The molecular mechanisms underlying the regulation of RET’s kinase 
activity are not fully determined.  
1.7.1 RET regulation by activation loop autophosphorylation 
RET has two autophosphorylation sites in its activation loop—Y900 and Y905. In the 
context of MEN2A mutation C634F, which results in constitutively active RET dimers, 
mutating Y905 to a phenylalanine abolishes cell transforming activity and inhibits, 
though does not abolish, both RET autophosphorylation and phosphorylation of an 
exogenous substrate in vitro (Kato et al., 2002). Y900F in the MEN2A context has no 
effect on transforming ability in cells or on in vitro kinase activity. However the Y900F 
Y905F double mutant shows even less activity than Y905F alone in vitro (Kawamoto et 
al., 2004). These data suggest a role for activation loop phosphorylation in the 
regulation of RET kinase activity and activation of downstream signalling.  
However recombinant RET-KD and RET-ICD show only a 3–4× increase in in vitro 
kinase activity towards an exogenous peptide substrate following autophosphorylation, 
which is modest in comparison to the 10–200× increases observed for known 
autophosphorylation-regulated RTKs (Knowles et al., 2006). In this context the Y905F 
mutant had the same catalytic activity as non-phosphorylated wild type RET-KD, 
linking the modest increase in kinase activity following autophosphorylation to Y905 
phosphorylation (Knowles et al., 2006). The crystal structure of non-phosphorylated 
RET-KD revealed an active, catalytically competent, conformation, with the same 
global conformation as the Y905 phosphorylated RET-KD structure (Figure 1.11a&b) 
(Knowles et al., 2006). Therefore the non-phosphorylated RET-KD structure did not 
reveal an in cis mechanism of inhibiting kinase activity, and implied that activation loop 
phosphorylation could not fully account for regulation of RET kinase activity.  
Understanding the RET autoinhibitory mechanism(s) is crucial for understanding how 
oncogenic mutations subvert RET autoinhibition. The lack of an identified in cis 
mechanism within the KD for inhibiting RET kinase activity led us to look both at the 
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other elements within the ICD and whether they play a role in kinase inhibition, and 
also at a potential in trans inhibitory mechanism, discussed below.  
 
Figure 1.11 Structural analysis of RET-KD activation mechanisms 
(a) Superposition of the non-phosphorylated RET-KD: cyclic adenosine monophosphate 
(cAMP) crystal structure (pink ribbon, with magenta activation loop and αC helix; PDB 
2IVS) and the pRET-KD:AMP structure (grey, with dark grey activation loop and αC 
helix; PDB 2IVT). The bound nucleotides are shown in stick representation. (b) Close 
up of the active site, with side chains of key catalytic and regulatory residues shown in 
stick representation. (c) Head-to-tail dimer of pRET-KD:AMP, as seen in the crystal, 
showing the occlusion of the substrate-binding site. Second protomer is coloured pale 
blue and with slate activation loop and αC helix. 
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1.7.2 Trans-inhibition of RET-KD: a putative RET regulatory mechanism 
Some proportion of RET has also been proposed to dimerise in the absence of ligand, 
since its TM is able to self-associate. This self-association, though not required for 
normal RET activation by GFL/GFRα’s, is the basis for the formation of disulphide 
linked RET dimers in MEN2A-associated cysteine mutants (also discussed in section 
1.5.3) (Kjaer et al., 2006). If ligand-independent dimerisation occurs, inhibitory 
mechanisms must then be present to prevent misfiring of the kinase in the dimer in the 
absence of ligand. 
All published RET-KD crystal structures contain a symmetric head-to-tail dimer within 
the crystal lattice (Figure 1.11c) (Knowles et al., 2006; Mologni et al., 2010). The 
asymmetric unit contains either a single molecule, in which case the dimer is 
crystallographic (e.g. PDB 2IVT), or the asymmetric unit contains a dimer and the two 
protomers are related by non-crystallographic two-fold symmetry (e.g. PDB 2IVS). 
Formation of this dimer buries a surface area of 1090–1380 Å2 (10% of the total surface 
area) involving 43 residues from each protomer. Given the proclivity of RET-KD to 
form this dimer in the high concentration environment of the crystal and the significant 
size of the dimer interface it was hypothesised that it could be a relevant in vivo 
(Knowles et al., 2006). This dimer buries the cleft between the N and C lobes 
containing the active site; and the substrate-binding P+1 loop, at the C-terminus of the 
activation loop, is intimately involved in the dimer interface.  
Formation of this dimer in vivo would occlude the substrate-binding site and prevent 
kinase activity—a trans-inhibitory mechanism (Knowles et al., 2006). It was therefore 
hypothesised that formation of this dimer could be part of the mechanism for regulating 
kinase activity. In line with this some MEN2 oncogenic mutation sites, including the 
highly transforming MEN2B M918T, are located at the dimer interface, and could 
therefore increase RET activity by destabilising this dimer (Knowles et al., 2006). A 
similar dimer is observed in the apo FGFR2-KD crystal structure (PDB 2PSQ), but not 
in the substrate peptide bound structure (PDB 2PVF) (Chen et al., 2007). This is 
particularly curious since phylogenetically the FGFR family is RET’s closest RTK 
relative (Manning et al., 2002b). 
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An autoinhibitory KD dimer, observed in crystal structures of inactive EGFR-KD, has 
similarly been proposed to contribute to the inhibition of kinase activity in ligand-free 
EGFR dimers (Endres et al., 2011; Jura et al., 2009). This dimer is stabilised by the 
EGFR C-tail, and in support of this dimer being relevant physiologically, loss of the C-
tail is oncogenic (Pines et al., 2010). 
1.7.3 The potential role of the RET JM and C-tail in kinase regulation 
The role of the ICD elements flanking the RET-KD in kinase regulation is not well 
characterised. The RET-JM contains one autophosphorylation site (Y687) and the C-tail 
contains three that are present in all RET isoforms (Y1015, Y1029, Y1062) (Kawamoto 
et al., 2004; Liu et al., 1996; Salvatore et al., 2000; Schuringa et al., 2001). However 
none of these phosphorylation sites have as yet been shown to involved in kinase 
regulation. The JM is implicated in RET kinase regulation, and contains a protein kinase 
A phosphorylation site (S696) which modulates RET activity (Asai et al., 2006). A 
small number of MEN2 and sporadic MTC associated mutations have also been 
identified in the JM, suggesting it normally plays an inhibitory role (Cordella et al., 
2006; Runeberg-Roos and Saarma, 2007). 
1.8 RET kinase inhibitors and cancer 
1.8.1 Targeting tyrosine kinases in cancer  
Deregulation of a tyrosine kinase is a common feature of many different cancers and 
tyrosine kinases have been a popular target for development of cancer therapies. The 
success of imatinib, a small molecule ATP pocket binding inhibitor of ABL kinase, in 
treating chronic myeloid leukaemia (Druker et al., 2001), showed that successful 
therapies could be discovered through rational design rather than simple serendipity 
(Cohen, 2002). As well as ATP pocket binding small molecule inhibitors, other 
strategies for targeting tyrosine kinases have also been tried, including protein substrate 
mimics, remote allosteric pocket binding inhibitors and RTK-ECD binding antibodies, 
minibodies and apatamers (Cowan-Jacob et al., 2009). Although thus far only ATP 
pocket binding inhibitors and antibodies have been successfully applied in the clinic 
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(Cowan-Jacob et al., 2009), but an allosteric inhibitor of ABL is also showing some 
promise (Zhang et al., 2010). 
1.8.2 RET is a validated target for cancer therapy 
MTC is recalcitrant to standard radiotherapy and chemotherapy. Surgery to remove the 
thyroid can be curative if the cancer has not metastasised. There was no approved 
treatment for non-resectable advanced or metastatic MTC until 2011 when vandetanib 
(ZD6474), a RET and VEGFR2/3 inhibitor, was approved by the FDA with a 44% 
objective response rate in the phase III trial (Thornton et al., 2012). Vandetanib was 
originally discovered as potent RET oncogenic mutant inhibitor (Carlomagno et al., 
2002), and targets the ATP pocket of the RET-KD (Knowles et al., 2006).  
Due to the success of vandetanib, targeting RET in MTC treatment is validated. 
However vandetanib is not curative, prolonging advanced MTC survival by just 6 
months over placebo (22 months over 16 months). It is also associated with a number of 
adverse reactions. Treatment was discontinued in 12.1% of vandetanib-treated patients 
versus 3.0% of placebo-patients due to adverse reactions and 2% of vandetanib-treated 
patients died as a result of adverse reactions (Thornton et al., 2012). 
1.8.3 RET inhibitors 
1.8.3.1 ATP pocket binding inhibitors 
There are a number of known small molecule RET inhibitors, which fall into two 
categories. Type 1 inhibitors bind in the ATP pocket, in particular they occupy the 
hydrophobic cleft where the adenine ring of ATP binds and make hydrogen bonds with 
residues in the linker between the N and C-lobes (the kinase hinge), which line the back 
of the ATP pocket (Liu and Gray, 2006). These inhibitors are generally compatible with 
the active conformation of the kinase, with the kinase conserved DFG motif at the start 
of the activation loop, adjacent to the nucleotide-binding site, in the catalytically 
competent DFG-in conformation (Liu and Gray, 2006). The crystal structures of the 
RET-KD bound to a number of type 1 inhibitors such as PP1 and vandetanib have been 
solved, showing that these inhibitors are compatible with the active RET DFG-in 
conformation (Knowles et al., 2006; Mologni et al., 2010).  
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Type 2 inhibitors specifically target the inactive DFG-out conformation, binding both in 
the ATP pocket and the neighbouring hydrophobic pocket, which is occupied primarily 
by the phenylalanine of the DFG motif when in the DFG-in conformation (Liu and 
Gray, 2006). Sorafenib is an example of a RET type 2 inhibitor (Carlomagno et al., 
2006), however no crystal structures of RET bound to a type 2 inhibitor have been 
published.  
Due to the high similarity between the structures of active kinases, achieving kinase 
specificity with type 1 inhibitors is difficult, leading to many off-target effects. It was 
thought that targeting the inactive forms of kinases would allow more specific inhibitors 
to be developed, although the type 2 inhibitors target an inactive conformation (DFG-
out) that is shared amongst many kinases. One problem with targeting the inactive 
conformation of kinases is that it opens the possibility for inhibitor resistance mutations 
that further activate the kinase, by inhibiting the inactive conformation (Johnson, 2009). 
1.8.3.2 Sunitinib and RET 
Sunitinib (Sutent®) is a type 1 inhibitor. It inhibits RTKs PDGFR, KIT, FLT3, VEGFR 
and RET and is a potent anti-tumour and anti-angiogenic agent (Chow and Eckhardt, 
2007; Mendel et al., 2003). It has been approved for the treatment of renal cell 
carcinoma and imatinib-resistant gastrointestinal stromal tumours. In vitro sunitinib 
inhibits VEGFR2 with a Ki of 9 nM and PDGFR-β with a Ki of 8 nM. Similarly the 
IC50 for sunitinib’s inhibition of RTK autophosphorylation following ligand 
stimulation in cells is 10 nM for both VEGFR2 and PDGFR-β (Chow and Eckhardt, 
2007). 
Sunitinib has been shown to inhibit oncogenic RET autophosphorylation in cultured 
human MTC cells with an IC50 of ~100 nM (Chow and Eckhardt, 2007). Because of 
this sunitinib has been trialled in a small number of patients with advanced MTC or 
PTC, including a phase II clinical trial for MTC, with some success (35% response rate 
in the phase II trial) (Bajetta et al., 2009; Bugalho et al., 2009; Carr et al., 2010; 
Higgins et al., 2009; Kelleher and McDermott, 2008; Lanzi et al., 2009). 
Despite being a type 1 inhibitor, binding predominantly in the ATP pocket, the crystal 
structure of KIT-KD bound to sunitinib surprisingly showed KIT-KD in an inactive 
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conformation with DFG-out. This crystallographic finding was corroborated by in vitro 
kinase assays showing that sunitinib preferentially inhibits the inactive form of KIT-KD 
(Gajiwala et al., 2009). This is a similar situation to imatinib and ABL kinase, where the 
crystal structure of the ABL:imatinib complex also surprisingly revealed imatinib 
binding to an inactive DFG-out conformation of ABL (Nagar et al., 2002). 
1.8.3.3 Other types of RET inhibitor 
The only RET inhibitors that have been used clinically are ATP pocket binding 
inhibitors. A RET-ECD targeted monoclonal antibody and a dimerisation inhibiting 
aptamer (D4) have however been developed and used in cells (Plaza-Menacho et al., 
2006).  
1.9 Project aims  
The overall aim of my thesis was to investigate and define the molecular architecture, 
protein:protein interactions and regulation of the RET receptor tyrosine kinase. The 
conformational changes underlie RET’s activation in response to ligand/co-receptor are 
unknown, as was the architecture of the entire RET-ECD. In this thesis I sought to 
address these questions as follows: 
To elucidate the architecture of the RET-ECD, I employed small-angle X-ray scattering 
(SAXS) to produce a model for the entire RET-ECD architecture, as described in 
Chapter 2. This chapter also describes progress towards determining the crystal 
structure of CLD(1–4). 
To investigate the basis for ligand/co-receptor recognition by the RET-ECD, I carried 
out the first single particle analysis electron microscopy (EM) 3D reconstruction for a 
mammalian RET ternary complex, as described in Chapter 3. From this I describe an 
interpretation of the reconstruction for the arrangement of RET, ligand and co-receptor 
in the RET ternary complex, based on known structures of the components, which is 
consistent with some of the published functional data.      
Biochemical and structural data have revealed mammal-specific structural elements 
important for human RET’s engagement with ligand/co-receptor. In order to explore 
how a lower vertebrate RET is able to recognise an essentially identical ligand/co-
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receptor, I reconstituted and purified a lower vertebrate RET ternary complex for future 
structural analysis, as described in Chapter 4. Preliminary negative stain EM data 
suggests the lower vertebrate RET ternary complex has a similar overall architecture to 
the mammalian complex.  
Current structural understanding of the regulatory mechanisms governing RET’s 
tyrosine kinase activity is limited since the RET-KD has only been observed 
crystallographically in one conformation in a single dominant crystal lattice. To develop 
our understanding, I sought to obtain the crystal structure of the RET-KD in a different 
crystal lattice arrangement. In Chapter 5 I present a high-resolution structure of the 
RET-KD obtained during these efforts, which revealed some previously unseen features 
and flexibility of the RET-KD. Alongside this I also sought to determine the mode-of-
action of sunitinib, a clinically relevant chemical inhibitor of RET, by solving the 
structure of sunitinib bound to the RET-KD, which is also presented in Chapter 5.  
 
Chapter 2 Results 
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Chapter 2. Structural analysis and architecture of 
the RET ectodomain 
2.1 Chapter aims 
The aim of this chapter was to produce a model for the RET-ECD architecture using 
experimental data from SAXS and X-ray crystallography. The RET-ECD is comprised 
of four CLDs, followed by a CRD. Previous studies in the laboratory defined the 
clamshell arrangement for the CLD(1–2) region of human RET and gave evidence of 
disulphide swapping within this region between lower and higher vertebrate RET (Kjaer 
et al., 2010). However, there is little data available concerning the relative position and 
interdomain contacts between the CLD2 and CLD3, between CLD3 and CLD4, as well 
as between CLD4 and the CRD regions of RET. A model for the RET-ECD was a pre-
requisite step before embarking on an EM analysis of the RET ternary complex with 
GDNF and GFRα co-receptor, since it would allow us to interpret the arrangement of 
the components in the EM 3D reconstruction map. 
Although efforts to crystallise the entire RET-ECD were unsuccessful, towards the end 
of the thesis crystals were obtained for CLD(1–4) from a lower vertebrate (zebrafish) 
RET. An X-ray diffraction dataset was collected and underwent a preliminary analysis. 
In parallel, high quality SAXS data were measured at Synchrotron SOLEIL, Paris. 
These data provided a description of the arrangement of the CLDs within the RET-ECD 
with an unexpected kink between CLD3 and CLD4. SAXS analysis of CRD deletion 
constructs revealed the location of CRD, packed against the CLD4. Furthermore 
production of CLD4CRD constructs highlighted a possible role for the CLD(1–3) in the 
proper arrangement of the CRD, consistent with the SAXS data and previous 
unpublished observations by Dr. Svend Kjær. Finally circular dichroism confirmed the 
CRD contains limited regular secondary structure, with its apparently globular fold as 
observed by SAXS defined by its 7 intramolecular disulphides. 
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2.2 RET-ECD sequence alignment and structural conservation 
I undertook structural characterisation of the RET-ECD using a lower vertebrate 
(zebrafish) RET-ECD in parallel to Dr. Svend Kjær’s work on the human RET-ECD. 
Amino acid sequence alignment of RET-ECDs from three mammalian and three lower 
vertebrate RETs (Figure 2.2) shows fairly high sequence divergence, with 41% 
sequence identity between human and zebrafish RET-ECD (excluding the signal 
sequence; Table 2.1). The highest sequence similarity is seen in the membrane proximal 
CRD, which shows 50% identity between human and zebrafish with complete 
conservation of 14 of the 16 cysteine residues in the human CRD. The greatest 
divergence is between the membrane distal CLD(1–2), with just 35% identity between 
human and zebrafish. Despite this, human and zebrafish RET-ECD are thought to adopt 





CLD1 80% 36% 
CLD2 76% 34% 
CLD3 80% 38% 
CLD4 74% 48% 
CRD 84% 50% 
ICD  93%  84% 
Table 2.1 Sequence identity between individual RET subdomains from vertebrate RETs 
Amino acid sequence identities between individual RET subdomains from human 
(Homo sapien) RET and another mammalian RET (rat: Rattus norvegius) and a lower 
vertebrate RET (zebrafish: Danio rerio).  
As shown in Figure 1.7, CLD(1–4) from both human and zebrafish align well to 
cadherin consensus elements including the 7 β-strand pattern, and are therefore 
predicted to share a 7-strand β-barrel fold. Furthermore, as discussed in section 1.6.4.2, 
the clamshell arrangement of CLD(1–2) is likely conserved between human and 
zebrafish due to the conservation of the disulphide tether between the CLD1 linker and 
CLD2. The calcium binding residues at the CLD2–CLD3 junction are also conserved, 
as is the long linker between CLD3 and CLD4, making it likely that the overall 
arrangement of the CLDs is conserved. The CRD contains a conserved pattern of 14 
cysteines between human and zebrafish, which likely define the fold of this domain.  
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The similarity between mammalian and lower vertebrate CLD4 and the CRD is further 
demonstrated by the ability of human-Xenopus RET chimeras containing Xenopus 
CLD4CRD to bind human ligand/co-receptor, despite CLD4CRD being involved in and 
required for ligand/co-receptor binding (Amoresano et al., 2005; Kjaer and Ibanez, 
2003b).  
Differences between human and zebrafish RET-ECD structure are likely different 
embellishments on the same overall fold. Mammalian-specific structural elements have 
been identified in CLD1, based on the human CLD(1–2) crystal structure, which are 
important for ligand/co-receptor binding (Kjaer et al., 2010). One further notable 
difference between zebrafish and all the other vertebrate RETs shown in Figure 2.2, is 
an 8 amino acid insertion in CLD4 between predicted strands βC and βD, which is also 
present in RET from other fish. 
Structural characterisation of the zebrafish RET-ECD would therefore provide a 
description of the overall RET-ECD architecture, most likely shared with mammalian 
RET, as well as revealing the structure of the lower vertebrate specific features 
providing insights into the differences in ligand/co-receptor recognition between 
mammalian and lower vertebrate RET. A number of different constructs including the 
whole zebrafish RET-ECD and a number of smaller fragments were produced in the 
course of this thesis for structural studies (Figure 2.1). The production and 
characterisation of these are discussed in this chapter. 
 
Figure 2.1 zRET-ECD constructs examined in this thesis 
Schematic of the zebrafish RET-ECD constructs produced as part of this thesis. 
Individual predicted domains are depicted as boxes with the linkers shown as lines. 
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Figure 2.2 Alignment of vertebrate RET-ECD amino acid sequences  
A CLUSTALW2 alignment of human (homo sapien), marmoset (Callithrix jacchus), rat 
(Rattus norvegicus), chicken (Gallus gallus), Xenopus tropicalis and zebrafish (Danio 
rerio) RET-ECD protein sequences. Secondary structure elements observed in the 
human RET-CLD(1–2) crystal structure (PDB 2X2U) are annotated above the 
alignment. Disulphide-linked pairs of cysteine residues seen in the structure are marked 
with green numbers beneath the alignment. Completely conserved residues are boxed 
and highlighted in red with white text, and similar residues boxed with red text. The 
consensus amino acid sequence is displayed beneath the alignment, absolutely 
conserved residues are capitalised. Domain boundaries indicated above the alignment 
are based on the alignment of the CLDs to cadherin EC domains (Anders et al., 2001). 
2.3 RET-ECD protein production  
2.3.1 Rationale for using the baculovirus system for protein expression 
To produce recombinant forms of RET-ECD for structural analysis, I prepared zebrafish 
RET-ECD (zRET-ECD) using a recombinant baculovirus to infect an insect cell host. 
Prior to this thesis, considerable efforts were made to produce recombinant human 
RET-ECD (hRET-ECD) in bacteria, insect cells and mammalian cells. Only the 
mammalian cell expression was successful (Kjaer and Ibanez, 2003b). After the crystal 
structure of hRET-CLD(1–2) was determined, it was rationalised that the presence of a 
tightly constrained cis-Pro loop within CLD1 and two unpaired cysteines may have 
contributed to the difficulty in producing recombinant hRET-ECD (Kjaer et al., 2010). 
We hypothesised that producing a lower vertebrate RET lacking the unpaired cysteines 
and without the cis-Pro loop found in higher vertebrates may allow protein production 
in insect cells. This eukaryotic expression host offers an ER and Golgi apparatus for the 
folding, glycosylation and export of membrane and extracellular proteins, which 
bacterial systems do not possess, whilst adding less complex glycans to extracellular 
proteins than unmodified mammalian cells meaning the resulting glycoproteins may 
crystallise more readily (Jarvis et al., 2009).  
 
 
Chapter 2 Results 
 
 70 
2.3.2 RET-ECD expression cassette development 
For zRET-ECD production, I engineered a construct containing the coding sequence for 
the entire zRET-ECD, ending at the final cysteine (C626) of the CRD (the zRET clone 
was kindly provided by Dr. Tiffany Heanue and Prof. Vassilis Pachnis). This was 
cloned into a baculovirus transfer vector within an expression cassette based on that 
used in the production of the hRET-CLD(1–2); utilising the native secretion signal 
sequence, and encoding a C-terminal Protein A tag (Kjaer et al., 2010).   
The linker between the RET-ECD and Protein A coding sequences initially just 
contained the TEV protease recognition site, however TEV cleavage of the resulting 
fusion protein was not efficient. I therefore extended the linker by addition of the 3C-
protease recognition site and three glycine residues (RET-3C-TEV-Protein A). RET-
ECD could then be cleaved efficiently from its tag by both TEV and 3C-proteases. All 
the proteins produced using this construct contain a short C-tail that is a 
cloning/protease site artefact following cleavage from the Protein A tag. In the 3C-
protease cleaved proteins used exclusively in this thesis, this tail is 10 amino acids long 
(GSEFLEVLFQ).  
Baculoviruses generated from this transfer vector were used for protein expression in 
Spodoptera frugiperda 9 (Sf9; Invitrogen) and Trichopulsia ni derived High Five™ 
(Hi5; Invitrogen) cells cultured in suspension. Initially cells were cultured in grace’s 
media, supplemented with fetal bovine serum. However yields were much improved, 
and more reliable, after transferring to serum-free media. The best protein expression 
yields were obtained in Hi5 cells grown in serum-free SfIII media (Invitrogen), with the 
media harvested 112 hours after infection.      
2.3.3 Large scale zRET-ECD production in insect cells 
Large-scale expression of zRET-ECD in Hi5 cells, infected with baculovirus at a 
multiplicity of infection (MOI) of 2, produced up to 4 mg protein per litre of cells. 
Affinity purification of the Protein A tagged material from the harvested media was 
carried out using IgG-sepharose resin (1ml/l culture). The zRET-ECD was eluted by 
3C-protease cleavage of the Protein A tag, and then subject to further purification by 
size exclusion chromatography and occasionally anion exchange chromatography.  
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The zRET-ECD protein was stable throughout purification. It eluted as a single peak 
from a size-exclusion column, and the eluted protein was highly pure by Coomassie-
stained SDS-PAGE (Figure 2.3a). The size-exclusion purified material bound to an 
anion exchange HiTrap Q column and could be eluted with increased salt concentration. 
About half the material eluted in a sharp peak with the remainder coming off as a broad 
shoulder at higher salt (Figure 2.3b&c). The basis for this elution profile is unknown, 
but it implies that the protein is heterogeneous with regard to its charge.  
The size exclusion purified protein was soluble to > 25 mg/ml in a simple buffer 
without glycerol or detergent, and was stable at 4 °C for at least two weeks. The protein 
was therefore suitable for structural studies by X-ray crystallography and SAXS. 
 
Figure 2.3 zRET-ECD purification 
(a) Size exclusion chromatography of affinity purified zRET-ECD using a Superdex 
200 column. Inset: Non-reducing SDS-PAGE of size exclusion peak material. (b) Anion 
exchange chromography of size exclusion purified zRET-ECD on a HiTrap Q column. 
(c) Non-reducing SDS-PAGE of anion exchange fractions from across the ion exchange 
chromatogram. MW = molecular weight markers. 
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2.3.4 Unsuccessful efforts to produce zRET-CLD(1–2)  
As a direct comparison to the hRET-CLD(1–2), I engineered a zRET-CLD(1–2) 
construct. It was hoped that this protein would be reasonably simple to prepare and to 
crystallise, since we predicted it would display the same overall compact globular shape 
as the human protein. My interest in CLD(1–2) was stimulated by the hope that a crystal 
structure of zRET-CLD(1–2) would allow us to determine how the structure of a lower 
vertebrate RET is different to the human RET. In particular I was keen to see the 
structural impact of the swapped disulphide and altered loop regions that prevent lower 
vertebrate RET interacting with human ligand/co-receptor complexes (Kjaer and Ibanez, 
2003a). A zRET-CLD(1–2) crystal structure would also reveal whether a similar 
crystallographic dimer to that observed for hRET-CLD(1–2) is present in the crystal 
lattice in the absence of the mammalian-specific elements, which mediate dimerisation 
in the human structure (Kjaer et al., 2010). 
Two different zRET-CLD(1–2) constructs were produced: one ending exactly where the 
final beta strand of hRET-CLD2 terminates (zRET-CLD(1–2)1–249); and the second 
including the four acidic calcium-binding residues from the CLD2–3 linker (zRET-
CLD(1–2)1–253; Figure 2.1). Baculoviruses expressing these constructs utilising the 
RET-3C-TEV-Protein A expression cassette, produced usable levels of soluble protein 
in insect cells (0.5 mg/l). However SDS-PAGE and size exclusion chromatography of 
the affinity-purified protein showed that the protein produced from both constructs 
tended to self-aggregate. The protein showed many higher molecular weight 
contaminating bands on SDS-PAGE (Figure 2.4a) and, consistent with this, size 
exclusion chromatography showed a broad elution profile consistent with overlapping 
monomer, dimer and higher molecular weight peaks (Figure 2.4b). This was the case for 
both constructs. 
The poor quality of the produced zRET-CLD(1–2)1–249 was also apparent in a thermal 
melt assay. No proper melt curve could be observed for this protein in a range of buffers, 
consistent with the protein not being properly folded at the starting temperature of 20 °C. 
This unexpected result led to a decision not to pursue this construct further. 




Figure 2.4 zRET-CLD(1–2) purification 
(a) Non-reducing SDS-PAGE of affinity purified zRET-CLD(1–2)1–249. (b) Size 
exclusion chromatography of affinity purified material using a Superdex 200 column. 
2.3.5 Successful zRET-CLD(1–4) protein production 
A construct containing just the four CLDs of zebrafish RET was also produced. This 
construct was originally generated in order to aid interpretation of zRET-ECD envelope 
produced by SAXS analysis (detailed in section 2.5.2). It was also hoped to be a good 
crystallographic target since it is made up of structured domains connected by fairly 
short linkers. 
zRET-CLD(1–4) was expressed and purified in the same way as the complete zRET-
ECD. The protein yield from Hi5 cells was about the same as the zRET-ECD—up to 4 
mg/l in serum-free media. 
Like zRET-ECD, zRET-CLD(1–4) was well behaved and stable. It eluted as a single 
peak from size exclusion chromatography, and the protein from the peak was pure by 
SDS PAGE and highly soluble (up to ~40 mg/ml). zRET-CLD(1–4) eluted with a 
slightly different profile to zRET-ECD from the same anion exchange column. As for 
zRET-ECD the trace shows a dominant sharp peak, but the shoulder eluting at higher 
salt is less broad and appears to consist of a single peak (Figure 2.5). Again the basis for 
this is unclear since the protein corresponding to both peaks is indistinguishable by 
SDS-PAGE.  




Figure 2.5 zRET-CLD(1–4) purification 
(a) Size exclusion chromatography of affinity purified zRET-CLD(1–4) using a 
Superdex 200 column. Inset: Non-reducing SDS-PAGE of size exclusion peak material. 
(b) Anion exchange chromatography of size exclusion purified zRET-CLD(1–4) on a 
HiTrap Q column. 
2.4 Recombinant RET-ECD biophysical characterisation 
2.4.1 zRET-ECD is monomeric in solution 
zRET-ECD elutes as a single peak from size exclusion as if it were 130–150 kDa, based 
on column calibration with molecular weight standards. Dynamic light scattering (DLS) 
of the size exclusion purified material, confirms it is monodisperse and gives an 
estimated molecular weight of 125–140 kDa. Similarly by native PAGE the dominant 
species runs at 150 kDa, with a small proportion running as a dimer of this species at 
around 300 kDa (Figure 2.6). Although since native PAGE separates proteins on the 
basis of both size and intrinsic charge the molecular weight values from reference to the 
molecular weight standards may not be a true reflection of the molecular weight of the 
protein. By SDS-PAGE the protein runs as a monomer at around 85 kDa—much closer 
to its predicted molecular weight of 80.8 kDa (69.3 kDa protein plus 11.5 kDa sugar). 
These results imply that the zRET-ECD could be a dimer in solution.  
However size exclusion coupled multi-angle light scattering (SEC-MALS), gave an 
estimated molecular weight of 83.5 kDa (Figure 2.11 and Table 2.5). Since this 
technique uses the differential refractive index to measure concentration based on 
standard values for proteins, the molecular weight of glycosylated proteins will be over-
estimated due to the different refractive index of the glycans. Nonetheless the estimated 
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molecular weight is consistent with the monomeric molecular weight by SDS-PAGE, 
and not with a dimeric molecular weight of 140–160 kDa. The protein is therefore 
predominantly monomeric in solution, with a small dimeric portion as shown by native 
PAGE. The overestimated molecular weight by size exclusion and DLS are likely due 
to the elongated shape of zRET-ECD, expected based on other tandem cadherin domain 
proteins.  
The molecular weight estimate across the size exclusion peak by SEC-MALS is 
reasonably constant, showing the material is homogeneous at the resolution of this 
method. The low level of dimer present in the purified material as seen by native PAGE 
shows that the protein does self-associate although only with low affinity. This is likely 
why the SAXS data, as discussed later, is improved by running the protein on a size 
exclusion column directly before data collection, since this should separate out the 
dimeric species (see section 2.7). 
All the biophysical properties described above for zRET-ECD also hold for zRET-
CLD(1–4). As for the zRET-ECD it appeared to be much larger than its predicted 
molecular weight of 57 kDa plus glycosylation by size exclusion, native PAGE and 
dynamic light scattering. However its estimated molecular weight by MALS was 67.5 
kDa, again in much better agreement with a monomeric species. 
 
Figure 2.6 Native PAGE of zRET-ECD proteins shows low-level dimerisation 
Coomassie stained native PAGE of size exclusion purified zRET-ECD and zRET-
CLD(1–4). Addition of 1% DDM or digitonin detergents does not alter the level of the 
dimeric species.   
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2.4.2 Recombinant zRET-ECD is properly folded and functional  
Circular dichroism of both the recombinant zRET-ECD and zRET-CLD(1–4) 
confirmed the proteins were folded and chiefly β-sheet in character, as expected for 
proteins consisting of predominantly cadherin-like domains (data shown in section 
2.10.4). Furthermore zRET-ECD binds immobilised zebrafish ligand/co-receptor in the 
presence of calcium (data shown in section 4.3.2). These results confirm that the 
recombinantly produced zRET-ECD proteins are properly folded and able to perform 
their native function. 
2.5 Preliminary structural studies of the RET-ECD 
2.5.1 Crystallisation screening of zRET-ECD 
Since the zRET-ECD could be produced at reasonable levels from insect cells, and the 
protein following purification was pure, highly soluble, homogeneous and properly 
folded, it was therefore suitable for crystallisation screening. The size exclusion purified 
zRET-ECD was subject to extensive crystallisation screening at both 4 and 20 °C, using 
a range of protein concentrations (3.5–20 mg/ml), salt concentrations (100–500 mM 
NaCl) and with or without 5% glycerol in the protein buffer.  The ion exchange step 
was also added to the purification scheme. However no protein crystals were produced. 
It was therefore clear that crystallisation of this protein would be non-trivial, and further 
work pursuing crystallisation would require changes to the construct and/or glycan 
content. A successful strategy is discussed later in this chapter. 
2.5.2 Preliminary efforts to produce a SAXS model of zRET-ECD 
In order to obtain some understanding of the architecture of the RET-ECD whilst 
crystal trials were ongoing, the low-resolution technique, SAXS was used. This 
technique provides information about the intramolecular distances within a 
macromolecule in solution and can therefore be used to generate a model of the overall 
shape of a macromolecule, without the need for crystals. The first round of SAXS 
experiments, which informed later experiments with improved sample handling and 
data collection procedures, are discussed in this section. 
Chapter 2 Results 
 
 77 
2.5.2.1 SAXS data collection at the European Synchrotron Radiation 
Facility (ESRF) 
SAXS data were collected over a range of protein concentrations from 2–7 mg/ml for 
both the zRET-ECD (produced by myself) and the hRET-ECD (produced in 
mammalian cells by Dr. Svend Kjær) at the ID14-3 beamline, ESRF. Samples were 
flowed continuously through a quartz capillary mounted in vacuum for data collection, 
such that fresh sample was exposed to the X-ray beam for each frame of data collected. 
Raw X-ray scattering images from the detector for each frame of data were then 
converted at the beamline to 1D SAXS profiles of intensity of the scattered beam (I) as 
a function of the modulus of the scattering vector (s). Ten frames of data were collected 
for each protein concentration and were compared. The frames with superimposable 
SAXS data profiles, and therefore not showing any radiation damage effects, were 
combined and averaged to improve the signal-to-noise ratio. Later frames of data from 
the highest protein concentration (~7 mg/ml) of both samples showed radiation-induced 
aggregation. This was indicated by the increased scattered beam intensity at low angles 
compared with the earlier frames, which corresponds to an increase in the longest 
distances within the sample in the beam. These frames were therefore discarded before 
averaging of the data from this protein concentration.    
Comparison between the averaged SAXS data curves from the four different 
concentrations of both proteins showed some evidence of association effects (or 
aggregation) at the higher protein concentrations (> 5.5 mg/ml). This was based on the 
radius of gyration (Rg) of the sample in the beam at each concentration, determined 
using the Guiner approximation (Guinier and Fournet, 1955) in PRIMUS (Konarev et 
al., 2003), which showed a slight upward trend at increased concentrations. 
2.5.2.2 ESRF SAXS data processing 
The SAXS data from the lower (2–5 mg/ml) protein concentrations of both zRET-ECD 
and hRET-ECD were then processed using the ATSAS (Konarev et al., 2006) suite of 
SAXS data processing programs. GNOM (Svergun, 1992) was used to fit the SAXS 
data and generate a pair distance distribution function of vectors within the sample in 
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the beam, based on an iteratively determined maximum distance of 200 Å (Table 2.2; 
Figure 2.7).  
Protein Rg (Å) Rg error (Å) Dmax (Å) 
zRET-ECD 51.3 0.13 200 
hRET-ECD 49.0 0.31 200 
Table 2.2 Zebrafish and human RET-ECD SAXS data processing statistics 
Processing of SAXS data with GNOM. The table details the maximum vector length 
(Dmax) used in fitting the data and the fit-derived real space radius of gyration (Rg). 
 
Figure 2.7 Zebrafish and human RET-ECD SAXS data processing 
Processing the SAXS data collected at ESRF with GNOM to produce pair distance 
distribution plots. (a) zRET-ECD (2 mg/ml) experimental SAXS data curve (pink, with 
black error bars) compared with GNOM processing fit (black line). s = modulus of the 
scattering vector, I = intensity of the scattered beam at S. (b) Distance distribution plot 
derived from fit to the SAXS data. R = vector distances within the sample, P(R) = pair 
distance distribution function. (c) & (d) hRET-ECD (2 mg/ml). 
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2.5.2.3 zRET-ECD and hRET-ECD ab initio models  
The GNOM processed data were then used to generate 20–30 ab initio models of zRET-
ECD and hRET-ECD using DAMMIF (Franke and Svergun, 2009). These models were 
then overlaid and the consistent features used in the generation of a consensus ab initio 
model using DAMAVER (Volkov and Svergun, 2003) (Table 2.3). 
Protein NSD mean NSD deviation 
zRET-ECD 0.871 0.039 
hRET-ECD 0.844 0.033 
Table 2.3 SAXS ab initio model generation statistics for human and zebrafish RET-ECD 
Generation of ab initio molecular envelopes with DAMMIF. The table details the mean 
correspondence (normalised spatial discrepancy, NSD) between the 20–30 generated 
models for each protein. Using DAMAVER these models were then overlaid and the 
common features were used in generation of the final models.  
The consensus ab initio models of zRET-ECD and hRET-ECD, showed pleasing 
similarity, and exhibit a curved but extended conformation (Figure 2.8). This suggests 
the overall architecture of the lower and higher vertebrate RET-ECD is the same in 
solution. The only difference between the ab initio models is the presence of a longer 
tail on the zebrafish model, creating an overall ‘question-mark’ shape. 
Fitting the CLD(1–2) crystal structure and 2 cadherin domains, representing CLD3 and 
4, into the ab initio envelopes was ambiguous, since the envelopes were apparently too 
large for the predicted ECD subdomain structure and the CRD is the same size as a 
CLD. One possible interpretation with CLD(1–2) at the top of the models (as depicted) 
with CLD3 and CLD4 arranged end to end is illustrated in Figure 2.8 b&d. However 
there are other interpretations consistent with these envelopes. CLD4 could be 
accommodated folded back on CLD3, like the CLD(1–2) arrangement. Furthermore the 
components would also fit in the alternative orientation with the CLD(1–2) structure at 
the bottom. Therefore the ab initio models, while similar, were not conclusive, and did 
not allow a reliable assignment of RET-ECD subdomains.  




Figure 2.8 Ab initio SAXS models of zebrafish and human RET-ECD 
Consensus SAXS ab initio molecular envelopes of (a) zRET-ECD and (c) hRET-ECD. 
One possible arrangement of the CLD domains (ribbon representation) is shown fitted 
into the (b) zebrafish and (d) human ab initio molecular envelopes. 
2.5.2.4 Approaches taken to improve the SAXS data 
In order to improve the SAXS data such that a reliable interpretation of resulting ab 
initio envelopes could be made, three avenues were taken. Firstly I began to pursue 
protein deglycosylation to reduce the potential impact of the sugar groups on the ab 
initio model (section 2.6). Secondly, as the higher concentrations of protein showed the 
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material had the propensity to aggregate consistent with the native PAGE results, and 
since even very low levels of aggregation can seriously impact the SAXS data, we 
applied for time at the SAXS beamline (SWING) at Synchrotron SOLEIL. This 
beamline has an online high pressure liquid chromatography (HPLC) system, allowing 
data collection on material directly after elution from a size exclusion column. Thus 
largely eliminating aggregation from the protein sample entering the data collection 
capillary (section 2.7). Finally, to define the orientation of the SAXS models—i.e. the N 
and C termini—I produced the zRET-CLD(1–4) construct, which lacks the C-terminal 
CRD (section 2.3.5).      
2.6 Deglycosylation  
Given the failure of crystallisation screening of the zRET-ECD and zRET-CLD(1–4), as 
well as the overlarge molecular envelope of zRET-ECD from SAXS analysis, 
deglycosylation of zRET-ECD and zRET-CLD(1–4) was pursued. Glycosylated 
proteins can be difficult to crystallise since the glycans attached to glycoproteins are 
flexible, heterogeneous and often prevent the close packing of glycoproteins required 
for crystal formation (Chang et al., 2007). I therefore hypothesised that this could be the 
reason why the zRET-ECD proteins were not crystallising. The impact of glycosylation 
on SAXS data is not well studied, but their removal would clarify whether the size of 
the ab initio envelopes is purely the impact of aggregation in the sample or partly the 
influence of the glycans decorating the protein. If the glycans were found to have an 
impact, deglycosylation would then provide more interpretable SAXS data. For these 
reasons I sought to reduce the sugar content of the zRET-ECD proteins, firstly by 
enzymatic deglycosylation and subsequently by site-directed mutagenesis of predicted 
N-linked glycosylation sites.  




Figure 2.9 Insect cell glycosylation 
A schematic representation of N-linked glycans attached to extracellular proteins 
produced and secreted by Hi5 cells. This figure is based on analysis of human β1,3-N-
acetylglucosaminyltransferase expressed in Hi5 cells (Dojima et al., 2009). It is 
important to note that the N-linked glycosylation pattern of proteins expressed in Hi5 
cells is different for different proteins (e.g. Hsu et al., 1997) and therefore the 
proportions and types of complex, high mannose and paucimannose glycans shown are 
intended to be illustrative only.  
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2.6.1 Glycosylation site prediction 
zRET-ECD has 12 potential N-linked glycosylation sites bearing the NXS/T consensus, 
where X can’t be a proline (Gavel and Heijne, 1990). Ten of these are predicted to be 
bona fide glycosylation sites using the NetNGlyc server (Table 2.4) (Gupta et al., 2004). 
Insect cell glycosylation produces a heterogeneous mix of sugar moieties (Figure 2.9), 
which varies dependent on the protein being expressed. The commonly dominant 
species is a five-sugar paucimannose group, which may be further modified by single or 
double fucosylation on the innermost N-acetylglucosamine (NAG) (Dojima et al., 2009). 
Each of these groups is between 1–1.3 kDa, adding an additional 10 – 13 kDa to the 
zRET-ECD protein.  
Domain Position Sequence Potential Jury agreement 
N-Glyc 
result 
CLD1 85 NKTL 0.7524 (9/9) +++ 
CLD1 137 NDTA 0.5549 (7/9) + 
CLD2 185 NYTI 0.7689 (9/9) +++ 
CLD3 259 NGTD 0.7864 (9/9) +++ 
CLD3 308 NDSW 0.5710 (7/9) + 
CLD3 346 NLSV 0.7008 (9/9) ++ 
CLD3 362 NDTT 0.5100 (6/9) + 
CLD4 378 NVTV 0.7172 (9/9) ++ 
CLD4 390 NVTY 0.6464 (9/9) ++ 
CLD4 433 NITA 0.4972 (4/9) - 
CRD 461 NDTK 0.6793 (9/9) ++ 
CRD 572 NISI 0.3132 (9/9) --- 
Table 2.4 Predicted N-linked glycosylation sites in zRET-ECD 
Analysis of all 12 NXS/T N-linked glycosylation consensus sites in zRET-ECD using 
the NetNGlyc server in ExPASY, which assesses whether the site is likely to be 
glycosylated on the basis of the primary amino acid sequence. Position = sequence 
position of the asparagine under consideration. Potential = the likelihood of 
glycosylation based on the averaged probability results of nine neural networks. A 
predicted site has a potential of > 0.5. Jury agreement = the number of the neural 
networks that support the prediction. N-Glyc result = indicates the prediction and the 
confidence level of the prediction: ‘+’ = predicted glycosylated; ‘-’ = predicted not 
glycosylated. The number of +/- indicates the confidence of the prediction, on a scale of 
1–3 +/-. 
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2.6.2 Enzymatic deglycosylation 
Since the stepwise removal of all 12 potential glycosylation sites would be a prolonged 
and slow process, as it is unknown which sites are required for protein folding and 
processing, the first strategy adopted for reducing the sugar content was enzymatic 
deglycosylation. I trialled three different deglycosylases: Peptide N-glycosidase F 
(PNGase F; produced recombinantly by Phillip Knowles), endoglycosidase F1 (Endo-
F1; initially from Calbiochem, then produced recombinantly from a construct kindly 
provided by Prof. Yvonne Jones) and endoglycosidase H (Endo-H; Sigma Aldrich). 
PNGase F cleaves between the asparagine residue and the innermost N-
acetylglucoamine (NAG), except when α(1–3) fucosylated, removing the entire sugar 
moiety. Endo-F1 and Endo-H cleave between the first and second NAG moieties, 
leaving a single NAG attached to the asparagine residue. Endo-H does not remove 
sugars that have been processed by the Golgi apparatus, where the conversion from high 
mannosidic to paucimannosidic and then complex N-glycans occurs. Therefore this 
enzyme should not deglycosylate the majority of sugars on the purified secreted protein, 
if it has been properly processed.  
The enzymes were compared at different temperatures (4, 20 and 37 °C) and reaction 
times (1–20 hours): PNGase F and Endo-F1 both deglycosylated the zRET-ECD, 
whereas Endo-H, as expected, did not (Figure 2.10). The PNGase F treated protein was 
prone to aggregation whereas the Endo-F1 treated material at 4 °C was much better 
behaved, with very minimal aggregation seen by size exclusion. This enzyme was 
therefore used in developing a standard protocol for zRET protein deglycosylation at 
4 °C for 20 hours, followed by size exclusion chromatography to remove any 
aggregated protein (Figure 2.10).   




Figure 2.10 Enzymatic deglycosylation of zRET-ECD and CLD(1–4) 
(a) Non-reducing SDS-PAGE shows results of deglycosylation of zRET-ECD at 4 °C 
over 3 hours with three different deglycosylases: Endoglycosidase F1 (Endo-F1), 
endoglycosidase H (Endo-H) and peptide N-glycosidase F (PNGase F). (b) Non-
reducing SDS-PAGE showing standard Endo-F1 deglycosylation of zRET-ECD and 
CLD(1–4) at 4 °C over 20 hours.  
Endo-F1 deglycosylation is however incomplete. Although Endo-F1 reproducibly 
reduces the sugar content of zRET-ECD and CLD(1–4), results from preliminary lectin 
column binding experiments, conducted to follow the completion of Endo-F1 
deglycosylation, indicate that some mannose containing sugar groups remain on every 
molecule. This is corroborated by the results from SEC-MALS, which estimates the 
molecular weight of the Endo-F1 deglycosylated proteins to be 6–10 kDa larger than 
their protein molecular weight (Figure 2.11; Table 2.5). This is probably due to the low 
activity of Endo-F1 against fucosylated glycans. I will therefore subsequently refer to 
Endo-F1-treated proteins as partially-deglycosylated. 




Figure 2.11 SEC-MALS shows the zRET-ECD proteins are monomeric in solution 
SEC-MALS was carried out using a Superose 6 column for analysis of the molecular 
weight of previously size exclusion purified (a) zRET-ECD, (b) partially-
deglycosylated (deglyco.) zRET-ECD, (c) zRET-CLD(1–4) and (d) partially-
deglycosylated (deglyco.) zRET-CLD(1–4). dRI = differential refractive index. 
Protein MALS estimate Protein MW 
Predicted 
Total MW 
zRET-ECD 83.5 kDa 69.3 kDa 80.8 kDa 
Partially-deglycosylated zRET-
ECD 77.4 kDa 69.3 kDa 69.3 kDa 
zRET-CLD(1–4) 67.5 kDa 55.7 kDa 67.2 kDa 
Partially-deglycosylated zRET-
CLD(1–4) 66.5 kDa 55.7 kDa 55.7 kDa 
Table 2.5 SEC-MALS determined molecular weights of zRET-ECD and CLD(1–4) 
The table details MALS determined molecular weights from the size exclusion peak 
compared with the theoretical protein molecular weight and predicted total molecular 
weight including an estimate for the sugar content (1.15 kDa per predicted N-linked 
glycosylation site).  
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2.6.3 N-linked glycosylation site (NXS/T) mutagenesis 
Given that enzymatic deglycosylation is incomplete, I next tested whether the zRET-
ECD constructs could tolerate elimination of multiple glycosylation sites and still fold 
correctly in insect cells. To do this, I mutated four of the NXT/S consensus asparagines 
to glutamine. These four were chosen from CLD3 and 4, since this is the region with the 
highest number of glycosylation sites, and reducing the sugar content here might 
therefore be of particular help in aiding packing in a crystal. The four selected are the 
least well conserved glycosylation sites and may therefore be less crucial for folding 
(N259, N308, N378 and N433). The NetNGlyc web server did not predict that N433 is 
glycosylated, although the degree of certainty in this result was poor (Table 2.4). 
These mutations were carried out in the context of zRET-CLD(1–4), as the most 
tractable crystallisation target, resulting in a construct referred to as zRET-CLD(1–4)  
reduced sugar (zRET-CLD(1–4)redsug), with 7 predicted N-linked glycosylation sites.  
zRET-CLD(1–4)redsug was expressed in insect cells and purified in the same manner as 
the wild type protein (section 2.3.5). The yield was around 1–1.5 mg protein per litre of 
culture, which is considerably lower than the wild type, but still good enough for 
crystallisation experiments. There was no noticeable difference in protein stability or 
propensity to aggregate compared to the wild type protein, as illustrated by the 
symmetric peak in size exclusion chromatography (Figure 2.12a). The anion exchange 
elution profile was slightly different to the wild type protein (see Figure 2.5), with three 
overlapping peaks rather than two, although as before one peak dominates (Figure 
2.12b). No difference in protein from the three anion exchange peaks could be observed 
by non-reducing SDS-PAGE (Figure 2.12c). It is assumed the difference in the protein 
between the peaks is to do with the different sugar species present, although this is 
speculative. 
This protein crystallised, as described later in this chapter (section 2.9), validating this 
approach for reducing sugar content in highly glycosylated regions of the target protein 
and thereby improving the chances of crystallisation.  




Figure 2.12 zRET-CLD(1–4)redsug purification 
(a) Size exclusion chromatography of affinity purified zRET-CLD(1–4)redsug using a 
Superdex 200 column. (b) Anion exchange chromography of size exclusion purified 
zRET-CLD(1–4)redsug on a HiTrap Q column. (c) Non-reducing SDS-PAGE of protein 
samples from various stages of purification. 
2.7 Defining the RET-ECD architecture by SAXS 
2.7.1 High quality SAXS data collection at SOLEIL using online HPLC 
purification 
In order to limit the observed effects of zRET-ECD protein aggregation on the previous 
SAXS data, I carried out my subsequent SAXS experiments at the SWING beamline at 
Synchrotron SOLEIL using their online HPLC set-up. Glycosylated (sugar content 
unaltered following secretion from insect cell expression hosts) and partially-
deglycosylated zRET-CLD(1–4) and ECD proteins were affinity purified, subjected to 
size exclusion chromatography and then concentrated to ~20 mg/ml for online HPLC 
SAXS analysis. Approximately 20 µl of sample was loaded onto the HPLC size 
exclusion column, and size exclusion was carried out with the material eluting from the 
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column passing directly in the data collection capillary. SAXS measurements were 
taken across the whole protein elution peak. The data was then analysed using 
FOXTROT (SOLEIL in-house software), converting the 2D scattering image on the 
detector to a 1D SAXS profile. The apparent Rg from each data collection across the 
peak was determined using the Guiner approximation. For all four protein samples the 
Rg remained constant across the peak implying homogeneity. The data curves 
corresponding to the very peak of the HPLC profile for each protein were then 
combined and averaged to remove noise and used for subsequent data analysis.  
2.7.2 Analysis of SAXS sample quality 
To confirm the quality of the protein in the X-ray beam the SAXS data was plotted on a 
Kratky plot, which shows whether a protein is folded. All four proteins follow Porod’s 
law and display a bell-shaped curve, confirming the zRET-ECD and CLD(1–4) proteins 
are all folded in the X-ray beam (Kratky and Porod, 1949; Putnam et al., 2007). (Kratky 
plots of unfolded proteins don’t reach a peak but only show increasing or stable I*s2 
with s.) 
 
Figure 2.13 Kratky plot shows zRET-ECD proteins are folded 
Kratky plot of HPLC coupled SAXS data generated in PRIMUS (Konarev et al., 2003). 
gly. = glycosylated; deg. = partially-deglycosylated; s = modulus of the scattering 
vector; I = intensity of the scattered beam at s. 
The Kratky plot can also be used to estimate the molecular weight of the sample. 
Determining the molecular weight from the SAXS data can reveal the oligomeric state 
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of the protein, and also indicate whether the sample is aggregated. This technique is 
generally accurate to within 10% of the actual protein molecular weight (Fischer et al., 
2009), although the presence of the sugars here may further decrease the accuracy of the 
calculation. The results of this analysis confirm that all four proteins are monomeric, in 
line with the SEC-MALS data (Table 2.6). Curiously the SAXS estimated molecular 
weight of partially-deglycosylated zRET-CLD(1–4) is larger than the glycosylated 
protein. The partially-deglycosylated zRET-CLD(1–4) also shows a larger Rg than the 
glycosylated sample (Table 2.7). This may indicate some aggregation in the partially-
deglycosylated zRET-CLD(1–4) sample. 
Protein Max S (Å-1) SAXS MW (kDa) 
MALS MW 
(kDa) Discrepancy 
zRET-CLD(1–4) 0.45 69.6 67.5 3% 
Partially-deglycosylated 
zRET-CLD(1–4) 0.4 77.0 66.5 16% 
zRET-ECD 0.4 94.9 83.5 14% 
Partially-deglycosylated 
zRET-ECD 0.45 87.5 77.4 13% 
Table 2.6 Estimated molecular weight of zRET-ECD and CLD(1–4) from SAXS data 
Molecular weight estimate of zRET-ECD proteins from SAXS based on the area under 
the curve from a Kratky plot of the HPLC coupled SAXS data (SAXS MW), compared 
with the molecular weight estimate from MALS (MALS MW). SAXS MW calculation 
was carried out using SAXS MoW server (Fischer et al., 2009).   
2.7.3 HPLC coupled SAXS data processing 
The SAXS data were then processed using GNOM to generate a distance distribution 
plot of vector distances within the protein molecules. This program generates a fit to the 
experimental data, based on a maximum vector length (Dmax), which is then used to 
generate the distance distribution plot. The results from the best fit to the experimental 
data for each of the zRET-ECD and CLD(1–4) protein samples are detailed in Table 2.7 
and shown in Figure 2.14.  
Comparing the zRET-ECD Rg of 46.0 Å from the HPLC coupled SAXS data collected 
at Synchrotron SOLEIL with the zRET-ECD Rg of 51.3 Å from the ESRF collected 
data (Table 2.2) shows a marked difference. This indicates that the setup at the 
Synchrotron SOLEIL beamline including the HPLC step has dramatically reduced 
sample aggregation.  
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There is only a small difference between the zRET-ECD and zRET-CLD(1–4) Rg’s and 
maximum vector lengths (Dmax) indicating that the CRD does not particularly increase 
the length of the molecule. The larger Dmax value using in fitting the partially-
deglycosylated zRET-ECD data produced the best fit to the data, but this larger value 
does not correspond to an increased particle length: The distance distribution plot of the 
partially-deglycosylated zRET-ECD (Figure 2.14h) shows no vectors larger than 140 Å, 
similar to the other three protein samples.    
The distance distribution plots of the two different glycosylation states of zRET-
CLD(1–4) show very similar profiles (Figure 2.14). The small difference in the amount 
of sugar in the sample is therefore not impacting the overall shape of the molecule. The 
profile is consistent with an elongated, rod-like shape. The plots of the two different 
glycosylation states of zRET-ECD are also very similar to each other. The profile is 
consistent with an elongated object but differs from the zRET-CLD(1–4) profiles by the 
presence of a larger second peak. This double peak profile is suggests the presence of 
two larger domains separated by a smaller linker.  





zRET-CLD(1–4) 44.69 0.067 144 5.44E-04 1.23E-06 
Partially-deglycosylated 
zRET-CLD(1–4) 45.24 0.038 145 3.29E-04 1.56E-07 
zRET-ECD 46.02 0.041 145 4.15E-04 2.46E-07 
Partially-deglycosylated 
zRET-ECD 45.24 0.068 160 4.91E-04 5.29E-07 
Table 2.7 HPLC coupled SAXS data processing statistics 
Processing of HPLC coupled SAXS data with GNOM. Table details the maximum 
vector length (Dmax) used in fitting the data, and the real space radius of gyration (Rg) 
and the intensity of SAXS scattering profile extrapolated to s = 0 (I(0)) derived from the 
fit. 
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Figure 2.14 zRET-CLD(1–4) and ECD SAXS data and distance distribution function 
Processing the HPLC coupled SAXS data of fully glycosylated and partially-
deglycosylated zRET-CLD(1–4) and ECD with GNOM to produce distance distribution 
plots. (a), (c), (e) & (g) Experimental SAXS profiles compared with GNOM processing 
fit. s (Å-1) = modulus of the scattering vector, I = intensity of the scattered beam at s. 
(b), (d), (f) & (h) Distance distribution plots derived from fit to the SAXS data. R (Å) = 
vector distances within the sample; P(R) = pair distance distribution function. 
2.7.4 Ab initio models of zRET-ECD and CLD(1–4) from HPLC-coupled 
SAXS data 
To gain a better understanding of the shape of the molecules the fitted data curves were 
used to generate ab initio models of the protein samples. Several models of each protein, 
consistent with the data, were generated in DAMMIF (Franke and Svergun, 2009), 
overlaid, and a final model based on the consistent features of the overlaid models was 
generated using DAMAVER (Volkov and Svergun, 2003) (Table 2.8).  
The final ab initio models of the zRET-CLD(1–4) and zRET-ECD proteins show 
similar characteristics (Figure 2.15). As expected from the distance distribution 
functions, all four models show an elongated shape with an end-to-end length of 140 Å. 
The models also are all ‘L-shaped’ with a consistent bend of around 100°.  
The zRET-CLD(1–4) ab initio models are very similar to each other, showing the same 
twists and bends in the long arm of the ‘L-shape’.  The partially-deglycosylated zRET-
CLD(1–4) data indicated the sample was apparently larger than the glycosylated zRET-
CLD(1–4) (section 2.7.2), which is reflected in the larger overall volume of the model. 
Therefore, it is difficult to attribute any differences in the two models to the differences 
in sugar content.     
The zRET-ECD ab initio models show some similarity in how they differ from the 
zRET-CLD(1–4) models. They both have a different arrangement at the top of the long 
arm of the L-shape to the zRET-CLD(1–4) models, creating more of a ‘C-shape’. They 
also both show a larger short arm of the ‘L-shape’. However there are some obvious 
differences between the two zRET-ECD models. The short arm of the ‘L-shape’ is 
longer in the glycosylated model, and more globular in the partially-deglycosylated 
model.  




Figure 2.15 Ab initio SAXS models of zRET-CLD(1–4) and ECD 
Final SAXS ab initio models. (a) Glycosylated zRET-CLD(1–4). (b) Endo-F1 partially-
deglycosylated zRET-CLD(1–4). (c) Glycosylated zRET- ECD. (d) Endo-F1 partially-
deglycosylated zRET-ECD. 
Protein NSD mean NSD deviation 
zRET-CLD(1–4) 0.939 0.031 
Partially-deglycosylated zRET-CLD(1–4) 0.941 0.064 
zRET-ECD 1.106 0.066 
Partially-deglycosylated zRET-ECD 1.067 0.052 
Table 2.8 zRET-ECD and CLD(1–4) SAXS ab initio model generation statistics 
Generation of ab initio models with DAMMIF. Table details the mean correspondence 
(normalised spatial discrepancy, NSD) between the 10–50 generated models for each 
protein. These models are then overlaid and the common features are used in generation 
of a final model.  
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2.7.5 zRET CLDs structure prediction 
In order to build a model of the arrangement of the domains within zRET-ECD based 
on the SAXS data, I needed the best possible structural models for each of the sub-
domains. Since there are no crystal structures for any of the zRET-ECD sub-domains I 
had to rely on structure prediction models. The CLDs could be modelled with 
reasonable confidence based on cadherin structures, since they align well to consensus 
cadherin structural elements (Figure 1.7). The CRD has no known structural homologs 
and could not be modelled.  
 
Figure 2.16 Structure prediction model of zRET-CLD1–2 
A model of zRET-CLD(1–2) was generated using PHYRE2 intensive mode (Kelley and 
Sternberg, 2009) based on hRET-CLD(1–2) crystal structure (PDB 2X2U). Indicated 
loops were built ab initio using ‘POING’, part of the PHYRE2 server. Fucosylated 
paucimannose groups were added using the GLYCAM server (Woods Group, 2005-
2012). (a) & (b) Ribbon representation of zRET-CLD(1–2) model, rainbow colouring, 
overlaid on hRET-CLD(1–2) structure, pale blue. (c) Glycosylated zRET-CLD(1–2) 
model with the sugars (red) and sugar-site asparagines shown as sticks. 
2.7.5.1 Structure prediction model of zRET-CLD(1–2) based on hRET-
CLD(1–2) 
zRET-CLD(1–2) was modelled on the hRET-CLD(1–2) crystal structure (Figure 2.16). 
The amino acid sequence identity between these proteins is 35%. The consistent pattern 
of hydrophobic residues in the 7 β strands, which define the core of the cadherin-like 
fold in both CLD1 and CLD2, allows the zebrafish to be modelled with confidence 
based on the human structure (see Figure 2.2). The peripheral elements of the CLD1 
structure that are not found in classic cadherin domains are not as well conserved 
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between zebrafish and human. These are the α1 helix, the short anti-parallel β strands 
and the cis-pro loop (annotated on Figure 2.16b). The α1 helix is predicted, by 
secondary structure prediction, to be present in the zebrafish, however the β-strands and 
cis-pro loop are not and therefore these loops were not based on the human structure.  
The final model was glycosylated on the three predicted N-linked glycosylation sites, 
with a fucosylated paucimannose group using the GLYCAM server (Woods Group, 
2005-2012). The fucosylated paucimannose group was chosen, as its molecular weight 
(1.15 kDa) is closest to the average N-linked glycan molecular weight in Hi5 produced 
proteins (Figure 2.9).  
2.7.5.2 Structure prediction models of zRET-CLD3 and zRET-CLD4 based 
on cadherin structures 
Structure prediction models of zRET-CLD3 and CLD4 were produced based on 
alignment to cadherin crystal structures (Figure 2.17). Different models were produced 
using PHYRE2 (Kelley and Sternberg, 2009) in normal and intensive mode and the best 
model for each was chosen based on the alignment to consensus cadherin elements 
shown in Figure 1.7. In particular the topology of the β strands and the location of the 
calcium-binding residues in CLD3 were compared carefully. A further constraint was 
the location of the predicted N-linked glycosylation sites. Models where these sites 
were buried were discarded. The predicted hydrophobic linker between CLD3 and 
CLD4 was not included in either model as its presence confused the alignments, 
resulting in models with incorrect β strand topology.  




Figure 2.17 Structure prediction models of zRET-CLD3 and CLD4 
(a), (b) & (c) Model of zRET-CLD3 based on extracellular cadherin (EC) domains from 
two cadherin crystal structures: C-cadherin (1L3W) and (2EE0). (a) & (b) Ribbon 
representation of zRET-CLD3 model, rainbow colouring. The calcium binding residues 
at the CLD2–3 junction are shown in stick depiction. The 7 β strands are labelled A–F, 
matching standard cadherin nomenclature. (c) Glycosylated zRET-CLD3 model with 
the GLYCAM modelled paucimannose groups (red) and linked asparagines shown as 
sticks. (d), (e) & (f) Model of zRET-CLD4 generated using PHYRE2 intensive mode. 
The model is based on 4 EC domains from three different protein structures (PDB 
1OP4, 1NCI, 2X2U) and ab initio modelling of a zRET specific 8 residue loop. (d) & 
(e) Ribbon representation of zRET-CLD4 model with rainbow colouring. (f) 
Glycosylated zRET-CLD4 model with the GLYCAM modelled paucimannose groups 
(red) and linked asparagines shown as sticks. 
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2.7.5.3 Modelling the CLD2–CLD3 calcium bound junction based on a 
classical cadherin 
The calcium-binding residues in the CLD2–3 junction are conserved with cadherins 
(Figure 1.7) and therefore the junction could be modelled based on the arrangement 
between EC domains from a classical cadherin crystal structure. However, the angle 
between calcium-linked cadherin domains observed in crystal structures does vary by 
~20–40° (angles between EC domains in C-cadherin vary from ~140–160°) and 
therefore the angle between CLD2–CLD3 might differ slightly from that modelled here 
(Figure 2.18).  
 
Figure 2.18 Structure prediction model of zRET-CLD(1–3) including calciums 
zRET-CLD(1–3) structure prediction model shown in ribbon representation with 
rainbow colouring. Modelled calciums are shown as red spheres. CLD(2–3) junction 
based on alignment to EC1–EC2 domains from C-cadherin (1L3W) crystal structure, 
which have a 150° angle between them (Boggon et al., 2002b). 
2.7.6 SAXS-based zRET-CLD(1–4) model  
In order to produce a model of zRET-CLD(1–4) based on the SAXS data I fitted the 
glycosylated CLD models into the zRET-CLD(1–4) ab initio molecular envelope using 
CHIMERA’s fit-in-map tool (Figure 2.19a). Fitting of the domains was carried out 
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based on a number of assumptions. I assumed that the CLD(1–2) clam shell 
arrangement, with CLD1 folded back on CLD2, as in the hRET-CLD(1–2) crystal 
structure, would be conserved. It was also assumed that the CLD2–3 arrangement 
would be similar to that observed in the cadherin structures. These assumptions 
appeared to be reasonable and the fit of the CLD(1–3) arrangement modelled above to 
the ab initio envelopes was very good. The final assumption was that the N-terminus of 
the modelled CLD4 would be next to CLD3. This seems reasonable, although the linker 
between CLD3–4 is 20 amino acids long and therefore could span the length of CLD4 
resulting in the other end of CLD4 forming the junction with CLD3. Based on these 
assumptions the fitted arrangement of the CLDs into the glycosylated zRET-CLD(1–4) 
ab initio envelope showed a ~100° bend angle between CLD3 and CLD4 (Figure 
2.19a&c). 
The goodness of fit of the resulting glycosylated CLD(1–4) model to the experimental 
data was determined by comparing the experimental data to a theoretical SAXS curve 
derived from the model. This gave a chi-square value (χ2) of 5.3 between the model and 
the experimental data (Figure 2.19b).   
Fitting the CLD(1–2), CLD3 and CLD4 structure prediction models in the alternative 
orientation into the ab initio envelope in CHIMERA was also attempted. The fit of the 
CLD(1–3) structure prediction model was not good in this orientation, since it places 
the 100° bend angle in the ab initio envelope at the CLD2–CLD3 junction. The best 
CLD(1–4) model from fitting CLD(1–3) and CLD4 in this orientation gave a chi-square 
value of > 9 when compared to the experimental data. If the CLD(1–2) and CLD3 
models are fitted separately in this orientation, producing a near 100° CLD2–CLD3 
angle not generally observed in calcium bound EC–EC junctions, CLD(1–2) lies partly 
outside the ab initio envelope. Therefore the model based on fitting into this orientation 
is not as good a description of the experimental data and is less consistent with a 
calcium bound CLD2–CLD3 junction.  
The CLD(1–4) arrangement, with a near-linear CLD2–CLD3 junction and an ~100° 
bend angle between CLD3 and CLD4, was corroborated by preliminary rigid body 
modelling of the hRET-CLD(1-2) structure and C-cadherin individual EC domains 
representing CLD3 and CLD4, against the experimental glycosylated zRET-CLD(1–4) 
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SAXS profile in SASREF (Petoukhov and Svergun, 2005). This method does not 
involve the use of the ab initio envelope. For this non-glycosylated CLD models had to 
be used since SASREF does not work with sugar moieties.  Even though the CLD(1–2), 
CLD3 and CLD4 representative models were used individually, such that the CLD2–
CLD3 junction angle was not enforced, the SASREF output showed a near-linear 
arrangement between CLD2 and CLD3 models, and an  ~100° bend between CLD3 and 
CLD4. (Dr. Andrew Purkiss-Trew conducted this rigid-body modelling analysis.) 
Furthermore the goodness-of-fit of a manually built CLD(1–4) model using the 
glycosylated CLD structure prediction models with a linear CLD3–CLD4 arrangement 
was poor (χ2 = 10.9).  
I used the ab initio envelope and experimental data from the glycosylated zRET-
CLD(1–4) in modelling, since from data analysis it appeared to be the better dataset. 
Furthermore, since it is not known exactly how much sugar is removed in 
deglycosylation, I could estimate the level of glycosylation of the untreated protein with 
greater confidence. Nonetheless the fit of the model described here to the partially-
deglycosylated zRET-CLD(1–4) dataset is actually better as measured by the chi-square 
value (χ2 = 4.2). Although the apparent improvement may simply be a factor of the 
larger experimental error (σexp) values in this dataset, since χ2 = Σ((Iexp(s) − 
Imodel(s))/σexp(s)), which are due to the lower amount of deglycosylated zRET-CLD(1–4) 
sample loaded on the HPLC column for SAXS data collection compared to the 
glycosylated zRET-CLD(1–4) sample.  
Overall the SAXS based model of the arrangement of the CLDs in CLD(1–4) (Figure 
2.19c) affirms an approximately linear CLD2–CLD3 arrangement and reveals a 100° 
angle between CLD3 and CLD4, an unusual arrangement for cadherin domains. This 
arrangement is likely the result of the RET-conserved 20 amino acid, predominantly 
hydrophobic, linker between CLD3 and CLD4. 




Figure 2.19 SAXS based models of the arrangement of the CLDs in the zRET-ECD 
(a) Fitting CLD models (green ribbon representation) into zRET-CLD(1–4) SAXS ab 
initio molecular envelope (green surface). (b) Experimental SAXS data for the 
glycosylated zRET-CLD(1–4) compared to theoretical SAXS curves of fitted CLD 
models in the CLD(1–4) envelope and ECD envelope. The residual plot below shows 
the correspondence between the models and the experimental data. Residual = 
((Iexperimental − Imodel)/σexperimental). (c) Model of zRET-CLD(1–4) shown in surface view, 
with SAXS ab initio molecular envelope shown as a green mesh. (d) Fit of CLDs 
(surface view) into zRET-ECD molecular envelope (purple mesh). (e) Comparison 
between the apparent position of CLD4 in zRET-CLD(1–4) versus zRET-ECD.  
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2.7.7 SAXS-based zRET-ECD model  
Since the CRD fold is unknown and therefore a structure prediction model cannot be 
produced with any confidence, I was restricted to simply fitting the CLDs into the 
zRET-ECD ab initio molecular envelope to define the domain arrangement. The 
absence of a good structural model for the CRD also meant that theoretical SAXS 
profiles of alternative CLD configurations could not be compared with confidence to 
the experimental data as I had done for interpretation of the zRET-CLD(1–4) data, since 
this requires a near complete model of the structure to be a useful comparison. The 
CLD(1–3) arrangement fitted very well into the partially-deglycosylated zRET-ECD ab 
initio envelope, leaving space for CLD4 and the CRD. CLD4 could be placed at a 100° 
angle to CLD3 as in the zRET-CLD(1–4) model, with the CRD folded back against 
CLD4 (Figure 2.19d). The CRD is the same size as a CLD in terms of amino acid 
sequence, and an additional CLD could almost be accommodated next to CLD4 in the 
zRET-ECD ab initio envelope. This implies that the majority of the CRD adopts a 
globular fold and is stably located, folded back on CLD4 in the zRET-ECD in solution. 
Although the bend angle between CLD3 and CLD4 is the same in the zRET-CLD(1–4) 
and zRET-ECD models, there is an apparent 60° rotation about the long axis running 
through CLD3 between the position of CLD4 in the two models (Figure 2.19e). Since 
SAXS data does not specify the hand of the molecule, it was initially thought that this 
difference could be the result of the ab initio envelopes of zRET-CLD(1–4) and zRET-
ECD corresponding to different hands. To test this I generated the enantiomorph of both 
envelopes to compare them. This revealed that the ab initio envelopes presented here 
show the greatest correspondence, and the rotation of CLD4 is not the result of the ab 
initio envelopes corresponding to different hands. Upon testing the goodness-of-fit of 
the CLD(1–4) model docked into the zRET-ECD ab initio envelope to the glycosylated 
zRET-CLD(1–4) SAXS data the chi-square value for this model was found to be 3.7, 
better than the chi-square value for the model generated by fitting in the zRET-CLD(1–
4) ab initio envelope (χ2 = 5.2) and better than 30° rotation angles of CLD4 either side 
of the zRET-ECD model position. The apparent rotation of CLD4 from fitting in the ab 
initio envelopes is therefore most likely not a true difference between zRET-CLD(1–4) 
and zRET-ECD in solution, but a reflection of the limitations of ab initio models. The 
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location of CLD4 in the zRET-ECD model is the best description of the SAXS data 
based on the chi-square value.  
Above I have discussed fitting into the partially-deglycosylated zRET-ECD molecular 
envelope as from the data analysis this appeared to be better zRET-ECD dataset (see 
section 2.7.4). The fit of the CLD(1–4) arrangement into the glycosylated zRET-ECD 
ab initio molecular envelope (Figure 2.15) is good but leaves unmodelled ‘density’ at 
both the CLD3–CLD4 junction and at the tip of CLD4. This could imply a more 
flexible arrangement of the CRD in the glycosylated protein than the partially-
deglycosylated zRET-ECD ab initio envelope, although this cannot be proved with the 
available data. 
2.8 Calcium-free RET-ECD architecture  
In generating a model of the arrangement of the CLDs based on the SAXS data 
described in the previous section, I assumed that the CLD2–3 junction was maintained 
in a roughly linear arrangement by calcium coordination. To test the role of calcium in 
the zRET-ECD architecture, and confirm the positioning of the CLD2–3 junction within 
the SAXS-based model, I collected SAXS data from zRET-ECD and CLD(1–4) 
purified in the absence of calcium.  
2.8.1 Calcium-free zRET-ECD protein production 
zRET-ECD and CLD(1–4) were expressed in Hi5 cells, affinity purified from the media 
and subjected to size exclusion chromatography as usual. However all the buffers used 
in purification did not contain any calcium. The size exclusion profiles of protein 
prepared in this way show a small peak, corresponding to a molecular weight of about 
double the main peak, next to the main monomeric peak (Figure 2.20). This additional 
peak is not present in the size exclusion profile of these proteins prepared in the 
presence of 2 mM calcium chloride (see Figure 2.3 and Figure 2.5). The lack of calcium 
is therefore resulting in an increased propensity of the protein to self-associate.   
In this preparation I have not tried to strip any calcium already bound to the proteins 
from the cell culture media. zRET-ECD produced in this way does not bind ligand/co-
receptor without the addition of calcium to the buffer (data shown in Figure 4.5), and 
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therefore protein produced in the absence of calcium, does not have sufficient calcium 
bound to adopt a ligand/co-receptor binding competent arrangement. 
 
Figure 2.20 zRET-ECD and CLD(1–4) purification in the absence of calcium 
Size exclusion profiles of (a) zRET-ECD and (b) zRET-CLD(1–4) purified without 
calcium in any of the purification buffers.  
2.8.2 SAXS data collection of calcium-free zRET-ECD proteins at 
SOLEIL with online HPLC 
SAXS data for calcium-free zRET-ECD and zRET-CLD(1–4) was collected at 
Synchrotron SOLEIL using the online HPLC set-up described in section 2.7. Although 
the protein for SAXS analysis was only taken from the monomer peak from size 
exclusion, the online-HPLC trace at the beamline showed the same profile as the 
previous size exclusion trace for both proteins. Analysis of the Rg across the HPLC 
peak, calculated using the Guiner approximation in FOXTROT, confirmed the presence 
of larger molecules in the first peak (Figure 2.21). The Rg across the main peak shows a 
downward trend from 42.2 Å to 40.8 Å for zRET-CLD(1–4) and 43.4 Å to 41.6 Å for 
zRET-ECD.  This is because the two peaks are not fully separated, and therefore the 
data from the main peak is slightly contaminated with larger species.  
This is reflected in the calculation of the molecular weight of the protein from the 
HPLC peak SAXS data (Table 2.9). The calculated molecular weights are still most 
consistent with the protein being predominantly monomeric, but they are higher than 
the calculated molecular weights from the SAXS data of the proteins in the presence of 
calcium by 5–20 kDa (see Table 2.6 for values in the presence of calcium).  




Figure 2.21 Calcium-free zRET-CLD(1–4) and zRET-ECD SAXS data collection with 
online HPLC 
Plots of the Rg of the sample in the beam across the entire HPLC elution peak. The Rg 
and I(0) was calculated from each data collection (frame) SAXS curve using the Guiner 
approximation in FOXTROT. (a) Calcium-free zRET-CLD(1–4). (b) Calcium-free 
zRET-ECD.  
Protein Max q MW from SAXS (kDa) 
Calculated 
MW (kDa) Discrepancy 
Calcium-free 
zRET-CLD(1–4) 0.4 92.8 67.2 38% 
Calcium-free 
zRET-ECD 0.45 101.7 80.8 26% 
Table 2.9 Estimated molecular weight from SAXS data of calcium-free zRET-ECD 
proteins 
Molecular weight (MW) estimate of calcium-free zRET-ECD proteins from SAXS 
based on the area under the curve from a Kratky plot of the HPLC coupled SAXS data. 
Calculation carried out using SAXS MoW server (Fischer et al., 2009).  
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2.8.3 Calcium-free HPLC coupled SAXS data analysis 
The SAXS data from the HPLC peak was fitted using GNOM to generate distance 
distribution functions for zRET-ECD and CLD(1–4) (Table 2.10 and Figure 2.22). The 
determined Rgs from the proteins in the absence of calcium were 2 Å lower than when 
calcium was present. This suggests that the overall shape of the zRET-ECD is more 
globular in the absence of calcium.  
The distance distribution profiles for the calcium-free proteins also indicate that the 
overall shape is more globular in the absence of calcium. Globular proteins distance 
distribution plots show a symmetric peak, and the profiles for the calcium-free proteins 
are more symmetric than those in the presence of calcium (calcium-free: Figure 2.22; 
calcium-bound: Figure 2.14).  
Protein Rg (Å) Rg error (Å) Dmax (Å) I(0) I(0) error 
Calcium-free 
zRET-CLD(1–4) 42.97 0.037 150 5.12E-02 1.46E-05 
Calcium-free 
zRET-ECD 43.9 0.048 160 7.23E-02 4.66E-05 
Table 2.10 Calcium-free zRET-ECD proteins SAXS data processing statistics 
Processing of HPLC coupled SAXS data with GNOM. Table details the maximum 
vector length (Dmax) used in fitting the data, and the real space radius of gyration (Rg) 
and I(0) derived from the fit. 
2.8.4 Ab initio models of calcium-free zRET-ECD proteins 
The fitted data was then used to generate ab initio models of calcium-free zRET-
CLD(1–4) and zRET-ECD, in order to determine a better idea of the shape of the zRET-
ECD without calcium (Table 2.11 and Figure 2.22).  
The final ab initio models of zRET-CLD(1–4) and zRET-ECD show a ‘Z-shape’, rather 
than the ‘L-shape’ of the models with calcium present (calcium-free: Figure 2.22; 
calcium-bound: Figure 2.15). The calcium-free zRET-ECD model is larger than the 
zRET-CLD(1–4) model both around the central portion of the Z and on one of the arms 
of the Z. The ‘Z-shape’ of these models indicates that, as expected, the linear 
relationship between CLD2 and CLD3 has been lost in the absence of calcium: The 
CLD(1–3) model can no longer fit at either end of the zRET-CLD(1–4) ab initio 
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molecular envelope. The ab initio envelopes therefore confirm the role of calcium in 
defining and rigidifying the linear CLD2–CLD3 arrangement.  
The CLD(3–4) arrangement from the calcium containing SAXS model, with 100° bend 
angle between the domains, does fit in both envelopes, and is therefore likely 
maintained. However it was not possible to properly model the arrangement of the 
CLDs in the calcium-free zRET-CLD(1–4) ab initio envelope as before. If the CLD(3–
4) arrangement is placed in the envelope there are two regions of spare density for the 
CLD(1–2): the second arm of the Z-shape, with about 100° bend angle between CLD2 
and CLD3; and folded back against CLD3 in the central region of the Z-shape. 
However neither of these regions properly accommodate the CLD(1–2) structure, and 
models of both these arrangements do not match the experimental data (chi-square > 
20).  I therefore assume that the structure is flexible in the absence of calcium, with the 
CLD(1–2) in more than one position relative to CLD3.  
Protein NSD NSD discrepancy 
zRET-CLD(1–4) 1.000 0.044 
zRET-ECD 0.928 0.039 
Table 2.11 Calcium-free zRET-ECD proteins SAXS ab initio model generation statistics 
Generation of ab initio molecular envelopes with DAMMIF & DAMAVER. Table 
details the mean correspondence (normalised spatial discrepancy, NSD) between the 50 
generated models for each protein. These models are then overlaid and the common 
features are used in generation of a final model shown in Figure 2.22.  




Figure 2.22 SAXS ab initio models of calcium-free zRET-CLD(1–4) and ECD 
Processing the HPLC-coupled SAXS data of zRET-CLD(1–4) and zRET-ECD purified 
in the absence of calcium with GNOM to produce distance distribution plots for ab 
initio modelling. (a) & (c) Experimental SAXS data curves compared with GNOM 
processing fit. S (Å-1) = modulus of the scattering vector, I = intensity of the scattered 
beam at S. (b) & (d) Distance distribution plots derived from fit to the SAXS data. R = 
vector distances within the sample, P(R) = pair distance distribution function. (e) Ab 
initio envelopes of calcium-free zRET-CLD(1–4) and (f) zRET-ECD. 
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2.9 zRET-CLD(1–4) crystals 
Crystallisation screening of the zRET-ECD was unsuccessful. Therefore a few 
additional strategies were tried, including screening zRET-CLD(1–4) and the partially-
deglycosylated zRET-ECD & zRET-CLD(1–4). The strategy that was successful was 
crystallisation of the zRET-CLD(1–4)redsug construct (details and purification of this 
construct are described in section 2.6.3). The equivalent construct of the entire zRET-
ECD has not yet been produced, but given the success of the zRET-CLD(1–4)redsug 
construct this may be a fruitful strategy for future crystallisation trials of zRET-ECD. 
Since the zRET-CLD(1–4)redsug crystals were only produced towards the end of my time 
in the lab, others carried out some of the work described in this section. I produced the 
protein, performed the initial crystallisation screening, and with the help of Dr. Andrew 
Purkiss-Trew, collected and processed the diffraction data from the initial crystals. Mr. 
Phillip Knowles then produced more protein and optimised the crystals. Diffraction data 
from these optimised crystals was collected and processed by Dr. Andrew Purkiss-Trew. 
2.9.1 Crystallisation screening of zRET-CLD(1–4)redsug and 
characterisation of crystals from initial crystallisation hits 
Crystallisation screening of zRET-CLD(1–4)redsug was carried out using material after 
size exclusion chromatography and after both size exclusion chromatography and anion 
exchange chromatography, with the three peaks from anion exchange screened 
separately. Crystals were produced in three different conditions, detailed in Table 2.12. 
Several crystals from each of the three conditions were harvested, cryoprotected and 
flash frozen in liquid nitrogen. Crystal X-ray diffraction screening was carried out at 
Diamond Light Source I-24. The smaller crystals from the sodium formate and the 
MMT buffer/PEG 1500 condition were not promising. No diffraction was seen for any 
of the sodium formate crystals and only a few spots around the beamstop were seen for 
the MMT buffer/PEG 1500 condition crystals.  
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Protein Kit reference 
Crystallisation 
condition Crystal size 
Test X-ray 
diffraction 




25% PEG 1500, 
0.1 M MMT buffer pH 6.5 
50×25×25 
μm a few spots 
SE & IE, 
7 mg/ml Salt Rx C7 
3.5 M sodium formate, 






7.6 mg/ml JCSG+ D1 
24% PEG 1500, 
20% glycerol 120×120 μm 7.5 Å 
Table 2.12 zRET-CLD(1–4)redsug crystals from initial screening 
Details of zRET-CLD(1–4)redsug crystals produced using commercial kits. Crystal X-ray 
diffraction screening was carried out at Diamond Light Source microfocus beamline 
I24. SE & IE = size exclusion and ion exchange purified protein. SE = just size 
exclusion purified (see Figure 2.12). Commercial kits listed: Wizard III/IV (Emerald 
Biosciences), Salt Rx (Hampton Research), JCSG+ (Qiagen). PEG = polyethylene 
glycol, MMT buffer = L-Malic acid, MES, Tris buffer. 
The larger crystals, produced in the PEG 1500/glycerol condition, were better (Figure 
2.23a). Diffraction to between 7.5 and 9 Å was seen. Some evidence of multiple lattices 
was observed. A dataset from the crystal giving the best-looking diffraction pattern was 
collected in order to calculate the unit cell parameters.  
The dataset was processed using D*TREK, which identified the space group as P2 (or 
P21), with refined cell dimensions of a = 78.51 Å, b = 88.86 Å, c = 195.6 Å, α =  90°, β 
= 92.71° and γ = 90°. Cell content analysis in CCP4 suggested there were 4 or 5 
molecules in the asymmetric unit (probability of 0.42 and 0.48 respectively). This 
crystal therefore has a reasonable lattice and so optimisation of this condition to 
generate crystals with a single lattice and to improve resolution was carried out.   
2.9.2 Optimisation of zRET-CLD(1–4)redsug crystals and data collection 
Phillip Knowles reproduced the PEG 1500/glycerol condition in a larger drop size (2 µl) 
resulting in some better diffracting, though not larger, crystals. The best diffracting 
dataset obtained so far from one of these zRET-CLD(1–4)redsug crystals was collected at 
the ESRF on beamline ID23. The dataset is anisotropic, with data to 3.5 Å in the best 
direction, and to only 6.5 Å in the other direction. Spots from a second lattice were also 
evident at low resolution (Figure 2.23b). Despite these limitations Dr. Andrew Purkiss 
attempted processing the dataset, and this analysis revealed some details about the 
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arrangement of the molecules in the crystal. (Data collection statistics are detailed in 
Table 2.13). 
Data collection 
X-ray source ESRF ID23-2 
Wavelength / Å 0.8726 
Space group P1 
Unit cell dimensions   
            a, b, c / Å 68.44, 108.86, 110.26 
            α, β, γ / ° 106.13, 98.00, 102.85 
Resolution / Å 40.5–3.77 (3.63–3.50) 
Total reflections 69366 
Unique reflections 36005 
Redundancy 1.93 
Completeness / % 98.1 (98.4) 
I/σ 3.7 (0.7) 
Rmerge / % 10.6 (50.7) 
Wilson B-factor / Å2 72.0 
Table 2.13 Data collection statistics for zRET-CLD(1–4)redsug 3.5 Å dataset. 
 
The data were processed in D*TREK. Indexing was carried out using spots between 3–
8 Å where data from only a single lattice was apparent. The spacegroup was found to be 
P1 with cell dimensions of a = 68.44 Å, b = 108.86 Å, c = 110.26 Å, α = 106.13°, β = 
98.00° and γ =102.85°. Cell content analysis suggested there were 4 zRET-CLD(1–
4)redsug molecules in the asymmetric unit. 
Patterson analysis of the processed data with MOLREP (Vagin and Teplyakov, 1997) 
showed a weak pseudo-translation peak half way along the z-axis (Figure 2.23c). The 
peak height at (x = 0, y = 0, z = 0.5) is 21.24, about a third of the height of the origin 
peak, which is 63.82, but significantly higher than the background peaks all with a 
height of < 3.25. There is also some evidence of two-fold non-crystallographic 
symmetry from the self-rotation function, with a noisy peak of 6.11 at chi-square = 180° 
(Figure 2.23d), which is half the height of the origin peak (12.89) and above the 
background peaks of < 4.5. These findings suggest the four zRET-CLD(1–4) molecules 
are found in pairs related by two-fold symmetry with each pair related to the next by 
translational pseudosymmetry in the crystal. The presence of translational 
pseudosymmetry may indicate that the unit cell was originally half the apparent size 
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along the z-axis, but the lattice was disrupted during freezing of the crystal. 
Optimisation of the cryoprotection may therefore be necessary.  
Optimisation of the crystallisation condition to produce better diffracting, single lattice 
crystals, to allow the zRET-CLD(1–4) structure to be solved is ongoing. It is hoped that 
with data to a reasonable resolution (3–3.5 Å or better) the structure will be solved by 
molecular replacement using the hRET-CLD(1–2) structure as the search model. If this 
is unsuccessful the calcium binding site will be exploited for heavy atom binding to 
determine the phases, analogous to the method used for solving the hRET-CLD(1–2) 
structure with a samarium derivative (Kjaer et al., 2010).  
 
Figure 2.23 zRET-CLD(1–4)redsug crystals, diffraction and patterson analysis 
(a) 120×120 µm zRET-CLD(1–4)redsug crystals grown in 24% PEG 1500 and 20% 
glycerol. (b) Best direction diffraction image from the anisotropic zRET-CLD(1–4)redsug 
dataset. (c) X-axis patterson image, showing a peak at half the unit cell length along the 
z-axis. (d) Self rotation function at chi = 180°. 
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2.10 Probing the structure of the CRD 
The zRET-ECD SAXS model indicated that the CRD is packed against the CLD4. This 
suggested that producing a construct containing both CLD4 and CRD together may be 
soluble compared to producing individual domains and could therefore be a tractable 
target for crystallisation. Given the CRD’s known involvement in binding ligand/co-
receptor, as well as being the site of a number of cancer-causing mutations, a structural 
understanding of this completely structurally unknown domain would be particularly 
valuable.  
2.10.1 CRD sequence analysis and secondary structure prediction 
The zebrafish RET-CRD contains 14 cysteine residues and the human 16. Secondary 
structure prediction suggests that the zRET-CRD may be 21% alpha helix and 9% beta 
strand, although the confidence of the prediction for some of the elements is low. The 
zRET-CRD is also predicted to be around 50% disordered (Figure 2.24).  
 
Figure 2.24 Secondary structure prediction for zRET-CRD 
Secondary structure prediction results for zRET-CRD using PHYRE2 (Kelley and 
Sternberg, 2009). 
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2.10.2 zRET-CLD4CRD protein expression and purification 
In order to probe the structure of this intriguing portion of the RET-ECD further I 
designed two zRET-CLD4CRD constructs with differing N termini. The longer 
construct contains residues 373–626 and the shorter residues 382–626. The ambiguity 
of the end of the hydrophobic CLD3–CLD4 linker and the start of CLD4 is reflected in 
the two constructs, since CLD4 doesn’t contain the cadherin consensus PXF/Y motif, 
which defines the start of most cadherin domains (CLD alignment to classical cadherin 
domains is shown in Figure 1.7). The same pBacPAK transfer vector and expression 
cassette used in the zRET-ECD production, featuring the zRET native signal sequence 
and a C-terminal Protein A tag, was used for the CLD4CRD baculovirus production. 
zRET-CLD4CRD protein expression in Hi5 cells from these baculoviruses was around 
1.4 mg per litre cells for both the longer and shorter constructs. 
The affinity purified proteins for both the longer and shorter constructs were part 
monomer, part dimer. The dimer is disulphide-linked, since the amount of dimer is 
reduced upon addition of reducing agent to the SDS-PAGE loading buffer (Figure 2.25). 
The two oligomeric forms could be separated by size exclusion chromatography and ion 
exchange chromatography (Figure 2.26). The second (monomer) peak from ion 
exchange of the shorter construct has a shoulder, which contains both monomer and 
dimer. Due to this I decided the best construct to pursue for crystallisation was the 
longer one (zRET-CLD4CRD373–626) since the purified and separated monomer and 
dimer would be more homogeneous. 
 
Figure 2.25 Disulphide-linked zRET-CLD4CRD dimer 
SDS-PAGE of affinity purified zRET-CLD4CRD373–626 with or without β-
mercaptoethanol (βME) in the sample loading buffer.  
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Figure 2.26 zRET-CLD4CRD purification 
Size exclusion and anion exchange chromatography of long and short zRET-CLD4CRD 
proteins, showing separation of the monomeric and dimeric species. Size exclusion 
using Superdex 200 column of (a) zRET-CLD4CRD373–626 and (d) zRET-CLD4CRD382–
626. Anion exchange using HiTrap Q column of (b) zRET-CLD4CRD373–626 and (e) 
zRET-CLD4CRD382–626. (c), (d), (g) and (h) Non-reducing SDS-PAGE of 
chromatography fractions. 
2.10.3 The intermolecular disulphide link in the CLD4CRD dimer 
The fact that the zRET-CLD4CRD proteins are expressed both as monomers and 
disulphide-linked dimers is curious since no disulphide-linked dimers are observed in 
the similarly produced whole zRET-ECD. Circular dichroism of the separated zRET-
CLD4CRD382–626 monomer and dimer showed that both species were folded and had 
almost identical circular dichroism spectra (Figure 2.27b). Dimerisation therefore does 
not affect the fold of the protein.  Furthermore the ability of zRET-CLD4CRD to form 
disulphide-linked dimers is not due to the produced protein being unfolded.  
To detect if any free cysteines were present in the purified zRET-CLD4CRD373–626 
monomer and dimer species we used Ellman’s reagent. This showed that the monomer 
contained no reactive unpaired cysteines and analysis of the dimer showed there was 
approximately one unpaired cysteine per five protein molecules. These data show that 
the monomers have been able form all the intramolecular disulphides and this species 
should therefore be stable. The presence of a low level of free cysteines in the dimer is 
presumably because the dimer must contain two intermolecular disulphides in order for 
all the cysteines to be paired, and therefore in a subset of the dimers there is only one 
intermolecular disulphide leaving two unpaired cysteines in the dimer. (Mr. Phillip 
Knowles performed this Ellman’s assay.) 
2.10.4 Circular dichroism suggests the CRD has a largely unstructured 
fold 
Circular dichroism measurements were carried out on purified zRET-ECD, zRET-
CLD(1–4) and zRET-CLD4CRD382–626 to give some indication of the secondary 
structure of the CRD. These measurements were carried out by Dr. Stephen Martin at 
the National Institute of Medical Research. As expected the zRET-CLD(1–4) profile 
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shows a folded, predominantly beta sheet protein. The zRET-ECD profile is fairly 
similar to that of CLD(1–4), again suggesting a predominantly beta sheet structure. 
There is a small difference between the two curves. Taking this difference and plotting 
it normalised to the average residue weight gives a noisy curve, from which some 
general interpretations about the CRD can be made (Figure 2.27). Analysis of the 
secondary structure content from the derived CRD curve suggests a folded domain with 
perhaps only a third of the domain consisting of beta sheet and alpha helical elements. 
Although given the high level of noise in derived CRD curve and the limitations of 
secondary structure prediction from circular dichroism data these values are indicative 
only (Table 2.14).  
 
Figure 2.27 Circular dichroism spectra of zRET-ECD proteins 
(a) Far-UV circular dichroism spectra of zRET-ECD, zRET-CLD(1–4) and zRET-
CLD4CRD382–626. The circular dichroism data is shown as the circular dichroism 
absorption coefficient calculated on a mean residue weight basis (ΔϵMRW). The 
derived zRET-CRD spectrum is calculated from the difference between the zRET-ECD 
and zRET-CLD(1–4) spectra. (b) Comparison between the circular dichroism spectra of 
size exclusion separated monomeric and dimeric zRET-CLD4CRD382–626. 
 









dimer ECD CLD(1–4) 
CRD 
(derived) 
Alpha helix 5% 5% 7% 5% 10% 
Beta strand 37% 38% 35% 36% 26% 
Turn 21% 21% 23% 25% 19% 
Unordered 36% 35% 36% 34% 46% 
Table 2.14 Predicted secondary structure of zRET-ECD proteins based on circular 
dichroism spectra 
The table details predicted secondary structure from analysis of the circular dichroism 
spectra. The values shown are the averaged results from three different standard 
programs (CONTIN, SELCON and CDSSTR; Martin and Schilstra, 2008; Sreerama 
and Woody, 2000). 
2.10.5 Crystallisation trials of zRET-CLD4CRD 
Preliminary crystal trials of the size-exclusion purified zRET-CLD4CRD monomer and 
dimer species, conducted by both Mr. Phillip Knowles and I at 20 °C using a range of 
commercial crystallisation screening kits failed to produce protein crystals. The 
monomer was screened at 9 mg/ml and the dimer at 3 mg/ml. Changes to the protein 
buffer composition or removal of the glycosylation sites could be tried in future 
attempts at crystallisation, although the ability of the zRET-CLD4CRD proteins to form 
disulphide-linked dimers hints at flexibility within this protein.  
2.11 Conclusions 
In summary in this chapter I have presented the successful production of properly 
folded, highly soluble zRET-ECD, zRET-CLD(1–4) and zRET-CLD4CRD proteins in 
insect cells, at yields amenable to structural characterisation using X-ray 
crystallography and SAXS methods.  
High quality SAXS data, collected for zRET-ECD and zRET-CLD(1–4) using an online 
HPLC purification step, revealed the arrangement of the four CLDs and the CRD in the 
zRET-ECD in solution. Due to conservation of the elements defining the overall 
architecture of the RET-ECD between lower vertebrates and mammals this arrangement 
is likely conserved amongst vertebrate RETs. The clamshell arrangement of CLD(1–2) 
previously observed in the human CLD(1–2) crystal structure, is maintained by a 
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conserved disulphide, and fits well into the zRET SAXS envelopes. The quasi-linear 
arrangement of CLD2–CLD3 is defined and rigidified by calcium binding to conserved 
acidic residues, confirmed by the flexibility at this junction observed by SAXS analysis 
of calcium-free zRET-ECD. The CLD3–CLD4 junction displays an atypical cadherin 
domain arrangement with a 100° bend between the two domains, presumably defined 
by the conserved hydrophobic linker between these domains. The CRD apparently folds 
back on CLD4 in the context of the whole zRET-ECD. However in the absence of 
CLD(1–3) the CLD4–CRD arrangement may be different, indicated by the formation of 
disulphide-linked trans-dimers when these domains are expressed alone. This model of 
the overall architecture and domain arrangement of the RET-ECD provided a necessary 
basis for interpreting an EM 3D reconstruction of the RET-ECD/GDNF/GFRα1 ternary 
complex presented in the next chapter.  
In this chapter I have also presented a method for the crystallisation of zRET-CLD(1–4), 
following reduction of the sugar content of CLD3 and CLD4 by site directed 
mutagenesis of N-linked glycosylation sites. These crystals require optimisation to 
improve the resolution of the X-ray diffraction data and allow the structure to be solved. 
If this is successful the crystal structure will provide key insights into the structural 
basis for the CLD3–CLD4 bend, as well as revealing the lower vertebrate specific 
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Chapter 3. Electron microscopy reconstruction of 
the human RET ectodomain bound to ligand and co-
receptor  
3.1 Chapter aims 
This chapter describes the production of a negative stain electron microscopy (EM) 3D 
reconstruction of the extracellular portion of a human RET/ligand/co-receptor ternary 
complex. Known or modelled structures of individual RET ternary complex 
components were fitted into the 3D reconstruction to give an interpretation of the 
arrangement of the components in the complex and generate a pseudo-atomic model. 
Other models were considered but a single ‘best’ interpretation emerged from this 
analysis. The overall aims of this chapter were to: (1) define the architecture of the 
RET-ECD/GDNF/GFRα1 ternary complex, including the relative positioning of protein 
subdomains and interaction regions; (2) aid the interpretation of published 
human/Xenopus chimeric RET studies as well as crosslinking and mutational 
investigations of the interaction between RET and ligand/co-receptor; (3) investigate 
any conformational changes which might occur in the RET-ECD upon ligand 
interaction by comparing a ligand-free form of RET-ECD with its conformation within 
the EM 3D reconstruction. 
3.2 A negative stain EM 3D reconstruction of a mammalian 
ternary complex 
3.2.1 Statement of contributions 
The work described in this chapter was a collaborative effort primarily between myself, 
Dr. Svend Kjær (Cancer Research UK, London Research Institute) and Dr. Fabienne 
Beuron (Imperial Cancer Research, London). Dr. Svend Kjær produced the mammalian 
ternary complex sample. Dr. Fabienne Beuron produced the EM grids of the sample, 
collected the images, and did the initial sample characterisation. Under the supervision 
of Dr. Edward Morris, Dr. Fabienne Beuron and Dr. Paula da Fonseca, I picked 
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particles, generated classes, and performed angular reconstitution to generate a 3D 
reconstruction. Dr. Fabienne Beuron did some additional particle picking and performed 
the subsequent projection matching procedure to generate the final 3D reconstruction. 
3.2.2 Protein production 
In order to look at the architecture of a human RET/ligand/co-receptor complex Dr. 
Svend Kjær produced and assembled a recombinant ternary complex of the human 
RET-ECD with human GDNF (ligand) and rat GFRα1 (co-receptor), subsequently 
referred to as the mammalian ternary complex (mTC). Specifically, the mTC sample 
consisted of: the entire human RET ECD (residues 29–634, following signal sequence 
cleavage; hRET-ECD); the whole rat GFRα1, excepting 41 C-terminal residues 
containing the GPI-link site and GPI signal sequence (residues 19–427, following signal 
sequence cleavage; rGFRα1); and the entire mature human GDNF (residues 77–211; 
hGDNF). The hRET-ECD construct contained two mutations (C87R and C216S) to 
remove the two unpaired destabilising cysteines in hRET-CLD(1–2), in order to 
improve expression levels in mammalian cells, as discussed in (Kjaer et al., 2010). The 
rGFRα1 construct contained a single asparagine to glutamine (N59Q) mutation to 
remove a partially occupied N-linked glycosylation site.  
The hRET-ECD and rGFRα1 were expressed in stably transfected Chinese Hamster 
Ovary (CHO) Lec8 cells as TEV-protease cleavable Protein A fusion proteins using the 
method described in (Kjaer et al., 2010). 2 litre batches of CHO cells were grown in 
suspension for 4–5 days prior to harvesting the cell supernatant. Both hRET-ECD and 
rGFRα1 Protein A fusion proteins were then purified from the harvested and filtered 
media by incubation with 0.5 ml IgG-sepharose resin overnight at 4 °C. Following 
washing of the resin hRET-ECD was eluted by cleavage of its Protein A tag with TEV-
protease. The washed rGFRα1-TEV-Protein A fusion protein bound to IgG-sepharose 
resin was set aside for ternary complex assembly. (Further details are provided in the 
Materials and Methods section 7.5.) Amgen (Thousand Oaks, USA) kindly supplied the 
recombinant mature human GDNF, which they produced in Escherichia coli.  
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3.2.3 Assembly of the mTC 
The rGFRα1 was produced with a C-terminal TEV cleavable Protein A tag. This fusion 
protein immobilised on IgG-sepharose and formed the basis for mTC assembly. Briefly, 
to assemble the mTC complex excess hGDNF (Amgen, Thousand Oaks) was added to 
the immobilised rGFRα1, allowed to bind for one hour, and then unbound protein was 
removed by washing. Affinity-purified hRET-ECD was subsequently added to the 
immobilised rGFRα1/hGDNF complex in the presence of 1 mM calcium chloride and 
allowed to bind for one hour at 4 °C. The assembled IgG-sepharose-bound mTC was 
then washed with mTC buffer to remove any unbound hRET-ECD. Finally the mTC 
was eluted from the IgG-sepharose by addition of TEV protease to cleave off the 
rGFRα1 Protein A tag and liberate the mTC from the resin. The mTC was subsequently 
purified by size exclusion chromatography and the complex stoichiometry assessed by 
SDS PAGE and TapeStation (Agilent) analysis. This confirmed equimolar of the three 
component proteins were present in the purified complex (Figure 3.1a). The theoretical 
molecular weight of the 2 hRET-ECD/2 rGFRα1/1 hGDNF dimer mTC is 264.4 kDa 
plus sugar. 
3.2.4 Negatively stained EM grid production and image collection 
mTC samples from individual 1 ml size exclusion fractions were applied to carbon grids 
and negatively stained with 2% (w/v) uranyl acetate. The ‘best’ fraction was selected by 
visual inspection on the basis of sample homogeneity. Images of the selected grid for 
subsequent analysis were taken on a Tecnai T20 electron microscope, equipped with a 
4000×4000 pixel CCD detector, at 80000× magnification giving a sampling of 2.17 
angstroms/pixel (Figure 3.1a). 
3.2.5 Particle picking and class generation 
Particle images were manually picked from EM grid images with a 192×192 pixel box 
size (416.64 Å2) using Boxer, part of the EMAN suite (Ludtke et al., 1999). A stack of 
11000 particles was generated. The particle images were coarsened to 4.34 Å/pixel, 
high pass filtered to 200 Å in IMAGIC (van Heel et al., 1996), normalised and initially 
low pass filtered to 30 Å in SPIDER (Frank et al., 1996). Given the low signal to noise 
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ratio in EM images of proteins, particles images of the same view are aligned, assigned 
to classes, and averaged to increase the signal to noise ratio. Classes were initially 
generated using EMAN reference-free alignment and classification (Ludtke et al., 1999), 
and subsequently by alignment to the 3D reconstruction using SPIDER (Frank et al., 
1996) and classification in IMAGIC (van Heel et al., 1996). Two distinctive class 
averages were immediately apparent: a ‘figure of eight’ view (third class in Figure 3.1c), 
containing an apparent two-fold axis, and a ‘leg’ view (sixth class in Figure 3.1c).  
 
Figure 3.1 Negative stain EM of the mTC 
(a) SDS-PAGE of the mTC following size exclusion chromatography with a Superose 6 
column (GE Healthcare). (b) Representative image of the mTC EM grid negatively 
stained with 2% (w/v) uranyl acetate. (c) Representative picked particle images after 
filtering and normalisation. (d) Corresponding representative class averages. 
3.2.6 Producing a 3D reconstruction by angular reconstitution 
Multi-variate statistical analysis (MSA) (van Heel, 1984) of the centred particle image 
stack was carried out to generate eigenimages, which indicated the particle likely 
possessed two-fold symmetry, commensurate with the apparent two-fold in the ‘figure-
of-eight’ view (Figure 3.2a). The eigenimages also indicated possible three-fold 
symmetry. However further analysis revealed these eigenimages resulted predominantly 
from the randomly rotationally orientated ‘leg’ view particles, which are not three-fold 
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symmetric, but since the legs are at a 120° angle they give rise to an apparent three-fold 
in the eigenimages when these particles are randomly rotationally orientated. The 3D 
reconstruction was therefore produced applying C2 symmetry, using the angular 
reconstitution method (van Heel, 1987) in IMAGIC.  
The 3D reconstruction process was started using a two-fold symmetrical ‘figure of eight’ 
view and a ‘leg’ view shown in Figure 3.2b, since these seemed likely to be orthogonal 
views. In the ‘start-up’ of the reconstruction using IMAGIC these views were assigned 
to be around 100° apart. These two class averages were then used as anchors (or 
references) to assign Euler angles to a larger selection of class averages. Generation of a 
3D reconstruction based on this Euler assignment, and visual comparison of re-
projections from this 3D with the input class averages allowed a small selection of 
classes with apparently correctly assigned Euler angles to be defined. These were then 
used as anchors for reassignment of Euler angles of the larger selection of class 
averages. Once again, correctly assigned class averages were selected and used as 
anchors for the next round of Euler assignment and 3D reconstruction generation. This 
process was then repeated until no new class averages were added to the anchor set. The 
resulting 3D reconstruction from the correctly assigned class averages was then used as 
a reference for the generation of new classes from the particle stack. These new class 
averages were assigned Euler angles using the anchor set, and the iterative process of 
trying to increase the number and range of class averages used in the 3D reconstruction 
repeated. 
Initial attempts using this method were unsuccessful at getting beyond a very small 
selection of correctly Euler angle assigned class averages. Alternative pairs of classes 
for the initial start-up were also tried, but this was also unsuccessful.  
Critical assessment of the stack of particle images showed a wide distribution of stain 
levels, and many poorly defined particle images. Since this variability and poor signal 
to noise ratio will negatively impact particle image alignment and class assignment, a 
stack of around 2000 well stained clearly defined particles images was selected. It was 
hoped that this would result in the production of better classes, due to improved particle 
alignment and class assignment, which would then aid the production of a 3D 
reconstruction. 
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Classes were generated from this new stack by alignment to forward projections of the 
best previous 3D reconstruction, followed by MSA based class assignment. Repeating 
the start-up, and anchor set development procedure using these class averages was 
successful. Fresh classes were then generated by alignment of the particle images to 
forward projections of the new 3D reconstruction followed by MSA class assignment. 
The resulting class averages were then assigned Euler angles using the previous anchor 
set, and a new 3D reconstruction was produced from the correctly assigned class 
averages. This process of improved class generation by alignment of the stack to the 
most recent 3D, alternated with Euler assignment and generation of a new 3D 
reconstruction, was iteratively repeated until no further improvement in the class 
averages or the 3D was observed. 
3.2.7 Refining the 3D reconstruction using projection matching 
The angular reconstitution generated 3D reconstruction was subsequently refined by 
projection matching. For this step the entire 11000 particle image stack was used, since 
fresh sample was not available (due to expression problems with rGFRα1) to expand 
the more critically selected stack. For this step the low-pass filter was changed to 18 Å. 
The forward projections from the angular reconstitution generated 3D reconstruction 
were much better references for particle alignment and class assignment, than those 
used in the initial development of the 3D reconstruction. Therefore, reasonable particle 
alignment and class assignment even with the less well-defined particle images was 
observed, allowing the use of this larger particle image stack.  
The projection matching procedure involved Euler angle assignment of classes based on 
matching to forward projections of the current 3D reconstruction, which was carried out 
using IMAGIC. Correctly Euler angle assigned class averages were selected by manual 
comparison between the class and the matched forward projection. These correctly 
Euler angle assigned classes were then used to generate a 3D reconstruction, which was 
then used as the reference for the next round of class generation and projection 
matching. This procedure was repeated until the range of class averages included in the 
reconstruction, and the quality of the match between class averages and re-projections 
ceased to improve. Details of the final 3D reconstruction at 27.8 Å resolution are shown 
in Figure 3.2, and images of the 3D reconstruction are shown in Figure 3.3. 




Figure 3.2 Details of the mTC 3D reconstruction 
3D reconstruction of the mTC from the 11000 particle stack. (a) Eigenimages of the 
whole stack and two subsets as annotated. (b) The two near orthogonal class averages 
used to initiate the 3D reconstruction process are shown. (c) A selection of input class 
averages (classes) and (d) the corresponding re-projections from the final 3D 
reconstruction are shown. (e) Map of Euler angles assigned to the input class averages 
in the final 3D reconstruction. (f) Fourier shell correlation to determine map resolution.  




Figure 3.3 Mammalian ternary complex 3D reconstruction  
Surface view of the mTC reconstruction, with the ‘wing’, ‘centre’ and ‘base’ regions 
(discussed in the text) coloured purple, green and blue respectively. 
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3.3 Producing a model of the mammalian ternary complex 
based on the EM 3D reconstruction 
3.3.1 Known structures and models of components 
Crystal structures of hRET-CLD(1–2) (Kjaer et al., 2010) and the hGDNF/rGFRα1-
D2D3 (Parkash et al., 2008) complex have been published previously. As described in 
Chapter 2, I have produced a SAXS-based model for the zRET-ECD defining the 
arrangement of the four CLDs. GFRα1 D1 is reliably predicted to have the same fold as 
the GFRα D2 and D3 (Leppanen et al., 2004), and can therefore be modelled with 
reasonable confidence using the PHYRE2 structure prediction program (Kelley and 
Sternberg, 2009). This leaves the RET-CRD, the 44 residue linker between GFRα1 D1 
and D2, the 75 residue C-tail of GFRα1 and the 39 residue N-terminal tail of GDNF, for 
which there is no structural information and which cannot be reliably modelled. As 
described in section 2.10.4, the 126 residue RET-CRD lacks regular secondary structure 
elements but is folded and likely defined by the 8 (in hRET) predicted disulphide 
bridges. The other un-modelled elements are all predicted to be unstructured 
tails/linkers (Figure 3.4). If any of these elements are completely randomly arranged 
they will not contribute to the EM 3D reconstruction, since they would have been 
‘averaged out’ in the class averages.  
3.3.2 Assumptions used in fitting mTC components into the EM map 
These crystal structures, homology models and the SAXS-derived RET-ECD model 
were docked into the final 3D reconstruction map (Figure 3.3) using CHIMERA in 
order to generate a preliminary model of the arrangement of the mTC components. This 
fitting was carried out based on the following assumptions:  
First, the intrinsic two-fold symmetry of the GDNF dimer was assumed to be co-
incident with the mTC two-fold symmetry. The hGDNF/rGFRα1-D2D3 complex 
crystal structure also exhibits two-fold symmetry and a 2:2 stoichiometry. Therefore it 
seemed reasonable to assume the ligand/co-receptor two-fold axis is coincident with the 
mTC EM map two-fold axis.  
 




Figure 3.4 Structural models for the RET ternary complex components 
(a) SAXS-derived model of zRET-ECD, with CLDs shown in surface view at 4 Å. It is 
assumed that the overall arrangement of the CLDs in hRET is equivalent to zRET. (b) 
Surface view at 4 Å of the hGDNF/rGFRα1-D2D3 crystal structure (PDB 2V5E; 
Parkash et al., 2008) and structure prediction model of hGFRα1-D1. Predicted 
unstructured elements of GFRα1 and GDNF are shown schematically as dashed lines. 
Second, the arrangement of the human RET CLDs is assumed to a lesser or greater 
extent to match that seen in the zebrafish RET-ECD SAXS-based model. The 
conservation of the structural elements that define the arrangement of the CLDs in RET 
between human and zebrafish was discussed in the previous chapter (section 2.2). The 
basis for assuming that the arrangement of the CLDs is mostly maintained between the 
RET-ECD alone, as defined by SAXS, and the RET-ECD when bound to ligand/co-
receptor in the mTC are as follows: The clamshell arrangement of CLD(1–2), as seen in 
the hRET-CLD(1–2) crystal structure, is assumed to be maintained in the mTC since the 
arrangement is tethered by a conserved disulphide between CLD1 and CLD2. The 
CLD2–CLD3 arrangement is maintained by calcium ions coordinated by conserved 
calcium binding residues at the CLD2–CLD3 junction. Calcium is known to be required 
for ternary complex formation (Anders et al., 2001; Nozaki et al., 1998), thus we 
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assume the CLD(1–3) interdomain angles will be conserved and maintained. However 
the 100° bend angle between the CLD3 and CLD4, as determined by my SAXS analysis, 
cannot be assumed to be maintained in the mTC with such confidence. The linker 
between CLD3 and CLD4 is conserved between human and zebrafish RET, but there is 
no reason to think it may not be subject to a conformational change upon ligand/co-
receptor binding. Furthermore, the possible apparent rotation of CLD4 between the 
SAXS-based models of zRET-CLD(1–4) and zRET-ECD, creates another layer of 
uncertainty about the arrangement of this interdomain junction in the ternary complex. 
As a starting point the zRET-ECD SAXS-based model including the CLD3–CLD4 
arrangement was used without alteration to fit into the 3D reconstruction, bearing in 
mind the possibility of variation in the CLD3–CLD4 arrangement.  
Finally, the arrangement of the hGDNF/rGFRα1-D2D3 complex was assumed to be the 
same as that observed in the crystal structures. Comparison between the published 
crystal structures of hGDNF showed that the intermonomer angle in the disulphide-
linked dimer can vary from 146–168° (Parkash and Goldman, 2009). However, despite 
differences in the hGDNF structure in the two published hGDNF/rGFRα1-D2D3 
complexes (PDB 2V5E (Parkash et al., 2008) & 3FUB (Parkash and Goldman, 2009)) 
the overall organisation of the complex is very similar with the distance between the 
putative RET binding sites on GFRα1 near identical (Parkash and Goldman, 2009). 
Both of these crystal structures were used in fitting and 2V5E, which has a GDNF 
intermonomer bend angle of 160°, was chosen based on a slightly improved fit for 
GDNF. The assumption that the arrangement of the hGDNF/rGFRα1-D2D3 complex is 
unchanged from this crystal structure in the mTC is reasonable for fitting in the first 
instance given the low resolution of the EM map, but the known flexibility of GDNF 
means that the precise arrangement may deviate from the PDB 2V5E structure by up to 
20°.  
3.3.3 Fitting the mTC components into the EM map 
Based on these assumptions and considerations, the models depicted in Figure 3.4 were 
fitted into the 3D reconstruction map. Fitting was carried out manually in CHIMERA 
followed by use of CHIMERA’s ‘fit-in-map’ tool whenever possible. To arrive at the 
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most appropriate interpretation of the arrangement of the RET ternary complex 
components we considered a number of different interpretations. The best fit for the 
GDNF/GFRα1-D2D3 crystal structure was found to be in the centre of the map co-
incident with the 2-fold (correlation coefficient = 0.81, Figure 3.5). This left the 
possibility of the RET-ECD either being on the ‘inside’ of the 3D reconstruction, 
occupying predominantly the base and central regions of the map or located wrapped 
around the ‘outside’ of the object, in the wing regions of the map (the different regions 
are annotated in Figure 3.3). The best interpretation, based on the correlation coefficient 
between the map and the fitted RET-CLD(1-4), was found to be with RET-ECD in the 
wings of the complex, which I will discuss below. Further on in this chapter I will also 
discuss one of the considered RET ‘inside’ interpretations, since it has important 
ramifications for the lack of involvement of the previously observed crystallographic 
CLD(1–2) dimer in the mTC.  
3.3.4 Interpretations of the 3D reconstruction with external RET-ECD 
With the GDNF/GFRα1-D2D3 crystal structure fitted in the centre of the map, the 
‘wings’ of the 3D reconstruction are the largest stretches of unexplained well-connected 
density. It is striking how well the zRET-ECD SAXS-model fits into these ‘wings’ 
without any alterations to the CLD arrangement. It is not a unique solution however, 
since either orientation of the RET-ECD model can be accommodated within the 3D 
map with the same correlation coefficient (0.82). I define each orientation as ‘central 
CLD4’ (Figure 3.5a) and ‘central CLD(1–2)’ (Figure 3.5b). Positioning RET with the 
CLD4’s towards the centre of the map, as in the ‘central CLD4’ model, is also the most 
logical of the two possible RET configurations since there is available density near to 
CLD4 for the CRD to occupy. This would position the CRDs near the base of the 
complex close to one another, consistent with the transmembrane domains interacting in 
the native full-length complex (Kjaer et al., 2006). This central CLD4 model was 
therefore selected as the current best interpretation since all the components with known 
structure fit well within the map, and the remaining unexplained density could readily 
accommodate the remaining elements (RET-CRD; GFRα-D1; GFRα-Ctail). The 
implications of this ‘central CLD4’ interpretation are discussed below.   




Figure 3.5 Fit of the RET-ECD into the wings of the 3D reconstruction 
(a) Surface view of the mTC reconstruction, with the ‘wing’, ‘centre’ and ‘base’ regions 
coloured purple, green and blue respectively. (b)&(c) Transparent surface view of the 
mTC 3D reconstruction, with fitted RET, GFRα1 and GDNF structures shown in 
ribbon representation. Two alternative orientations of RET are shown in (b) and (c). 
3.3.5 Implications of the ‘central CLD4’ interpretation of the mTC 3D 
reconstruction 
Of the possible models based on the assumptions and considerations described in 
section 3.3.2, the best model places the ligand/co-receptor complex in the centre of the 
complex, with RET-CLD4CRD drawn together towards the base of the complex, and 
CLD(1–3) splayed apart wrapping around the ligand/co-receptor (Figure 3.6). This 
arrangement results in multiple contacts between RET and both GDNF and GFRα1-
D2D3, and also predicts the location of the unmodelled elements.  
3.3.5.1 RET-CLD(1–3):GFRα1-D3 contacts 
Intriguingly, the mammal-specific CLD1 surface, involved in the hRET-CLD(1–2) 
crystallographic dimer, is contacting the GFRα1-D3. The CLD(1–2)-CLD3 junction is 
also weakly contacting the co-receptor. This may explain both the calcium dependence 
of the interaction with ligand/co-receptor, and the higher vertebrate species specificity 
conferred by CLD1, 2 and 3 in the ligand/co-receptor interaction (Kjaer and Ibanez, 
2003a).  




Figure 3.6 Best interpretation of the EM map 
Transparent surface view of the mTC 3D reconstruction, with fitted RET, GFRα1 and 
GDNF structures shown in surface representation at 4 Å. 
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3.3.5.2 RET-CRD:GDNF contacts 
CLD4 is close to the ligand/co-receptor junction, and by extension the CRD is 
presumably, at least in part, occupying the available density adjacent to CLD4 engaging 
GDNF and GFRα1-D2. This places the CRD, at least partly, in a similar position to that 
observed by SAXS folded back against CLD4. The central location of the CRD may 
explain unpublished data by Dr. Svend Kjær, showing that two antibody epitopes within 
the CRD become inaccessible upon ternary complex formation. This is also in 
agreement with crosslinking data, which suggested the CLD4CRD junction and GDNF 
N-terminal tail are in close proximity in the mTC.  
3.3.5.3 The position of GFRα1-D1 
The GFRα1-D1 model fits neatly into the density above the GFRα1-D2D3’s observed 
in the leg view as shown in Figure 3.6. It could also fit in the base region of the ‘leg’ 
view adjacent to the CRD in this interpretation. Since it is linked to D2 by a fairly long 
linker, there aren’t any known steric constraints on its position. I have shown it above 
GFRα1-D2D3 as the best explanation for that region of density. However, since D1 has 
been shown to crosslink with the CRD and confers stability to the mTC, it may be more 
consistent with these data to place it in the base region engaging the CRD.  
3.3.5.4 The membrane facing elements: RET-CRD and GFRα1-Ctail 
In this interpretation the RET-CRDs are presumed to be engaging GDNF in the central 
region of the map, as well as extending into the base region towards the putative 
position of the cell membrane. Since the structure of the CRD is unknown this is purely 
speculative. However the juxtaposition of the CRDs in this interpretation is consistent 
with the dimerisation of the TMs in the full-length RET context.  
I have placed the 75 residue C-tail of GFRα1 in the unexplained base region density, 
since it would face the membrane along with the CRD in the membrane-localised full-
length complex. However given that this tail has no predicted secondary structure, and 
contains a long string of threonine residues and only a single potential intramolecular 
disulphide, it may be too flexible to contribute much to the 3D reconstruction. 
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3.3.5.5 The hand of the EM map has not been determined 
A tilt pair analysis to determine the hand of the EM map de novo (Rosenthal and 
Henderson, 2003) has not been conducted as yet. Fitting was therefore carried out using 
both the map shown here and its enantiomorph (generated in IMAGIC). We had hoped 
that the fitting would unambiguously reveal which was the correct hand. Unfortunately, 
at the current resolution of the map the fit of the components is comparable between the 
map and its enantiomorph. The correlation coefficient of RET-CLD(1-4) is 0.78 in the 
enantiomorph map and 0.82 in the displayed map and the correlation coefficient of 
GDNF/GFRα1-D2D3 is 0.80 in the enantiomorph vs 0.81. The central CLD4 
arrangement of the components is the same in the map and its enantiomorph, although 
the precise interaction sites between components differ. RET-CLD1 and the CLD(1–2)-
CLD3 junction still contact GFRα1-D3 in the enantiomorph model. However the 
interfaces are swapped with the region on GFRα1-D3 that contacts CLD1 in the model 
described above contacting the CLD(1–2)-CLD3 junction in the enantiomorph model, 
and vice versa. Similarly the RET-CRD still contacts GDNF, but on an opposing 
surface of GDNF. The map used in the figures above was chosen for two reasons. 
Firstly, the previously proposed RET-binding surface on GFRα1 faces inside the 
complex in the fit into this map, whereas it is facing outside the complex in the 
enantiomorph map fit. Secondly, in the enantiomorph map the central CLD4 
arrangement results in the RET-CRD contacting the longest helix in GDNF (the GDNF 
‘heel’). This helix contains a centrally located conserved N-linked glycosylation site, 
making it unlikely to be a protein interface site. These reasons are not conclusive 
however, and improved map resolution to unambiguously determine the hand by fitting 
or tilt-pair analysis to determine the hand de novo will be needed before the contact 
sites between components in the ternary complex can be discussed with more 
confidence.  
3.3.6 The CLD(1–2) crystallographic dimer does not fit in the EM map 
The crystal structure of hRET-CLD(1–2) revealed a crystallographic dimer. Mutation of 
the dimer interface reduced the apparent affinity of immobilised hRET-ECD for 
ligand/co-receptor ten-fold, and therefore formation of the hRET-CLD(1–2) dimer was 
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deemed to be important for ternary complex stability (Kjaer et al., 2010). However the 
RET-ECD fit into the EM map was poor (correlation coefficient = 0.53) if the dimer 
arrangement was imposed.  
The CLD(1–2) dimer, like the ligand/co-receptor complex, possesses a 2-fold axis, 
which was therefore assumed to be coincident with the EM map two-fold in fitting. The 
presence of the CLD(1–2) mediated dimer in the context of the CLD(1–4) model, 
results in a ‘tweezer’ shaped object (Figure 3.7a). The fit of this object in the EM map is 
shown in Figure 3.7b (correlation coefficient = 0.53). It is a poor fit however since 
CLD3 is largely outside of the map. Furthermore it leaves a large amount of 
unexplained density, possibly far too much to be explained by the unmodelled elements 
or by a different CLD3–4 arrangement. 
The lack of a good fit of the CLD(1–3) dimer into the EM map strongly suggests that 
the crystallographic dimer is not present in the ternary complex. We therefore sought an 
alternative explanation for the impact of the R77E/R144D dimer interface mutations on 
ternary complex assembly, and the role of the CLD1 elements in conferring ligand/co-
receptor specificity (discussed in section 1.6.4.2). One possibility is that, as originally 
proposed by Kjær et al. (Kjaer and Ibanez, 2003a), these elements are directly involved 
in binding ligand/co-receptor, as indeed is observed in the current interpretation. 




Figure 3.7 Imposing the CLD(1–2) crystallographic dimer on the SAXS based zRET-
CLD(1–4) arrangement and fitting in the mTC EM map 
(a) Ribbon representation of the SAXS-derived zRET-CLD(1–4) model with the 
CLD(1–2) dimer, observed in the hRET-CLD(1–2) crystal structure (Kjaer et al., 2010), 
imposed. (b) Transparent surface view of the mTC 3D reconstruction, with fitted RET, 
GFRα1 and GDNF structures shown in ribbon representation. The best fit of the 
components with the CLD(1–2) crystallographic dimer imposed is shown. (c) Surface 
view of the mTC reconstruction, with the ‘wing’, ‘centre’ and ‘base’ regions coloured 
purple, green and blue respectively. 
3.4 Aids in interpreting the EM map 
There are a number of possible experiments that can be conducted to validate 
interpretations and help identify the location of components within the EM map of 
macromolecular complexes. These include domain deletions, addition of an EM-visible 
protein domain or tag to particular components or improvement of the resolution of the 
3D map. Our current strategy is to try to improve the resolution of the EM map both by 
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increasing the number of particle images used in the negative stain reconstruction and 
hopefully moving to cryo-EM. Dr. Svend Kjær has recently produced a better quality 
sample of the mTC using an additional ion exchange chromatography step for 
purification. This additional purification step has improved sample homogeneity, as 
judged by visual analysis of negatively stained EM grids, and this sample is currently 
being analysed and worked up into a new 3D reconstruction.   
3.4.1 Assessing the role of the GFRα1-D1 in the mammalian ternary 
complex 
The rGFRα1-D1 is only 88 residues (10 kDa) in size and therefore is not a particularly 
good marker within a negative stain EM map. However its location is ambiguous and it 
is the only structured domain believed to be dispensible for ternary complex formation, 
although it may enhance mTC complex stability (Virtanen et al., 2005). A rGFRα1ΔD1 
construct was produced, corresponding to residues 150–427 to test this hypothesis. 
Initially it appeared that the ternary complex could still be assembled using this 
truncated co-receptor immobilised on IgG-sepharose resin.  However size exclusion 
chromatography of the complex showed peaks only for the individual component 
proteins, and not the intact mTC complex. This was confirmed by inspection of 
negatively stained EM grids prepared from fractions from the highest MW peak, which 
showed either aggregates or very small particles (Figure 3.8). This complex is therefore 
too unstable for EM analysis, indicating rGFRα1ΔD1 may be indeed be important for the 
stability of recombinant mTC. 
 




Figure 3.8 Negatively stained EM grid of GFRα1ΔD1 mTC sample 
EM grid negatively stained with 2% (w/v) uranyl acetate. No particles of a similar size 
to the intact mTC are evident. 
3.5 Conclusions 
In summary, we have produced a 27.8 Å resolution negative stain EM 3D 
reconstruction of the mTC, which has internal two-fold symmetry. Preliminary fitting of 
known structures and homology models into this EM map resulted in an interpretation 
for the arrangement of the RET-ECD, GDNF and GFRα1 in the mTC. This 
interpretation shows the GDNF dimer/ 2 GFRα1 complex lies at the heart of the mTC, 
with the RET-ECD wrapped around the outside. The RET-CRDs are drawn together at 
the base of the complex and also make contacts with GDNF. The RET-CLD(1–3) 
regions are splayed apart from each other interacting with GFRα-D3 at the distal ends 
of the GDNF/GFRα1 complex. Surprisingly, we do not observe the crystallographic 
RET-CLD(1–2) dimer within the mTC 3D reconstruction. Instead, CLD1–2 interface, 
previously shown to be important for ternary complex stability, appears to be involved 
in contacting GFRα1-D3 rather than in mediating a CLD(1–2) dimer in the mTC.  
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Chapter 4. Towards structural analysis of a lower 
vertebrate RET’s interaction with ligand/co-receptor 
4.1 Chapter aims 
As detailed in the introduction, human RET-CLD(1–2) has mammal-specific structural 
elements, which are required for interaction with mammalian ligand/co-receptor 
complexes (section 1.6.5). Homologue-scanning mutagenesis studies, combined with 
the hRET-CLD(1–2) crystal structure, revealed an unexpected diversity separating 
higher and lower vertebrates both at the sequence and structural levels (Kjaer et al., 
2010; Kjaer and Ibanez, 2003a). In this thesis I have sought to define and understand 
these differences by looking at a lower vertebrate (zebrafish) RET alongside the human 
orthologue. Towards this aim I endeavoured to produce a zebrafish ligand and co-
receptor in order to characterise their interaction with zebrafish RET by structural 
methods as a comparison with the mammalian complex described in the preceding 
chapter.  
A second rationale was that the amount of mammalian RET ternary complex we were 
able to produce was very limited even from large-scale mammalian cell expression. We 
were therefore not able to pursue crystallisation of this complex. An additional 
motivation for developing a protocol for production of a zebrafish ligand and co-
receptor was therefore to try to obtain sufficient quantities of each of the zRET ternary 
complex components to initiate crystallisation trials of the zRET ternary complex. Since 
atomic resolution of protein structures can be obtained more readily by X-ray 
crystallography compared to EM (excepting cryo-EM analysis of very high quality 
and/or high symmetry samples) it was hoped this approach would provide a much more 
detailed description of the interactions between RET and ligand/co-receptor. 
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4.2 Vertebrate ligand and co-receptor sequences and 
alignments 
Alignment of the amino acid sequences of the GFRα1 co-receptor reveals high 
sequence identity between lower and higher vertebrate GFRα1, except between the 
membrane proximal C-tails. Overall the sequence identity between human GFRα1 and 
zebrafish GFRα1a is 63%. The identity without the C-tail is 73%, with all three 
structured domains (D1–D3) and the D1–D2 linker showing high conservation (Figure 
4.1). 
Alignment of the GDNF amino acid sequences from lower and higher vertebrate species 
shows that the sequence of the mature protein, excluding the pro-sequence, is highly 
conserved, particularly in the structured region (Figure 4.2). The sequence identity of 
the mature protein between human and zebrafish is 60%, rising to 69% in the structured 
region. The N-terminal tail of zebrafish GDNF contains a fish specific highly charged 
14 amino acid insertion. 
 




Figure 4.1 Alignment of vertebrate GFRα1 amino acid sequences 
CLUSTALW2 alignment of GFRα1 amino acid sequences from three higher and three 
lower vertebrates: mouse (Mus muscularis), rat (rattus norvegicus), human (homo 
sapien), chicken (Gallus gallus), Xenopus (Xenopus tropicalus) and zebrafish (Danio 
rerio) isoform a. The secondary structure elements from the rat GFRα1(D2D3) crystal 
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structure (PDB 2V5E) are annotated above the alignment. Disulphide-linked pairs of 
cysteine residues present in the crystal structure are marked with green numbers beneath 
the alignment. Completely conserved residues are boxed and highlighted in red with 
white text, and similar residues boxed with red text. Dashed black lines indicate domain 
boundaries. 
 
Figure 4.2 Alignment of vertebrate GDNF amino acid sequences 
CLUSTALW2 alignment of GDNF amino acid sequences from three higher and three 
lower vertebrates. The secondary structure elements present in the human GDNF crystal 
structure (PDB 2V5E) are indicated above the alignment. The alignment is annotated as 
described for the GFRα1 alignment above (Figure 4.1). Dashed black lines indicate 
domain boundaries. 
4.3 Reconstitution of the zebrafish ternary complex 
4.3.1 Production of ligand/co-receptor 
In order to generate a zebrafish RET ternary complex (zTC) for structural analysis it 
was necessary to develop a method of producing a RET ligand and corresponding co-
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receptor. Given the availability of the clones and the direct comparison to the mTC I 
worked on producing zebrafish GDNF and GFRα1a (DNA courtesy of Iain Shepherd, 
Emory University). The mammalian GDNF/GFRα1 and Artemin/GFRα3 complexes 
have been produced using the baculovirus system, with sufficient yields for 
crystallisation screening (Parkash et al., 2008; Wang et al., 2006), and since I already 
had this expression system set up for the zRET-ECD production this was the clear 
starting point.  
 
Figure 4.3 Zebrafish ligand and co-receptor constructs examined in this thesis 
 (a) zGFRα1a and (b) zGDNF constructs used in this thesis.   
4.3.1.1 Co-receptor construct design and protein expression 
GFRα1a consists of three discrete domains, designated D1 – D3, and an unstructured C-
tail containing the GPI site. Using the crystal structure of mammalian GDNF/GFRα1 as 
a guide for the GFRα1 domain boundaries (Parkash et al., 2008), I produced a 
zGFRα1a C-terminal truncated construct containing just the structured D1–D3 domains 
(zGFRα1aΔC; residues 1–352; Figure 4.3a). I used the same expression cassette in the 
pBacPAK transfer vector as the zRET-ECD, with the native (zGFRα1a) signal sequence 
and cleavable C-terminal Protein A tag (section 2.3.2). Protein expression from the 
resulting baculovirus in Hi5 cells produced around 1 mg zGFRα1aΔC per litre cell 
culture. When expressed alone the protein tends to spontaneously proteolyse within 24 
hours at 4 °C into two fragments: D1 alone and D2D3 (Figure 4.4b). This was not 
observed when co-expressed with GDNF suggesting the ligand protects the co-receptor 
from degradation to some extent. 
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4.3.1.2 Ligand construct design and protein expression 
Since zGDNF is normally produced in the cell as a pro-protein, which is subsequently 
processed proteolytically, I designed a construct containing just the mature portion of 
protein (residues 89–235). This involved truncating the N-terminus of the gene, thus 
removing the native signal sequence. I therefore used a baculovirus transfer vector 
containing a honeybee melittin signal sequence (Tessier et al., 1991). I left the protein 
untagged and co-expressed it with zGFRα1aΔC. The yield of zGDNF however was very 
low, only detectable by western blotting following affinity purification of its binding 
partner zGFRα1aΔC. This was the case even when infecting the Hi5 cells with the 
zGDNF baculovirus at an MOI of 5 and reducing the expression temperature to 18 °C.  
In order to try to increase the protein expression I removed the unstructured N-terminus, 
which was disordered in the GDNF crystal structures (Eigenbrot and Gerber, 1997; 
Parkash et al., 2008) and is not required for RET binding and activation (Baloh et al., 
2000). This construct defined as zGDNFΔN, corresponding to residues 135–235, led to 
an improved yield of zGDNFΔN when co-expressed with zGFRα1aΔC. Varying the ratio 
of the two viruses allowed similar levels of zGDNFΔN and zGFRα1aΔC to be obtained, 
with an overall protein yield of around 1 mg per litre (Figure 4.4a).    
Non-reducing SDS-PAGE of the purified zGDNFΔN/zGFRα1aΔC showed that the 
zGDNFΔN is mostly monomeric rather than a disulphide-linked dimer directly after 
affinity purification. During subsequent preparation of the ternary complex with zRET-
ECD some of the zGDNF forms disulphide-linked dimers. The extent of dimerisation 
observed appears to be pH dependent, with zGDNFΔN remaining monomeric at pH 6.5, 
whereas at pH 7 some dimerisation occurs.  




Figure 4.4 Ligand and co-receptor production 
(a) Non-reducing SDS PAGE of affinity purified zGFRα1aΔC expressed alone (lane 1), 
and with zGDNFΔN (lane 2). (b) Non-reducing SDS PAGE of affinity purified 
zGFRα1aΔC alone after storage of the protein at 4 °C for 24 hours. The protein shows 
spontaneous proteolysis over time, with the identity of the fragments, as annotated, 
determined by mass spectrometry. 
4.3.2 Assembly and calcium dependence of the zTC 
To confirm the insect cell expressed proteins are functional and interact to form a 
RET/ligand/co-receptor ternary complex I performed a pull down assay. Briefly, the 
zGDNFΔN/zGFRα1aΔC/zRET-ECD ternary complex (zTC) was assembled on 
immobilised Protein A tagged zGFRα1aΔC as follows. Affinity purified zRET-ECD was 
added to zGFRα1aΔC attached to IgG-sepharose via its C-terminal Protein A tag in the 
presence or absence of both zGDNFΔN and calcium (2 mM CaCl2). zRET-ECD binding 
to zGFRα1aΔC required the presence of both ligand and calcium (Figure 4.5). zRET-
CLD(1–4) did not bind zGFRα1aΔC under these conditions, confirming the need for the 
CRD for ligand/co-receptor binding. It has not yet been tested whether the zRET-CRD 
can bind zGDNFΔN/zGFRα1aΔC alone, although evidence from RET-ECD chimera 
studies suggests that the CRD is not sufficient for GDNF/GFRα binding (Kjaer and 
Ibanez, 2003a). 




Figure 4.5 Assembly of the zTC 
Non-reducing SDS PAGE of samples from zTC assembly on immobilised zGFRα1aΔC. 
Ternary complex components and calcium (2 mM CaCl2), as detailed below the gel, 
were added to the immobilised zGFRα1aΔC and allowed to bind for 1 hour on ice. 
Unbound protein was washed off, and the zGFRα1aΔC with bound proteins was eluted 
from the IgG-sepharose resin by 3C-protease. Eluted proteins were identified by SDS-
PAGE, stained with Coomassie. 
4.3.3 Purification of the zTC for structural analysis 
The assembled zTC complex was eluted from the IgG-sepharose by 3C cleavage of the 
Protein A tag on zGFRα1aΔC. The complex was then further purified by both size 
exclusion chromatography and anion exchange chromatography (Figure 4.6). The 
resulting complex appears stoichiometric by SDS-PAGE (bearing in mind the differing 
levels of Coomassie staining of the larger versus smaller proteins), is homogeneous and 
is stable in buffers containing up to at least 250 mM NaCl. The yield of zTC after size 
exclusion of complex assembled from a 2l culture of zRET-ECD and 5.5l culture of 
coexpressed zGDNFΔN/zGFRα1aΔC is ~3 mg. Even better yields can be achieved by co-
expressing all three proteins in Hi5 cells. However, since both the zRET-ECD and 
zGFRα1aΔC constructs carry the same Protein A tag, this method allows for less control 
over complex assembly/quality—although the complex can be separated from the 
constituent proteins by size exclusion chromatography. These yields make the zTC, 
unlike the mTC, a tractable target for crystallisation studies. 




Figure 4.6 zTC purification 
(a) Size exclusion chromatography of the zTC using a Superdex 200 column. (b) Anion 
exchange chromatography of the zTC, using a HiTrap Q column, following size 
exclusion. (c) Non-reducing SDS-PAGE of size exclusion and (d) anion exchange 
fractions. 
4.3.4 Deglycosylation of the zTC 
There are two predicted N-linked glycosylation sites in zGDNF, both of which reside 
within the structured region of the mature protein (Table 4.1). zGFRα1a has three 
predicted N-linked glycosylation sites, although all three are predicted with low 
confidence (Table 4.1). The N62 site is conserved and located in D1, N163 is not 
conserved and is in D2, and N350 is conserved and is at the very C-terminus of D3. 
 Deglycosylation of the zTC with Endo-F1 produced a smeared zRET-ECD band, 
suggesting that some of the N-linked glycans are protected by formation of the ternary 
complex (Figure 4.7). The upper band of zGFRα1a (see Figure 4.6d) is lost upon Endo-
F1 treatment, suggesting it corresponds to a partially occupied glycosylation site.   
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Position Sequence Potential Jury agreement N-Glyc result 
zGDNF     
150 NVTD 0.7628 (9/9) +++ 
186 NLTH 0.6570 (9/9) ++ 
zGFRα1a     
62 NFSM 0.5458 (7/9) + 
163 NDTC 0.5309 (5/9) + 
350 NGTD 0.6290 (7/9) + 
417 NNTI 0.4877 (4/9) - 
441 NSSP 0.1052 (9/9) --- 
Table 4.1 Predicted N-linked glycosylation sites in zGDNF and zGFRα1a 
Analysis of all the NXS/T N-linked glycosylation consensus sites in zGDNF and 
zGFRα1a using the NetNGlyc server in ExPASY, which assesses whether the site is 
likely to be glycosylated on the basis of the primary amino acid sequence. Position = 
sequence position of the asparagine under consideration. Potential = the likelihood of 
glycosylation based on the averaged probability results of nine neural networks. A 
predicted site has a potential of > 0.5. Jury agreement = the number of the neural 
networks that support the prediction. N-Glyc result = indicates the prediction and the 
confidence level of the prediction: + = predicted glycosylated; - = predicted not 
glycosylated. The number of +/- indicates relative confidence in the prediction. 
 
Figure 4.7 Deglycosylation of assembled zTC with Endo-F1 
Non-reducing SDS PAGE of purified zTC after incubation with Endo-F1 for 20 hours 
at 4 °C. 
4.3.5 zTC instability 
The purified zTC was initially thought to be reasonably stable since it can be separated 
from the excess constituent proteins by size exclusion, is stable in anion exchange 
chromatography, and if a second size exclusion is carried out the complex elutes as a 
single peak. The size exclusion purified complex also gave a single peak in DLS, with 
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an approximate MW of 480–500 kDa. However, when the size exclusion and anion 
exchange chromatography purified zTC complex was visualised by negative stain EM, 
intact complexes of a similar size to those seen in the mTC were few: The grids were 
dominated by much smaller particles, consistent with individual components of the zTC 
and indicating that the complex is not stable under negative stain EM conditions.   
Subsequent experiments to look into this apparent instability revealed that the purified 
complex consisted of a mixture of different sub-complexes. Native PAGE showed four 
bands (Figure 4.8b). The smallest, running at 150 kDa, corresponds to where zRET-
ECD alone runs, although peptides from all three proteins could be detected by mass 
spectrometry of this and all the other bands. The other three bands correspond to MWs 
of approximately 500 kDa, 360 kDa and 250 kDa. Given that zRET-ECD runs much 
larger than its actual MW by native PAGE (even considering the glycosylation) it is 
tempting to speculate that the top band corresponds to the 2RET:2GFRα1:2GDNF 
complex, with the second band corresponding to the loss of a RET, and the third either 
both RETs or, more consistently with the relative MWs, a RET and a GFRα1. This 
hypothesis would fit with the proposal of (Schlee et al., 2006); that the ternary complex 
assembles in vivo via 1RET:1GFRα1:2GDNF and subsequent 1RET:2GFRα1:2GDNF 
intermediates. A SEC-MALS experiment with the purified zTC complex also showed 
that the complex sample is not homogeneous, with the calculated MW of the eluted 
material decreasing from 420 kDa to 200 kDa (Figure 4.8).  
This instability of the recombinant zTC is not seen for the mTC. This could be due to 
the zTC simply being less stable than the mTC, or a sub-optimal buffer composition for 
the zTC. It could also be due to the recombinant protein production methods: The zTC 
components were produced in insect cells, which means the glycans added to the 
proteins will not be precisely the same as those added natively in the zebrafish. This 
may have an impact on the complex if any of the glycans play a role in complex 
assembly/stability. In the mTC, the hRET-ECD and rGFRα1 were both produced in 
mammalian cells, and therefore their glycosylation is likely to be closer to native. 
Secondly the zTC zGDNFΔN and zGFRα1aΔC are not the full-length proteins but had 
predicted unstructured elements removed during cloning, whereas the components of 
the mTC are all full length, aside from the GPI-link site of rGFRα1. It may be that the 
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N-terminal tail of zGDNF, which has been shown by crosslinking to interact with RET 
(Amoresano et al., 2005), or the C-tail of zGFRα1 are important for complex stability. 
 
Figure 4.8 zTC instability 
(a) SEC-MALS results, using a Superose 6 column, of size exclusion purified zTC. dRI 
= differential refractive index. (b) Coomassie stained native PAGE of size exclusion 
purified zTC. 
4.4 SAXS analysis of the zebrafish ternary complex  
The heterogeneity of the purified zTC means that it is not a good sample for SAXS 
analysis, since SAXS requires a homogeneous sample for molecular shape analysis of 
samples of unknown structure. The decreasing complex size across the size exclusion 
peak as seen in SEC-MALS (Figure 4.8) is reflected in the decreasing radius of gyration 
(Rg) observed across the HPLC peak in an online-HPLC SAXS experiment (Figure 4.9). 
The Rg decreases from 61.7–59 Å across the HPLC peak.  
Analysis of averaged SAXS curves from small sections across the HPLC peak, 
corresponding to similar Rg’s, does result in apparently reasonable pair distance 
distribution function, based on analysis of the data with GNOM. However, as expected 
given the known heterogeneity, no meaningful results can be produced with ab initio 
model generation from these data.   




Figure 4.9 Analysis of SAXS data with online HPLC of zTC 
(a) Graph showing the radius of gyration (Rg) and the extrapolated intensity at s = 0 
(I(0)) calculated, using the Guiner approximation, for each data collection. The I(0) 
indicates the protein concentration in the beam, and therefore represents the HPLC 
peak. (b) Close up of the variation in Rg across the HPLC elution peak profile.  
4.5 Negative stain EM of the zebrafish ternary complex 
4.5.1 Statement of contributions 
The work described in this section (4.5) was a collaborative effort primarily between Dr. 
Fabienne Beuron (Imperial Cancer Research, London) and myself. I produced the zTC 
sample, as described above. Dr. Fabienne Beuron prepared the EM grids of the sample 
and collected the images. I picked particles, generated classes, and performed projection 
matching to generate a preliminary 3D reconstruction.  
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4.5.2 Preparation of cross-linked zTC for negative stain EM 
As previously stated (section 4.3.4), negatively stained EM grids of the size exclusion 
and anion exchange purified zTC were dominated by smaller particles than seen for the 
mTC. This observation was supported by the native PAGE and SEC-MALS data, 
showing the zTC sample to consist of a mixture of different sub-complexes. This 
untreated sample was therefore not useful for EM analysis of the complete complex. 
However, crosslinking of EM samples has been shown to stabilise labile biological 
samples on occasion (Kastner et al., 2008). Indeed we found that addition of 
glutaraldehyde to a final concentration of 0.05% for 3 minutes resulted in a 
homogeneous sample with particles of similar size to the mTC (Figure 4.10). The EM 
grids were negatively stained with 2% (w/v) uranyl acetate and images were collected 
on a Tecnai T20 electron microscope, equipped with a 4000×4000 pixel CCD detector, 
at 80000× magnification as for the mTC (see section 3.2.4). 
 
Figure 4.10 Negative stain EM of zTC 
(a) Example image of the cross-linked zTC EM grid, negatively stained with 2% (w/v) 
uranyl acetate. (b) Examples of picked particle images after filtering and normalisation. 
(c) Corresponding class averages from MSA-based classification following particle 
alignment to the mTC 3D reconstruction. 
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4.5.3 Particle picking and generation of class averages 
From the collected images I picked 7500 particle images, which were filtered and 
normalised as for the mTC (see section 3.2.5). The particle image stack was dominated 
by the ‘figure of eight’ view (first image in Figure 4.10c), which was one of the 
characteristic views of the mTC. The other defining view of the mTC was the ‘leg’ view, 
which occurs with far less frequency in the zTC images, and appears altered. In 
particular ‘leg’ views with clear base group regions and triangularly splayed ‘legs’ do 
not appear to be present in the current zTC stack, although it may simply be that it is 
underrepresented in the zTC sample on the EM grid. The views most similar to the 
mTC ‘leg’ view show more of a squared top, at the point where the legs come together 
(second and third image in Figure 4.10c). 
The dominance of the ‘figure of eight’ view in the zTC particle image stack meant class 
assignment based on reference-free alignment using EMAN (Ludtke et al., 1999) 
resulted in very few non-‘figure of eight’ class averages (Figure 4.11). Aligning the 
stack to forward projections of the mTC 3D reconstruction in SPIDER (Frank et al., 
1996) followed by MSA-based class assignment in IMAGIC (van Heel et al., 1996), 
resulted in a much better classification. The class averages corresponding to the ‘figure-
of-eight’ view are still the most abundant, but other views, such as the ‘leg’-type view 
described above are also represented (Figure 4.10b&c).  
 




Figure 4.11 zTC representative class averages from reference-free alignment and 
classification 
A selection of zTC class averages from the 300 generated by reference-free alignment 
and classification using EMAN from the 7500 particle image stack.  
4.5.4 Projection matching to the mammalian ternary complex 
reconstruction 
Given the similarity between the classes from the mTC and the zTC, I tried to see if I 
could generate a reasonable 3D reconstruction of the zTC by starting with projection 
matching to the mTC using IMAGIC. The results of an initial round of projection 
matching to the mTC are shown in Figure 4.12. The zTC classes used in this projection 
matching procedure were generated following alignment of the zTC particle image 
stack to mTC re-projections. Comparison between the zTC classes and the matched 
mTC re-projections showed a good correspondence for around half of the input zTC 
classes. The map showing the Euler angles assigned to these classes (Figure 4.12c) 
further highlights the dominance of the ‘figure-of-eight’ view, which corresponds to the 
cluster around (0,0) and (180,0). Expansion of the particle image stack and further 
improvements in classification will be needed to improve the coverage of the Euler 
sphere and to lead to a final 3D reconstruction of the zTC. 




Figure 4.12 Towards a zTC 3D reconstruction 
Projection matching of the zTC classes to re-projections of the mTC 3D reconstruction. 
(a) A selection of zTC class averages. (b) Corresponding re-projections from the mTC 
3D reconstruction. (c) Map of Euler angles assigned to the zTC classes showing a good 
match to an mTC re-projection. 
4.6 Conclusions 
In this chapter I have presented a method for the production of the zebrafish 
RET/GDNF/GFRα1a ternary complex using the recombinant baculoviruses to infect an 
insect cells host for protein production. The protein yields and purity are sufficiently 
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high to consider crystallisation screening. However, the recombinant zTC is unstable, 
with the purified sample made up of a mixture of the complete 2:2:2 complex and 
different sub-complexes when subjected to native PAGE or observed by EM following 
staining with 2% (w/v) uranyl acetate. Low level cross-linking with glutaldehyde was 
sufficient to produce a visually homogeneous sample in negative stain EM. Further 
buffer screening may lead to increased complex stability allowing the zTC to then be 
used confidently in crystallisation screening.   
Analysis of the cross-linked zTC negative stain EM images revealed the zTC looks very 
similar to the mTC, suggesting the overall arrangement of the complex components is 
the same. In particular, the unchanged nature of the ‘figure-of-eight’ view would 
indicate that the arrangement of RET is unchanged, assuming the interpretation of the 
mTC EM 3D reconstruction presented in the previous chapter is correct, and RET is 
indeed located in the wings of the ‘figure-of-eight’. There are some hints of differences 
between the complexes from the class averages, particularly in the ‘base’ region of the 
‘leg’ view, although these could simply be a reflection of different preferred 
orientations of the complexes on the EM grid. Increasing the size of the particle image 
stack to allow production of a 3D reconstruction of the zTC will be required to assess 
the impact of these apparent differences fully. It should be noted that the zGFRα1aΔC 
construct lacks the C-tail, which is present in the rGFRα1 within the mTC. Since this 
rGFRα1 C-tail may be contributing to the observed density in the ‘base’ region of the 
mTC 3D reconstruction, one might expect a reduction in the size of the ‘base’ region in 
the zTC.   
Finally pull-down assays confirmed that zRET-ECD, like hRET-ECD (Anders et al., 
2001), requires calcium for binding the ligand/co-receptor, consistent with the 
conservation of the calcium-binding residues at the CLD2–CLD3 junction. Furthermore, 
I have also shown that the CRD is required for zRET binding to ligand/co-receptor 
supporting a key role for this domain in ligand/co-receptor engagement.  
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Chapter 5. RET tyrosine kinase domain regulation 
and chemical inhibition 
5.1 Chapter aims 
This chapter describes efforts to crystallise the RET tyrosine kinase domain (RET-KD) 
with different ligands and inhibitors bound within the RET nucleotide-binding pocket to 
characterise the interaction of these small molecules with the RET-KD. I present the 
crystal structures of the RET-KD bound to the clinically relevant RET inhibitor 
sunitinib, whose mode of binding to RET was unknown; and a high-resolution structure 
of the RET-KD bound to adenosine, which revealed some new insights into the RET-
KD structure and flexibility.  
In addition, efforts were made to obtain a different crystal form of the RET-KD without 
the dominant head-to-tail dimer observed in all other RET-KD crystal forms and to 
attempt to capture novel RET-KD conformations that may give clues to cis- or trans-
inhibitory mechanisms operating within RET. Previous RET-KD crystal structures 
identified a trans-inhibited dimer of the RET-KD, whose physiological relevance 
remained to be proven. The significant size of the protein interaction interface within 
the trans-inhibited dimer and the observation that several interface residues were MEN2 
oncogenic mutation sites, including the aggressive M918T mutation, suggested a closer 
look may be important (Knowles et al., 2006). The longer-term goal in understanding 
RET regulation was to be able to interpret how oncogenic RET-KD mutations subvert 
RET regulation leading to tumourigenesis. 
At the start of this thesis, no structure was yet available for the RET-KD bound to either 
ATP (or an analogue) or a peptide substrate. Therefore a further aim of this chapter was 
to determine a RET-KD structure bound to an ATP-analogue and a tyrosine-containing 
peptide substrate, since it was hoped this would allow us characterise the RET-KD fully 
poised for catalysis as well as the interactions with ATP and substrate peptide. I present 
successful crystallisation of such a complex, although further optimisation of these 
crystals is required to improve the resolution of X-ray diffraction data and allow the 
structure to be solved by molecular replacement. 




Figure 5.1 Alignment of vertebrate RET-ICD amino acid sequences 
CLUSTALW2 alignment of 3 higher and 3 lower vertebrate RET-ICDs: human (homo 
sapien), rat (Rattus norvegicus), mouse (Mus musculus), Xenopus (Xenopus laevis), 
chicken (Gallus gallus), and zebrafish (Danio rerio). Completely conserved residues are 
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boxed and highlighted in red with white text, and similar residues boxed with red text. 
Secondary structure elements observed in the human RET-KD crystal structure are 
annotated above the alignment and domain boundaries are indicated by dashed black 
lines.  
5.2 Protein production 
5.2.1 Sequence alignment of RET intracellular domains 
Alignment of RET-ICD amino acid sequences from three mammalian and three lower 
vertebrate RETs shows very high sequence conservation throughout the ICD, with 85% 
sequence identity between human and zebrafish (Figure 5.1).  Within the KD the most 
amino acid sequence divergence occurs in the glycine and serine rich kinase insert 
region (residues 820–845) 
5.2.2 Protein expression and purification 
Tyrosine kinases have been difficult to produce in E. coli, although newer approaches 
of co-expressing tyrosine phosphatases alleviate some of the toxicity of overexpressing 
tyrosine kinases in bacteria (Seeliger et al., 2005). Nevertheless, a detailed protocol was 
available in the laboratory to produce recombinant human RET-KD (hRET-KD; 
residues 705–1013) using an insect cell expression host and a recombinant baculovirus 
(Knowles et al., 2006). This protocol was robust and gave reasonable yields (~1 mg/l 
cell culture) of monodisperse protein. In order to improve yields further we purchased a 
hRET-KD gene codon-optimised for insect cell expression from GeneART, which I 
subcloned into the same baculovirus transfer vector used previously for hRET-KD 
baculovirus production. Use of the codon-optimised construct improved yields 4× with 
the same protein production protocol.  
Briefly hRET-KD, excluding the highly flexible kinase insert (residues 827–840), was 
expressed with a 3C-protease cleavable N-terminal glutathione S-transferase (GST) 
affinity tag, in both Hi5 and Sf9 cells. The single step affinity-purified protein was 
judged to be pure by SDS-PAGE (Figure 5.2a), and was known to crystallise without 
further purification. The RET-KD is non-phosphorylated as purified out of insect cells. 
To produce a single fully phosphorylated species, hRET-KD was phosphorylated by 
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addition of 5 mM ATP and 10 mM MgCl2 for 6 hours on ice. The ATP and MgCl2 were 
then removed by dialysis. 
To characterise the phosphorylated hRET-KD protein (pRET-KD), size exclusion 
chromatography was carried out. Using a standard 100 mM NaCl concentration in the 
size exclusion buffer the majority of the pRET-KD is associated as an aggregate (Figure 
5.2b). However at higher salt (300 mM NaCl), the proportion of monomer is greater 
(Figure 5.2c). This result is reflected in the long concentration times required to obtain 
pRET-KD concentrations of  > 3 mg/ml, particularly in the absence of 
nucleotide/inhibitor binding in the active site.   
 
 
Figure 5.2 pRET-KD purification 
(a) Reducing SDS-PAGE of RET-KD affinity purification samples. GST-RET-KD was 
affinity purified from cell lysates using glutathione-sepharose resin, followed by elution 
of RET-KD using 3C-protease. (b) & (c) Size exclusion chromatography of pRET-KD, 
using Superdex 75 columns, with (b) 100mM NaCl, or (c) 300 mM NaCl in the running 
buffer.  
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5.3 Structure of sunitinib bound to the RET-KD 
All previous RET-KD structures bound to chemical inhibitors solved in the Structural 
Biology Laboratory show the compounds binding to an ‘active’ DFG-in conformation 
(Knowles et al., 2006). One example is the RET-KD structure bound to vandetanib, a 
clinically relevant inhibitor that became the first drug approved by the FDA for use in 
MTC (Thornton et al., 2012). However issues with the efficacy of vandetanib are 
known and discussed in Chapter 1 (section 1.8.2). Furthermore vandetanib exhibits no 
activity against RET gatekeeper mutations such as V804M, therefore resistance 
mutations to vandetanib would be expected at the gatekeeper. This would suggest a 
need for other potent clinically relevant RET inhibitors such as sorafenib and sunitinib 
(Sutent®) to treat resistance or as a combination therapy. These compounds have been 
suggested to bind an inactive DFG-out conformation (Chow and Eckhardt, 2007; 
Gajiwala et al., 2009; Plaza-Menacho et al., 2007). I therefore sought to crystallise the 
RET-KD with sunitinib bound to structurally characterise the interaction and determine 
whether sunitinib binding in the RET-KD ATP-cleft could trap a DFG-out 
conformation. 
5.3.1 Crystallisation and crystal optimisation 
To characterise structurally the binding of sunitinib to the RET-KD co-crystallisation 
experiments were carried out. To do this sunitinib (Toronto Research Chemicals) was 
dissolved in DMSO and added to pRET-KD at a 3:1 inhibitor:protein molar ratio. 
Following incubation for 1 hour at 4 °C to allow binding, the protein:inhibitor complex 
was concentrated to 3–5 mg/ml for crystal trials. Crystals were obtained in sodium 
formate and ammonium sulphate-based conditions previously identified for other RET-
KD:inhibitor complexes (Knowles et al., 2006). The ammonium sulphate crystals were 
hexagonal, whereas the sodium formate crystals were predominantly stacked square 
plates (Figure 5.3).  
Crystal X-ray diffraction screening of these two crystal forms showed that the plate 
morphology crystals diffracted to a much higher resolution (up to 2.6 Å) than the 
hexagonal crystal form (up to 10 Å). Therefore I proceeded to further optimise the plate 
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crystals in order to produce single crystals and eliminate multiple lattices evident from 
the diffraction data. 
Optimisation experiments involved varying the protein concentration, the 
protein:precipitant ratio in the crystallisation drop and performing an additive screen. 
Increasing the protein concentration from 3 to 4 mg/ml, accompanied by a slight 
reduction in the sodium formate concentration to 1.8–2 M resulted in some single 
crystals, as well as stacked plates (Figure 5.4a).  
 
Figure 5.3 Initial pRET-KD:sunitinib crystals 
(a) Chemical structure of sunitinib. (b) Hexagonal pRET-KD:sunitinib crystals grown in 
0.8–1 M ammonium sulphate and 0.1 M sodium citrate (pH 5) with 5 mg/ml protein 
using 1:1 protein:precipitant drops. (c) Stacks of square plate crystals grown in 2.1 M 
sodium formate, 0.1 M sodium citrate (pH 5.5), with 3 mg/ml RET-KD using 3:2 
protein:precipitant drops. 
5.3.2 pRET-KD:sunitinib structure determination 
Around 30 of the apparently single plate crystals, each around 80 µm long, were 
cryoprotected with n-paratone and flash-frozen in liquid nitrogen. These crystals were 
screened for diffraction at Diamond Light Source, and datasets were collected from 
those exhibiting better than 3 Å resolution. The best dataset obtained showed diffraction 
to Bragg spacings of 2 Å (Figure 5.4b&c). However, as indicated by the high Rmerge in 
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the outer shell (60.2%), the data quality was poor beyond 2.2 Å, and was therefore 
reprocessed to 2.2 Å (Table 5.1).  
 
Figure 5.4 pRET-KD:sunitinib optimised crystals and diffraction 
(a) Optimised pRET-KD:sunitinib crystals. (b) & (c) Diffraction image from the 2.2 Å 
dataset used in structure determination.  
Data collection 
X-ray source Diamond Light Source I-03 
Wavelength / Å 0.9800 
Space group C2 
Unit cell dimensions   
            a, b, c / Å 73.32, 70.01, 78.97 
            α, β, γ / ° 90.00, 101.54, 90.00 
Resolution / Å 45.04–2.20 (2.32–2.20) 
Total reflections 53468 (7939) 
Unique reflections 19457 (2866) 
Multiplicity 2.7 (2.8) 
Completeness / % 97.7 (99.4) 
I/σ 10.1 (3.6) 
Rmerge / % 7.5 (32.4) 
Rp.i.m. / % 5.3 (22.8) 
Wilson B-factor / Å2 28.7 
Table 5.1 Data collection statistics for pRET-KD:sunitinib 
Values for the outermost shell are shown in parenthesises. 
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5.3.2.1 Structure determination by molecular replacement 
The dataset was processed using MOSFLM (Powell, 1999) and scaled and merged in 
the CCP4 suite (Collaborative Computational Project, 1994). POINTLESS (Evans, 
2006) confirmed the space group was C2, and cell content analysis indicated that 1 
molecule was present in the asymmetric unit. The structure was solved by molecular 
replacement in PHASER (McCoy et al., 2007), using the pRET-KD:PP1 structure 
(2IVV) as a model. PHASER identified a single solution with rotation function Z-score 
of 41.5 and translation function Z-score of 28.5. The final solution following automatic 
refinement in PHASER had a log-likelihood gain of 2611.5 and an Rfactor of 35.2%. 
5.3.2.2 Structure refinement with REFMAC 
The pRET-KD:sunitinib structure was refined at 2.2 Å using REFMAC (Murshudov et 
al., 1997) and model building was carried out in COOT (Emsley and Cowtan, 2004). 
Each round of refinement in REFMAC was carried out using ten rounds of TLS 
(translation, libration, screw rotation) refinement followed by ten rounds of restrained 
refinement. TLS groups used corresponded to the N and C-lobes (residues 716–808 and 
812–1011), and this refinement procedure allowed separate rigid body refinement of 
these two relatively mobile subdomains.  
The final refined model contains five N-terminal vector derived residues and residues 
705–1011 from the RET-KD, excepting the 711–715 loop and 823–843 from the kinase 
insert (residues 827–840 were absent from the construct). It also contains one sunitinib 
molecule and two formate molecules per KD. The Rwork and Rfree are 19.8% and 26.0% 
respectively, and the structure has good geometry (see Table 5.2). 




Resolution / Å 45.04–2.20 (2.26–2.20) 
Completeness / % 97.4 (99.3) 
No. of reflections 18467 (1366) 
Rwork / % 19.8 (20.4) 
Rfree / % 26.0 (27.0) 
Correlation coefficient (Fo-Fc) / % 93.9 
Protein residues 279 
Ligand molecules 3 
Water molecules 52 
Total non-hydrogen atoms 2246 
Mean B-factor / Å 26.9 
            Protein 28.7 
            Sunitinib 28.1 
            Water 29.6 
Ramachandran Plot / %  
            Favoured 94.98 
            Allowed 3.58 
            Outliers 1.43 
RMSD from ideal values  
            Bonds / Å 0.023 
            Angles / ° 2.064 
No. of TLS groups 2 
Table 5.2 Refinement statistics for pRET-KD:sunitinib 
Values for the outermost shell are shown in parenthesises. 
5.3.3 pRET-KD:sunitinib structure analysis 
The pRET-KD:sunitinib structure, as with all the RET-KD structures, displays a 
classical bilobal protein kinase structure (Figure 5.5). The smaller N-lobe consists of 
five anti-parallel beta strands (β1–5) and the catalytically important αC helix, between 
strands β3 and β4. The flexible glycine-rich loop (gly-rich loop), which lines the top of 
the active site, is found between β1 and β2.  
In addition to the classic N-lobe features, RET-KD has an N-terminal helix dubbed αN, 
which contains 5 vector-derived residues (GPLSL) and 6 de novo RET residues 
(SVDAFK). Since the vector-derived residues are not similar to those found in RET 
(MENQV) it is unclear whether this helix is present in full length RET (discussed 
further in section 5.4.3.2). The linker (I711–P715) connecting the αN helix to the rest of 
the KD is disordered.  
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The linker between the N and C-lobes, referred to as the kinase ‘hinge’ since the 
relationship between the N and C-lobes is flexible, connects strand β5 to helix αD. The 
kinase hinge residues line the back of the nucleotide-binding pocket and engage ATP 
pocket inhibitors, including sunitinib. 
The larger C-lobe of RET-KD is predominantly α helical, with 7 α helices (αD–αI) and 
contains the glycine and serine-rich kinase insert region, between αD and αE. Residues 
G823–Y826 and P841–E843 from the kinase insert, which are present in the protein 
construct, are absent from the refined electron density map and are therefore disordered 
in the crystal.  The long linker region between αE and αEF, contains antiparallel beta 
strands β7 and β8, which form the base of the nucleotide binding pocket; and the 
activation loop, including the phosphorylated Y905, which is functionally required for 
RET kinase signalling in vivo (Kawamoto et al., 2004). Y905 is the only visibly 
phosphorylated residue in this structure. Y900, the other invariant activation loop 
autophosphorylation site, is solvent exposed and the side chain is disordered. 
Overall the pRET-KD:sunitinib structure presented here is very similar to the published 
phosphorylated and non-phosphorylated RET-KD structures. The root mean square 
deviation (RMSD) between pRET-KD:sunitinib and pRET-KD:AMP (PDB 2IVT) is 
only 0.206 Å over 264 Cα’s. The RMSD between pRET-KD:sunitinib and non-
phosphorylated RET-KD:PP1 (PDB 2IVS) is slightly greater at 0.410 Å over 260 Cα’s. 
Furthermore the symmetric head-to-tail dimer seen in all published RET-KD structures 
is also present in the pRET-KD:sunitinib crystal, burying a surface area of 1382.6 Å2. 
(The RET-KD crystallographic dimer is described in section 1.7.2).   




Figure 5.5 pRET-KD:sunitinib structure key features  
The pRET-KD:sunitinib architecture is essentially the same as the published pRET-KD 
structures, with sunitinib bound in the ATP binding pocket. (a) Ribbon representation of 
the pRET-KD structure, with rainbow colouring from N to C termini. The α helices and 
β strands are annotated according to the standard kinase nomenclature. The two regions 
not seen in the electron density map, the αN linker and the kinase insert, are indicated 
by dotted lines. (b) The bilobate kinase structure is shown, with the N-lobe coloured 
light green (highlighted regions coloured light pink), and the C-lobe coloured green 
(highlighted regions in magenta). Key regulatory and RET specific elements are 
highlighted and labelled, with the crucial phosphorylated tyrosine (Y905) side chain 
shown in stick view. Sunitinib (coloured yellow) is also depicted in the stick view. 
5.3.3.1 pRET-KD bound to sunitinib adopts an ‘active’ kinase 
conformation 
The RET-KD molecule in the pRET-KD:sunitinib structure adopts an essentially 
catalytically competent, or ‘active’, conformation. Organisation of the kinase such that 
the catalytic site residues are properly positioned for catalysis involves the correct 
positioning of a number of structural elements within the KD. These are described 
below.  
Firstly the αC helix is positioned close enough to the active site to allow E775 to 
hydrogen bond with K758, an interaction important for the orientating K758 for binding 
to the α and β phosphates of ATP. K758 side chain itself is in a slightly different 
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conformation to those observed in published ATP-analogue bound active RTK KD 
structures. This is likely due to the absence of ordered coordinating ATP-phosphates in 
pRET-KD:sunitinib. 
The catalytic loop, located between αE and β7, contains the catalytic base D874, which 
is orientated by R878 and N879 to interact with the attacking hydroxyl from the 
substrate tyrosine side chain. In the pRET-KD:sunitinib structure this key residue is 
properly orientated when compared to equivalent residues in a substrate-peptide and 
ATP-analogue bound FGFR KD structure (PDB 2PVF).  
In the pRET-KD:sunitinib structure the conserved DFG sequence motif at the start of 
the activation loop (following β8) adopts the DFG-in conformation consistent with an 
active kinase. The positioning of this motif is generally linked to the conformation of 
the whole activation loop in KD structures. The DFG-in conformation observed here 
positions D892 ready for magnesium coordination. The D892 side chain is rotated 
slightly relative to the adopted position in the presence of Mg2+ and ATP seen in the 
FGFR structure, but the movement required is small.  
The activation loop itself is ordered and displays catalytically competent conformation, 
which does not impinge upon substrate binding. As previously mentioned Y905 in the 
activation loop is phosphorylated. The phosphate group provides an anchor point for 
this conformation, making hydrogen bonds to R770, R897 and K907 side chains from 
the αC helix and within the activation loop. Although in RET-KD crystals Y905 
phosphorylation is not required for adoption of this conformation (Knowles et al., 2006).  
All these features described for the pRET-KD:sunitinib structure are also observed in 
the published pRET-KD structures, excepting the positioning of K758, indicating that 
sunitinib is not effecting the overall arrangement of the pRET-KD structure. This shows 
that sunitinib is capable of binding to the active conformation of the RET-KD, thereby 
rendering the enzyme inactive solely by occupying the ATP-binding pocket. The details 
of sunitinib’s binding to this pocket are described below. 




Figure 5.6 Sunitinib-binding in the nucleotide pocket 
 (a) & (b) Close up of the sunitinib-binding pocket. Sunitinib (yellow sticks) and 
residues within 4 Å of sunitinib in the crystal structure are shown. Predicted hydrogen 
bonds are depicted as dotted lines. (e) Overlay of sunitinib-binding pocket residues with 
those same residues from the AMP bound pRET-KD structure (grey sticks) and AMP 
(dark grey sticks). (d) Relative positions of AMP and sunitinib in pRET-KD crystal 
structures, viewed from above. The C-lobe of the pRET-KD is shown in ribbon 
representation.  
5.3.3.2 Sunitinib-binding in the ATP pocket 
Well-defined electron density was observed for sunitinib for all but two ethyl groups of 
the solvent exposed diethylamino moiety. Sunitinib binds RET in the hydrophobic cleft 
with the β1, β2 and β3 strands forming the roof (residues T729, L730, V738, A756 and 
K758); the kinase hinge at the back (V804–G810); and β7 and β8 strands at the base 
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(L881 and S891) (Figure 5.6a-d). Sunitinib forms four hydrogen bonds with RET. 
Three of these are between the sunitinib ring system and main chain groups from the 
kinase hinge: the indolylidine nitrogen to the E805 main chain carbonyl (2.71 Å N to O 
distance); the indolylidine group carboxyl to the Y806 main chain nitrogen (2.98 Å); 
and the pyrrole group nitrogen to the A807 main chain carbonyl (3.42 Å). The final 
hydrogen bond is between the nitrogen from the carboxyamide group on the sunitinib 
pyrrole ring and the N-lobe L770 main chain carbonyl (2.94 Å) (Figure 5.6c&d). These 
hydrogen bonds are all with main chain groups, which partly indicates the basis for 
sunitinib’s lack of specificity for RET.   
The planar ring system of sunitinib overlaps with the binding site for the adenine group 
of ATP (Figure 5.6e&f), but inserts further into the hydrophobic pocket pressing up to 
the V804 gatekeeper residue. Despite this, sunitinib-binding results in very little 
conformational change in the nucleotide pocket residues when compared with those 
from the AMP-bound structure (Figure 5.6e). A small movement of the V804 side chain 
to accommodate the indolylidine group, a slight movement of the main-chain carbonyl 
of L770 as a result of the hydrogen bond, and a different conformation of the flexible 
K758 residue due to the lack of an ATP phosphate group are the most noticeable 
changes. 
5.3.4 Comparison with other sunitinib-bound KD structures 
There are three sunitinib-bound protein kinase structures in the PDB: Two tyrosine 
kinases: the receptor tyrosine kinase KIT’s KD (Gajiwala et al., 2009), and the 
intracellular tyrosine kinase IL-2-inducible T cell kinase (ITK) (Kutach et al., 2010); 
and one serine threonine kinase: phosphorylase kinase’s catalytic subunit gamma 2 
(unpublished).  
The sunitinib-bound KIT-KD structure has the kinase activation loop in an inactive 
conformation, blocking the substrate-binding site, with the magnesium-coordinating 
DFG motif adopting a DFG-out conformation. Furthermore Gajiwala et al. show that 
sunitinib preferentially inhibits the non-phosphorylated and inactive (DFG-out) state of 
KIT-KD using an in vitro kinase assay. The observed IC50 values for non-
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phosphorylated versus phosphorylated KIT-KD were 42 nM and 7 µM respectively 
(Gajiwala et al., 2009).  
As mentioned above, RET-KD exhibits an active DFG-in conformation in the sunitinib-
bound structure (Figure 5.7a&b), as for all published RET-KD structures. To test 
whether there is any difference in sunitinib inhibition of kinase activity between non-
phosphorylated and phosphorylated RET-KD, as seen for KIT, I performed a similar in 
vitro kinase assay. The polyE4Y peptide was used as a substrate, and ATP consumption 
was measured at varying sunitinib concentrations (Figure 5.7c). The IC50 values for 
sunitinib with non-phosphorylated and phosphorylated RET were very similar: 0.56 ± 
1.21 µM (IC50 ± standard error of the mean) and 1.44 ± 1.14 µM respectively. 
Therefore there does not seem to be an appreciable difference between sunitinib’s 
inhibition of the two phosphorylation states of RET in vitro. This could reflect either a 
lack of specificity by sunitinib for a particular DFG conformation or the absence of a 
DFG-out conformation of RET-KD in solution. The difference in activity between 
phosphorylated and non-phosphorylated RET-KD by this assay is only 2.5–3×, and the 
non-phosphorylated RET-KD structure still shows an active activation loop structure 
with DFG-in (Knowles et al., 2006). Therefore unlike KIT where the non-
phosphorylated KD can be reasonably assumed to be predominantly in the DFG-out 
conformation, this cannot be assumed for non-phosphorylated RET-KD. As such the 
similarity between IC50 values for sunitinib with RET-KD in both phosphorylation 
states may reflect sunitinib-binding essentially the same conformation of the kinase—as 
observed in the crystal structures—with DFG-in.    
Sunitinib targeting the active conformation of kinases is more consistent with it being a 
Type 1 multi-kinase ATP-competitive inhibitor. This is because the active conformation 
of the active site of protein kinases is very similar, whereas there is greater divergence 
between inactive conformations and mechanisms of autoinhibition (Huse and Kuriyan, 
2002). Consistent with this the other two sunitinib-bound protein kinase structures 
exhibit an active activation loop conformation with DFG-in like the RET structure 
(Figure 5.7). Notably the tyrosine kinase ITK structure shows an active conformation 
despite the protein being non-phosphorylated. This is not due to a preference for the 
active conformation in the crystal, since in the same study two other inhibitors were 
also co-crystallised with ITK and both of these exhibited an inactive arrangement 
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(Kutach et al., 2010). KIT may therefore be an exception to a general preference by 
sunitinib for the active conformation. 
The major differences between the three sunitinib-bound active KD structures are seen 
in the positions of the flexible gly-rich loop and the αC helix (Figure 5.7d&e). Neither 
of these differences is likely to be linked to sunitinib-binding. The gly-rich loop of RET, 
as seen in all current RET-KD structures, collapses over the active site in such a way 
that would prevent ATP binding (were sunitinib not there).  The gly-rich loop of ITK is 
disordered, and in phosphorylase kinase the gly-rich loop is raised away from the active 
site allowing ATP access. The αC helix contains magnesium-coordinating residues 
required for catalysis; therefore in active kinase structures the αC helix is positioned 
close the active site. The N-terminus of the RET αC helix is bent further towards the 
kinase cleft than in the other two DFG-in sunitinib-bound kinase structures, despite 
their active conformation (corroborated by the inactive KIT structure where the αC 
helix is even further from the catalytic centre). The αC helix in the active insulin 
receptor KD structure has the same arrangement as RET-KD however, so this is not a 
RET specific arrangement.   
Comparison of the three kinases bound to sunitinib highlights the uncommon nature of 
the interaction of KIT-KD with sunitinib, and also highlights some of the macro 
structural differences between the RET-KD and other ‘active’ KD crystal structures. 




Figure 5.7 Sunitinib can bind both active and inactive kinases 
(a) Superposition of sunitinib-bound RET-KD (green ribbon and highlighted with teal) 
and KIT-KD (PDB 3G0E, yellow ribbon and highlighted with orange) revealing the 
different activation loop (A-loop) conformations. (b) Close up, from above, of sunitinib 
binding RET-KD in the active DFG-in conformation and KIT-KD the inactive DFG-
out. Sunitinib, and the DFG motifs at the start of the activation loop, are highlighted and 
shown as sticks. (c) Results of an in vitro ADP-coupled kinase assay comparing 
sunitinib inhibition of phosphorylated and unphosphorylated RET-KD kinase activity 
towards a polyE4Y peptide substrate. (d) & (e) Superposition of the sunitinib-bound 
‘active’ KD structures, depicted as ribbons with sunitinib shown as spheres. RET-KD is 
coloured green, IL-2-inducible T cell kinase (ITK), magenta (PDB 3MIY), and 
phosphorylase kinase gamma 2, purple (PDB 2Y7J). 
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5.4 A high resolution adenosine-bound RET-KD structure 
5.4.1 Rationale and crystallisation 
The RET-KD has been co-crystallised with a number of inhibitors, as discussed in the 
previous section, along with two ATP derivatives: AMP and cyclic AMP (Knowles et 
al., 2006). No structures with an ATP-analogue bound have so far been published, and 
in all RET-KD structures the gly-rich loop is in a ‘closed’ conformation (collapsed over 
the active site) precluding ATP-binding.  
A structure containing all three phosphate groups of ATP would be desirable, since this 
would best represent the enzyme in a catalytically productive state, and may help trap a 
substrate-peptide engaged by the kinase. I therefore conducted crystal trials using RET-
KD mutations discussed in section 5.5 with AMPPNP. These mutants were produced in 
an attempt to obtain a different crystal form, and since it was unknown whether the 
current crystal form—obtained in the sodium formate condition—would accommodate 
an ATP-analogue these mutants were a possible way of obtaining an ATP-analogue 
bound structure.  
As a control I set up the wild type pRET-KD with AMPPNP in the sodium formate 
condition, to see whether RET-KD could crystallise in this condition when bound to 
AMPPNP. Sitting drops of 3 mg/ml pRET-KD with 3 molar excess AMPPNP were set 
up against a well solution of 0.1 M sodium citrate pH 5.5, and 1.8–2.3 M sodium 
formate. No crystallisation was observed after 6 days, so I tried seeding some of the 
drops using crushed pRET-KD:sunitinib crystals. This did result in the formation of 
plate crystals, as seen for pRET-KD:sunitinib, but only in the seeded drops. In house 
testing for X-ray diffraction gave spots to around 4 Å. 
Due to other priorities, these crystals were not pursued further at the time. However 
upon looking at the tray again 20 months later, crystals had formed in the unseeded 
drops. In particular, one large 3D single crystal had formed in the 2.1 M sodium formate 
condition (Figure 5.8). This crystal was harvested, cryoprotected with mother liquor 
plus 25% glycerol and flash frozen in liquid nitrogen.  
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5.4.2 Structure determination of pRET-KD:adenosine 
5.4.2.1 Data Collection 
This single crystal was taken to Diamond Light Source and Dr. Andrew Purkiss-Trew 
collected diffraction data. Test shots showed diffraction to around 1.6 Å, although only 
data to 1.8 Å was used due to low completeness (Figure 5.8 and Table 5.3). A dataset 
was collected using the Pilatus detector over 102o, with an oscillation of 0.2o per image. 
The data showed some low-level ice contamination, particularly in one crystal 
orientation. This is the highest resolution dataset obtained for RET-KD and we were 
keen to see if this dataset would allow identification of flexible regions, disordered in 
previous structures. 
 
Figure 5.8 pRET-KD:adenosine crystal and X-ray diffraction pattern 
(a) Image of 300 µm pRET-KD:adenosine crystal grown in 2.1 M sodium formate, 0.1 
M sodium citrate pH 5.5, 3mg/ml protein. (b) Representative diffraction pattern image, 
collected on a Pilatus detector at Diamond Light Source I-24. 




X-ray source Diamond Light Source I-24 
Wavelength / Å 0.9700 
Space group C2 
Unit cell dimensions   
            a, b, c / Å 73.162, 68.980, 78.631 
            α, β, γ / ° 90.00, 101.78, 90.00 
Resolution / Å 39.24–1.80 (1.86–1.80) 
Total reflections 64144 
Unique reflections 33908 
Mosaicity / ° 0.57 
Redundancy 1.89 (1.93) 
Completeness / % 95.4 (94.2) 
I/σ 13.6 (1.8) 
Rmerge / % 3.7 (29.2) 
Table 5.3 Data collection statistics for pRET-KD:adenosine 
Values for the outermost shell are shown in parenthesises. 
5.4.2.2 Solving the structure by molecular replacement 
D*TREK (Pflugrath, 1999) was used to process the data, since it deals with Pilatus data 
particularly well. The spacegroup was determined to be C2, with cell parameters as 
detailed in Table 5.3. After removal of a single poor image, and cutting back the 
resolution to 1.6 Å to give an I/σ of 1 and Rmerge of 47% at the highest resolution shell, 
the data was integrated, scaled and merged in D*TREK. 
Molecular replacement was carried out using the CCP4 suite (Collaborative 
Computational Project, 1994). Cell content analysis predicted that there was one 
molecule in the asymmetric unit with a 60% solvent content. The RET-KD protein 
coordinates from the pRET-KD:PP1 structure (PDB 2IVV) were used as the search 
model for molecular replacement in PHASER (McCoy et al., 2007). A single good 
solution was found. 
5.4.2.3 Refinement using PHENIX and BUSTER 
The structure was refined initially using the maximum-likelihood automated refinement 
program PHENIX.REFINE (Adams et al., 2010) with model building carried out in 
COOT (Emsley and Cowtan, 2004). Refinement was carried out using three TLS 
groups: residues 700–713 (αN helix), 715–805 (N-lobe), and 811–1012 (C-lobe). The 
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improvement in the Rfactors stalled during refinement. We reasoned this could be due to 
poor data quality at high resolution and the data was therefore cut back to 1.8 Å, which 
resulted in a moderate improvement in Rwork and Rfree. Electron density for adenosine in 
the nucleotide pocket was observed and built, but throughout refinement no density for 
the phosphate groups of AMPPNP was seen. Electron density for 10 formate molecules 
and 2 glycerols was also observed and these were added. Previous structures only 
contained between two and four formate molecules; the number here is likely a 
reflection of the higher resolution of this structure. 
The gly-rich loop was found to be in two different conformations, and the electron 
density for this region was too poor to build in both conformations with confidence. A 
different refinement program, BUSTER (Blanc et al., 2004), was therefore tried. 
BUSTER uses maximum-likelihood and maximum entropy techniques for refinement. 
It was designed to overcome the bias towards the modelled incomplete structure, which 
occurs in other refinement programs, and limits the improvement in the electron density 
map for unmodelled regions of the structure. We therefore tried BUSTER to see if it 
would improve the electron density for the gly-rich loop. Refining the structure with 
BUSTER did improve map connectivity, and particularly the gly-rich loop density, 
although the overall Rfactors were not improved. Six rounds of model building and 
refinement in BUSTER (with TLS groups as before) were carried out, resulting in a 
final structure with Rwork  = 19.8% and Rfree = 21.3% (Table 5.4). 




Resolution / Å 39.28–1.80 (1.85–1.80) 
Completeness 95.27 (95.27) 
No. of reflections 33858 (2898) 
Rwork / % 19.77 (24.23) 
Rfree / % 21.33 (28.66) 
Correlation coefficient (Fo-Fc) / % 95.68 
Total protein atoms 2317 
Total ligand atoms 182 
Total solvent atoms 105 
B-factor (Å2) 43.28 
            Protein 42.42 
            Ligand 44.40 
            Water 52.56 
Ramachandran Plot / %  
            Favoured 97.38 
            Allowed 2.25 
            Outliers 0.37 
RMSD from ideal values  
            Bonds / Å 0.01 
            Angles / ° 0.97 
No. of TLS groups 3 
Table 5.4 Refinement statistics for pRET-KD:adenosine 
Values for the outermost shell are shown in parenthesises. 
5.4.3 Analysis of the pRET-KD:adenosine high resolution structure 
The refined 1.8 Å structure from the 20 month old crystal grown from pRET-KD + 
AMPPNP, showed that only adenosine was present in the nucleotide pocket. 
Presumably the phosphodiester bonds had undergone water-mediated hydrolysis over 
time leaving just adenosine. 
The overall structure of the kinase is very similar to the sunitinib-bound structure 
presented in the previous section, and the AMP bound pRET-KD structure (PDB 2IVT), 
which only differs in the presence of a single phosphate on the ligand. The RMSD is 
0.267 Å over 248 Cα’s between the sunitinib and adenosine structures, and 0.231 Å 
over 243 Cα’s between the AMP and adenosine structures. As with these structures 
RET contains a single phosphorylated tyrosine residue on the activation loop, pY905. 
As expected the activation loop is in an open, ordered, ‘active’ conformation (Figure 
5.9) with DFG-in. Unsurprisingly the adenosine-bound pRET-KD crystals contain the 
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same symmetric head-to-tail dimer seen in the pRET-KD:sunitinib and other RET-KD 
structures.  
The questions of whether an ATP-analogue can be accommodated in this crystal lattice 
and what conformational changes in the gly-rich loop would be required for ATP 
accommodation are not answered by this structure. Fresh pRET-KD:AMPPNP crystals 
with better diffraction than those produced in this study (section 5.4.1) are needed. 
However the pRET-KD:adenosine structure does contain some notable differences and 
additions, due to the improved resolution and original presence of AMPPNP, compared 
to previously solved RET-KD structures. These include electron density for the linker 
between the αN helix and the rest of the KD, and two distinct conformations of the gly-
rich loop (Figure 5.9). These features are discussed further below.     
 
Figure 5.9 Comparison of all published RET-KD structures showing the unique features 
in the adenosine-bound structure 
(a) Alignment of all published RET-KD structures along with the two presented in this 
thesis. Protein structures shown as tubes: pRET-KD:adenosine, cyan; pRET-
KD:sunitinib, green; non-phosphorylated RET-KD:cAMP (2IVS), magenta; pRET-
KD:AMP (2IVT), grey; pRET-KD:PP1 (2IVV), pale yellow; pRET-KD:ZD6474 
(2IVU), pale green; pRET-KD:X2K  (2X2K), pale pink; pRET-KD:X2L (2X2L), light 
orange; pRET-KD:X2M (2X2M), pale blue. Adenosine is shown as cyan sticks to mark 
the nucleotide pocket. (b) Close up of the ‘open’ and ‘closed’ gly-rich loop 
conformations, with the F735 side chain shown in stick depiction. 
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5.4.3.1 Multiple conformations of the flexible gly-rich loop 
The gly-rich loop is known to be flexible and has been seen in a variety of positions in 
KD crystal structures, ranging from an ‘open’ conformer positioned away from the 
kinase cleft to a ‘closed’ conformer with the gly-rich loop folded down over the cleft, 
sterically blocking binding of ATP phosphate groups. In active ATP-bound KDs the 
gly-rich loop engages the nucleotide’s phosphates and facilitates proper positioning of 
the γ-phosphate for phosphoryl transfer. An ‘open’ conformer of the gly-rich loop is 
proposed to facilitate ADP-release (Khavrutskii et al., 2009). ATP-pocket inhibitors can 
also influence the conformation of the gly-rich loop, with the conserved phenylalanine 
(F735 in RET) often folding back to contact hydrophobic moieties in the bound 
inhibitor (Johnson, 2009). However in all the published RET-KD structures the gly-rich 
loop is in the same ‘closed’ position, with some slight variation evident (Figure 5.9b). 
This loop is present in two conformations in the pRET-KD:adenosine structure. One of 
which is similar to that seen in other RET-KD structures, with F735 packed against the 
αC helix, but the alternate is a new ‘open’ conformation, with F735 accessible. This 
‘open’ conformation has the gly-rich loop bent away from the kinase cleft and the active 
site.  
As is shown in Figure 5.10, overlaying the pRET-KD:adenosine structure with an ATP-
analogue and substrate-peptide bound KD structure of the closely related FGFR2 (Chen 
et al., 2007), reveals that the usual ‘closed’ conformation of the RET gly-rich loop in 
the crystal, as exemplified by the pRET-KD:AMP structure, would clash with the β and 
γ phosphates from ATP (Figure 5.10b). The usual gly-rich loop conformation is 
therefore an inhibitory conformation since it would impede ATP (or ADP) binding.  
The alternative ‘open’ conformation of the gly-rich loop in the pRET-KD:adenosine 
structure is similar to the conformation of this loop in the pFGFR2:ATP-
analogue:substrate peptide structure, showing that this conformation could 
accommodate ATP, and could therefore be described as an ATP-competent 
conformation. It does not precisely match the conformation seen in the FGFR2 structure 
however, due to the lack of the hydrogen bonds between the γ phosphate oxygens and 
gly-rich loop main chain nitrogens. Instead this ‘open’ conformation of the gly-rich 
loop is stabilised by two hydrogen bonds with the loop that precedes the αC helix, 
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located above the gly-rich loop. These H-bonds are formed between the main chain 
carbonyls of the gly-rich loop and the side chain nitrogen of N763 and the main chain 
nitrogen of K761. 
The two different gly-rich loop conformations of RET are defined by the conformation 
of two residues (Figure 5.10c). One is E768 from the αC helix, which points upward 
when the gly-rich loop is in the more commonly observed ‘closed’ position, a 
conformation stabilised by a hydrogen bond between one of its side chain oxygens and 
the main chain nitrogen from S765 at the top of the αC helix. However this 
conformation is not compatible with the gly-rich loop in the ‘open’ position, with the 
side chain clashing with the gly-rich loop F735 side chain. The E768 side chain 
therefore adopts a different conformation when the gly-rich loop is in the ‘open’ 
position. In this case the side chain is pointing down in a way that would be 
incompatible with the ‘closed’ position of the gly-rich loop. The E768 rotamer is 
therefore linked to the position of the gly-rich loop. Similarly the F735 side chain must 
adopt a different rotamer in each of the two gly-rich loop conformations to avoid a clash 
with the αC helix.   
The required conformations of E768 and F735 to accommodate the gly-rich loop ‘open’ 
position in RET are not required for the equivalent residues in FGFR2. This is due 
largely to the different position of the top end of the αC helix. The αC helices of RET 
and FGFR2 overlay well towards the base of the helix, where the magnesium 
coordinating glutamate resides (E775 in RET), however the top part of the helix in 
FGFR2 is bent away from the gly-rich loop. The gly-rich loop of FGFR2 is also slightly 
lower down and further away from the αC helix than RET. This means that although the 
D527 side chain (equivalent to RET E768) is pointing upwards it is not clashing with its 
gly-rich loop in the ‘open’ position. The side chain of F492 (equivalent to RET F735) is 
disordered and there is space for it to adopt either rotamer observed in RET.  
Intriguingly E768D is an oncogenic mutation, although how it activates RET is 
unknown, particularly since it is such a subtle and conservative mutation. Its location 
close to the hypothesised inhibitory dimer interface, led to speculation that the presence 
of the shorter aspartate could weaken this interaction (Knowles et al., 2006), but the 
glutamate side chain doesn’t directly contact the other molecule in the dimer. If the 
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switching of E768 side chain rotamer is necessary for the gly-rich loop to adopt the 
active ATP accessible ‘open’ conformation, perhaps the smaller aspartate side chain 
more readily allows this enzyme to assume this conformation.  
The reason both conformations are present in this pRET-KD:adenosine structure, is 
likely due to there originally being AMPPNP bound, which would require the gly-rich 
loop to be in the ‘open’ position. Over time water-mediated hydrolysis of 
phosphodiester bonds led to loss of all three phosphates, allowing the gly-rich loop to 
flip over into the kinase cleft. The steric constraint imposed by the necessity of the 
rotamer change of the F735 and E768 to allow this movement to occur in the crystal, 
may be the reason why the gly-rich loop is still found in the ‘open’ position at least 50% 
of the time.   
In conclusion the pRET-KD:adenosine structure presented here reveals two 
conformations of the gly-rich loop. The first, seen in all other RET-KD structures, with 
the loop bent into the kinase cleft is incompatible with ATP binding. Whereas the 
second with the loop bent upwards, would be compatible with ATP binding, and 
therefore reveals a hitherto unseen active arrangement. The movement of the gly-rich 
loop is constrained by E768, an oncogenic mutation site, and therefore the E768D 
mutation may increase kinase activity by allowing the gly-rich loop to switch 
conformation more readily.   




Figure 5.10 'Open' and 'closed' conformations of the gly-rich loop 
The adenosine RET-KD structure contained two different gly-rich loop conformations. 
(a) Superposition of pRET-KD:adenosine structure (coloured cyan, highlighted features 
in green), AMP-bound pRET-KD structure (PDB 2IVT, coloured light grey, highlighted 
features in dark grey) and ATP-analogue and substrate-peptide bound pFGFR2-KD 
structure (PDB 2PSQ, coloured orange, highlighted features in yellow). (b) Close-up of 
the gly-rich loops from these structures, showing the inability of RET to accommodate 
ATP with the gly-rich loop in the ‘closed’ position. (c) View of the gly-rich loops of the 
two RET structures from beneath the αC helix. The two positions of the gly-rich loop in 
the adenosine-bound structure are reflected in the rotamer switch of F735 and the two 
conformations of E768 (side chain shown) from the αC helix. 
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5.4.3.2 First complete look at the N-terminal linker preceding the first 
beta-strand of the N-lobe 
The pRET-KD:adenosine structure contains 10 ordered formates and 2 glycerols. One 
of the glycerols is bound in a pocket beneath the linker connecting the αN helix to the 
rest of the KD (αN linker). The entire linker is uniquely present in this structure (Figure 
5.9), though with relatively high B factors for the previously absent residues (I711–
P715 Cα’s 70–78 Å2). The bound glycerol molecule from the cryoprotectant is likely 
contributing to loop stabilisation (Figure 5.11).  
The αN helix itself provides an anchor point for this linker. This helix packs against a 
hydrophobic surface formed the entire length of the exposed face of the αC helix. The 
αN helix residues L702, V706 and F710, lie close to the hydrophobic side chains of αC 
helix residues P766, L769, L773 and F776, and potentially L800 from the β4–β5 linker, 
stabilising both helices. However as previously mentioned (section 5.3.3) the first five 
residues of the αN helix are pBacPAK vector-derived, and unrelated to the equivalent 
residues in RET. These residues form the first turn of the αN helix, and include L702. 
The equivalent RET residue is an asparagine, which wouldn’t fully recapitulate the 
hydrophobic interactions of L702. The presence of these vector-derived residues means 
that it is uncertain whether the αN helix is a true feature of the RET structure or is an 
artefact. An unpublished RET-ICD structure, including the native JM sequence, by Dr. 
Ivan Plaza-Menacho, shows an extended conformation of this region of RET that also 
presents hydrophobic contacts to the αC helix. The αN helix is therefore likely 
highlighting a true protein-protein interaction surface. Furthermore engagement of the 
hydrophobic surface of the αC helix is a regulatory mechanism in other kinases, 
including the RTK EGFR (Jura et al., 2011), and could be regulatory in RET.  




Figure 5.11 RET-KD N-terminal linker 
(a) Ribbon representation of the pRET-KD:adenosine structure (cyan), with N-lobe 
structural elements labelled. The RET-derived N-terminal linker residues, preceding the 
N-lobe β1 strand, are coloured green, with the previously unseen residues in yellow. 
The glycerol molecule bound in the pocket formed by this linker, the β4 and β5 strands, 
and the αC helix is shown in stick view, in pink. (b) Close up of the N-terminal linker 
region, with the side chains shown as sticks. (c) & (d) The glycerol binding pocket, with 
residues within 4 Å of the glycerol shown as sticks. The hydrogen bonds are shown as 
yellow dotted lines.  
A central anchor point for the αN linker is W717, which packs against the start of β4 
near the base of the αC helix (Figure 5.11). This residue, which is conserved among 
FGFR kinases as well as RET, caps the regulatory spine in these kinases. This spine of 
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hydrophobic residues, formed when the DFG motif is in the catalytically competent 
DFG-in conformation, is conserved throughout protein kinases, and is proposed to be 
important for stabilising the active conformation of the kinase, since it connects the αC 
helix of the N-lobe, via the activation loop DFG motif F893, to the C-lobe αF helix 
(Kornev et al., 2008) (Figure 5.12a). The presence of W717 at the top may confer 
additional stability to the spine and may also provide an additional source of regulation 
if its position can be altered. The spine residue it packs against, L790, is an oncogenic 
mutation site, and links W717 to L779 in the αC helix. The oncogenic mutation is 
L790F, and so perhaps the phenylalanine side leads to increased kinase activation by 
conferring greater stability to the spine than the native leucine. 
The section of the αN linker between the αN helix and W717 has not previously been 
seen in its entirety, and even in this structure there is electron density only for the main 
chain of I711–D714, and the exact position of the P715 ring was difficult to model. The 
glycerol (shown in Figure 5.11c&d) ordering this linker is bound in a pocket with the 
αC helix at the base, the β4–β5 loop to one side, the αN helix to another, and the αN 
linker covering another side and the top. Glycerol forms four hydrogen bonds with 
pocket residues: Two with the main chain and one with the E718 side chain from the 
αN linker and the fourth with the S795 side chain from the β4–β5 linker. The base of 
this pocket is hydrophobic with F709, F776 and A793 all within 4 Å of the glycerol.     
Further along the linker F719, also conserved with FGFR, provides an anchor point, for 
the highly charged E718–N723 section (Figure 5.11b). This residue packs into another 
hydrophobic pocket formed by residues from β1, β2, β5 and the β2–β3 linker (L724, 
A743, I803 and L746).  
In conclusion the αN linker and the αN helix hide otherwise exposed hydrophobic 
surfaces from the RET N-lobe, with W717 and the αN helix hydrophobic residues (or 
the extended juxtamembrane domain hydrophobic residues) potentially playing a role in 
regulation of catalytic activity by their interactions with the regulatory spine and the αC 
helix respectively. 
 




Figure 5.12 Hydrophobic regulatory and catalytic spines 
Ribbon representation of the adenosine (green sticks) bound pRET-KD structure (cyan), 
with the hydrophobic residues forming the regulatory (a) and catalytic (b) spines shown 
as green and yellow spheres respectively. (a) RET (and its close ortholog, FGFR) 
contain a conserved tryptophan (W717, yellow spheres) found in the N-terminal linker, 
which lies at the top of the regulatory spine. (b) The adenine ring of adenosine 
completes the catalytic spine of the RET-KD, anchored by the αF helix (green). 
5.5 Accessing a different RET-KD crystal form 
All the RET-KD structures, including the two presented here, display the same head-to-
tail dimer in the crystal. Along with this there are very few differences between the 
structures, aside from the gly-rich loop conformation discussed above. In particular the 
activation loop is in an active conformation in all the structures with DFG-in. This is 
frustrating since seeing the kinase in different conformations allows much greater 
insight into the regulatory mechanisms that govern its activity. Furthermore, although 
the active conformation of proteins kinases across the superfamily is very similar, there 
is much greater divergence in the structure of their inactive conformations, which are 
therefore a promising target for designing specific inhibitors for use in the clinic. 
Obtaining the structure of a kinase in its inactive form can both reveal the kinase 
specific mechanisms involved in its regulation and provide a basis for rational drug 
design.  
It may be a constraint of the crystal lattice that allows only the active state of the kinase 
to be observed in this crystal form, which is corroborated by our inability to produce 
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crystals with known DFG-out targeting inhibitors such as sorafenib. Since the dominant 
interaction in the crystal lattice is the head-to-tail dimer interface, we hypothesised that 
generating mutants, which weakened this interaction, may improve the chances of 
obtaining a crystal form with a different arrangement of the kinase. A further motivation 
for producing mutants that weakened the dimer interaction was to generate tools for 
testing the ‘trans-inhibitory’ dimer hypothesis (discussed in section 1.7.2) in cell-based 
assays.  
5.5.1 Design and production of ‘dimer-deficient’ mutations 
Crystal structures of the MEN2B mutation, M918T, and the harsher P766R mutation 
showed these mutations failed to disrupt dimer formation in the crystal, although the 
P766R mutation did result in a movement of the two monomers in the dimer relative to 
each other (unpublished data). I therefore identified two additional residues—Q910 and 
P957—at the dimer interface, mutation of which to arginines in a P766R context was 
hoped would result in complete disruption of the dimer in crystals (Figure 5.13a&b). I 
therefore produced two double mutant RET-KD constructs RET-KDP766R/Q910R and 
RET-KDP766R/P957R, dubbed dimer-deficient mutants. 
Baculoviruses expressing the GST-RET-KD dimer-deficient mutants were produced by 
the protein production facility. Large-scale expression trials in Hi5 cells showed similar 
levels of expression to the wild type protein (up to 4 mg/l), and affinity purification 
resulted in stable, pure protein (Figure 5.13c). 
Having produced the dimer-deficient mutants I first tested whether kinase activity was 
intact. These mutations were designed to disrupt dimer formation, which may be 
relevant to kinase activity in vivo, however RET-KD is a monomer in solution and 
therefore these mutations should not impact kinase activity in solution. Kinase activity 
was tested in an in vitro ADP-coupled kinase assay using a peptide substrate (polyE4Y). 
The activity of the phosphorylated RET-KD dimer-deficient mutants was 
indistinguishable from phosphorylated wild type RET-KD showing that the kinase was 
still fully functional in solution (Figure 5.13d).  




Figure 5.13 Design and production of ‘dimer-deficient’ mutants 
(a) Head-to-tail dimer of RET-KD seen in all current crystal structures. The dimer from 
the pRET-KD:sunitinib structure shown in the ribbon representation with one monomer 
in green and the other teal. (b) Close up of the dimer interface between the N-lobe of 
one monomer (teal) and the C-lobe of the second (green). Side chains of the two 
oncogenic mutation sites found at this interface, M918 from the EF loop and E768 on 
the αC helix, are shown. The side chains of the three chosen ‘dimer-deficient’ mutation 
sites—Q910 at the end of the activation loop, P766R from the αC helix and P957R from 
the αG helix—are shown. (c) SDS-PAGE of samples from affinity purification of the 
‘dimer-deficient’ RET-KD double mutants. B = resin bound GST-RET-KD; E = eluted 
RET-KD. (d) In vitro ADP-coupled kinase activity assay of RET-KD mutants with 
polyE4Y peptide substrate. The experiment was carried out in triplicate and the graph 
shows average values ± standard error of the mean (SEM). Data table shows catalytic 
values based on fitting to the data with Prism (GraphPad). 
5.5.2 Dimer-deficient pRET-KDP766R/Q910R crystallisation and data 
collection  
I then began crystallisation screening of the dimer-deficient mutants. Initially I was 
using phosphorylated protein with AMPPNP, since the phosphorylated dimer-deficient 
RET-KDs could be concentrated up to 5 mg/ml without a significant loss of material, 
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whereas the solubility of the non-phosphorylated protein was poor above 2 mg/ml. 
Using phosphorylated material would most likely produce an active conformation of the 
RET-KD in the crystal, further promoted by the binding of the ATP-analogue AMPPNP. 
This strategy would therefore not achieve the eventual goal of observing an inactive 
conformation of the RET-KD, but would determine whether the mutations could induce 
a different arrangement of the RET-KD in the crystal, with an accessible active site. A 
crystal structure of the RET-KD without the previously observed trans-inhibited dimer, 
even in an active conformation would reveal whether the previously observed 
arrangement of the structural elements involved in the dimer interface are at all due to 
crystal packing effects. It may also allow the RET-KD to adopt a different conformation. 
Should crystallisation of the dimer-deficient RET-KDs lead to a different lattice 
arrangement being observed the mutants could then be used in screening known 
inactive conformation binding inhibitors such as sorafenib, once improvements in the 
solubility of the unphosphorylated protein had been achieved.    
To test whether these mutants could crystallise in the standard sodium formate 
condition, used for crystallisation of wild type RET-KD, I set up a small screen around 
the 2 M sodium formate and 0.1 M sodium citrate pH 5.5 condition, alongside screening 
using a range of commercial kits. Following seeding hexagonal crystals of the 
P766R/Q910R mutant but not the P766R/P957R mutant were produced in this condition. 
Crystals of pRET-KDP766R/Q910R with AMPPNP were also obtained in the first round of 
crystallisation screening in two non-formate based conditions. Both contained 
ammonium sulphate and used sodium citrate as a buffer (pH 4 and pH 5.6). These 
conditions were very similar to the condition that produced the low resolution crystals 
of pRET-KD:sunitinib (section 5.3.1), and these crystals were also hexagonal (Figure 
5.14a). Following production of larger crystals in a larger drop size, the crystals were 
harvested, cryoprotected in mother liquor plus 25% glycerol, and flash frozen. Crystal 
X-ray diffraction screening was carried out at Diamond Light Source. The best 
diffraction obtained went to a resolution of around 7.5 Å. The data could not be indexed 
from the test shots and therefore data was collected over 180° with a 1° oscillation 
(Figure 5.14). The dataset images showed evidence of multiple lattices in some 
directions, although one lattice dominated the diffraction pattern. 




Figure 5.14 pRET-KDP766R/Q910R with AMPPNP crystals and diffraction image 
(a) Hexagonal crystals of pRET-KDP766R/Q910R with AMPPNP. (b) & (c) Diffraction 
image from the best pRET-KDP766R/Q910R dataset collected at Diamond Light Source I-
03. 
5.5.3 pRET-KDP766R/Q910R diffraction data processing 
Despite the low resolution the collected pRET-KDP766R/Q910R diffraction dataset was 
processed in the hope of determining the arrangement of the RET-KD molecules in the 
crystal lattice, in order to determine whether the double mutation had successfully 
disrupted the crystallographic dimer. The dataset was indexed, integrated and scaled and 
averaged using XDS (Kabsch, 2010) since MOSFLM failed to index the data. Data 
statistics, including the refined cell dimensions are detailed in Table 5.5. POINTLESS 
was used to confirm the correct spacegroup, which was P6322. Cell content analysis in 
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CCP4 indicated that there was 1 RET molecule in the asymmetric unit with a 57% 
solvent content. 
Given the low resolution and poor data quality the structure could not be solved by 
standard molecular replacement using MOLREP (Vagin and Teplyakov, 1997) or 
PHASER (McCoy et al., 2007) using two different pRET-KD structures. Even 
separating the search model into the N-lobe (residues 717–803) and C-lobe (848–1005), 
did not lead to a solution with a reasonable Z score.  
However a 3.3 Å RET-KD structure had already been determined in the lab with the 
same space group and similar unit cell (a = 97.736, b = 97.736, c = 144.982, α = β = 
90.00°, γ = 120.00°). Since all we wanted to know at this stage was whether the double 
mutation had successfully disrupted dimer formation, we simply combined the protein 
coordinates from this structure with the scaled pRET-KDP766R/Q910R data, having altered 
the cell parameters to match those of pRET-KDP766R/Q910R. This was put through ten 
rounds of restrained refinement with REFMAC. The results are detailed in Table 5.6, 
with a final Rfree of 43%. This was sufficient to confirm the overall arrangement of the 
RET-KD molecules in the crystal, although the data was certainly not good enough for 
any further interpretations to be made. 
Data collection 
X-ray source Diamond Light Source I-03 
Wavelength / Å 0.9800 
Space group P6322 
Unit cell dimensions   
            a, b, c / Å 96.37, 96.37, 141.91 
            α, β, γ / ° 90, 120, 90 
Resolution / Å 142.57–7.48 (7.88–7.48) 
Total reflections 7019 (1038) 
Unique reflections 649 (88) 
Redundancy 10.8 (11.8) 
Completeness / % 100.0 (100.0) 
I/σ 9.2 (4.2) 
Rmerge / % 19.3 (59.4) 
Rp.i.m. / % 6.3 (18.0) 
Table 5.5 Data collection statistics for pRET-KDP766R/Q910R with AMPPNP 
Values for the outermost shell are shown in parenthesises. 




Resolution / Å 19.70–7.48 
Completeness / % 100 
No. of reflections 694 
Rwork / %  30.68 
Rfree / % 42.98 
Correlation coefficient (Fo-Fc) / % 79.5 
Total protein atoms 2195 
Total ligand atoms 21 
Total solvent atoms 3 
Mean B-factor / Å2 170.7 
Ramachandran Plot / %  
            Favoured 90.64 
            Allowed 7.12 
            Outliers 2.25 
RMSD from ideal values  
            Bonds / Å 0.008 
            Angles / ° 1.138 
Table 5.6 Refinement statistics for pRET-KDP766R/Q910R with AMPPNP 
 
The RET-KDs in this lattice still form the head-to-tail dimer (Figure 5.15). As for the 
P766R mutation alone, the P766R/Q910R double mutant dimer shows a 20° rotation of 
the monomers relative to each other compared to the dimer in the wild type RET-KD 
structure. The P766R/Q910R mutation is therefore not sufficient to prevent head-to-tail 
dimer formation during crystallisation.  
 
Figure 5.15 pRET-KDP766R/Q910R crystals still contain the symmetric dimer 
(a) Dimer of pRET-KD:sunitinib structure (teal and green ribbon), with superposition of 
one monomer of the pRET-KDP766R/Q910R crystallographic dimer (orange ribbon), 
showing retention of the head-to-tail dimer. A small rotation of the relative position of 
the two monomers has occurred in the mutant, opening up the activation loop region 
slightly. This change is likely a reflection of the different space group.  
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5.5.4 Dimer-deficient pRET-KDP766R/R957R further crystallisation screening 
Initial screening of pRET-KDP766R/P957R with AMPPNP did not yield any crystals. This 
included the sodium formate/sodium citrate and ammonium sulphate/sodium citrate 
conditions, which was encouraging since it means this double mutant is unable to 
crystallise in the same way as the wild type or pRET-KDP766R/Q910R with AMPPNP. 
Therefore the P766R/P957R mutation is likely truly ‘dimer-deficient’.   
To try and encourage crystallisation the pRET-KDP766R/P957R was subjected to a further 
purification step. Size exclusion chromatography was carried out with a high salt 
concentration in the buffer (400 mM). The protein eluted almost exclusively as a 
monomer (Figure 5.16a), unlike the wild type protein, which showed a much higher 
level of aggregation (though at 300 rather than 400 mM NaCl, Figure 5.2). Following 
addition of AMPPNP and concentration to 5 mg/ml, DLS was carried out, which 
confirmed the protein was monomeric at the concentration used in crystal trials (Figure 
5.16c). 
Using the size exclusion purified material I tried co-crystallisation with PP1 and 
sunitinib as well as AMPPNP, so see whether a smaller molecule in the nucleotide 
pocket would encourage crystallisation. This was unsuccessful; so one further 
modification was made. I tried co-crystallisation with AMPPNP and a 16 residue 
peptide of the RET activation loop (AL-peptide; residues S896–G911: 
SRDVYEEDSYVKRSQG). Screening of this did produce apparently crystalline objects 
in a PEG monomethyl ether 5000 based condition. These disintegrated during 
harvesting and cryoprotection however, and an initial round of optimisation, varying the 
PEG concentration and the pH with an increased drop size, did not result in improved 
crystal stability. Since better crystals were produced using the wild type protein with 
this peptide (see section 5.6), further attempts at crystal optimisation were not carried 
out.   




Figure 5.16 pRET-KDP766R/P957R further purification by size exclusion chromatography 
(a) Size exclusion of pRET-KDP766R/P957R on a Superdex 75 column with 400 mM NaCl 
in the buffer. (b) Coomassie stained reducing SDS PAGE of peak fractions from size 
exclusion shows purity of protein. (c) Dynamic light scattering results of size exclusion 
purified pRET-KDP766R/P957R with AMPPNP showing the protein in monodisperse in 
solution. 
5.6 Towards a crystal structure of the RET-KD with a 
substrate peptide 
Another way of obtaining a different crystal form of the RET-KD, this time specifically 
to look further at the active conformation of the kinase, would be to crystallise RET in 
complex with a substrate or substrate peptide and ATP-analogue. Since the previously 
observed the crystallographic dimer is incompatible with substrate binding (see section 
1.7.2) this would require an alternative arrangement of the RET-KD molecules in the 
crystal. Were this successful the resulting crystal structure would reveal the details of 
substrate interaction with the RET-KD as well as the ATP compatible arrangement of 
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the gly-rich loop. This might provide insights into the oncogenic mutations near the 
substrate binding site, such as M918T, as well as providing a basis for development of 
substrate-mimetic inhibitors.   
I screened pRET-KD with a three fold molar excess of both AMPPNP and the 
activation loop peptide (AL-peptide) and initially obtained crystals in two conditions 
(top two in Table 5.7). The AL-peptide has a very low pH, so in order to have greater 
control over the pH in the crystallisation trials the peptide was brought to pH 7 with 
sodium hydroxide. Further screening with fresh protein was then carried out in PEG 
based kits. The conditions that produced crystals, all with plate morphology, are listed 
in Table 5.7. Common themes in the conditions are the absence of salt and the presence 
of a low to medium molecular weight PEG, often with a citrate-containing buffer (pH 
5.5–8).  It is assumed that the AL-peptide is bound to the pRET-KD in the crystal since 
pRET-KD does not crystallise in these conditions without peptide present, however 
until the crystal structure is solved this cannot be definitively proven.  
Kit reference Buffer Precipitant Additive 
Index H10 - 20% (w/v) PEG 3350 0.2 M sodium citrate 
tribasic 
PEG Rx F10 0.2 M ammonium 
citrate pH 7 & 0.1 M 
imidazole pH 7 
20% (w/v) PEG 
2000mme 
- 
PEG/Ion E7 0.1 M di-sodium 
malonate pH 6 
12% PEG 3350 - 
PEG/Ion F2 8% tacismate pH 6 20% PEG 3350 - 
PEG/Ion F3 12% tacismate pH 7 12% PEG 3350 - 
PEG/Ion F5 4% tacismate pH 8 12% PEG 3350 - 
PEG Rx B5  0.1 M sodium citrate 
pH 5.5 
22% PEG 1000 - 
PEG Rx F2 0.1 M sodium citrate 
pH 5.5 
20% PEG 1000 0.1 M LiSO4 
PEG Rx G2 0.1 M imidazole pH 7 
& 2% tacismate pH 7 
8% PEG 3350 5% 2-propanol 
Table 5.7 pRET-KD + AMPPNP + AL-peptide crystallisation conditions 
Index, PEG Rx and PEG/Ion are crystallisation screening kits from Hampton Research. 
For crystallisation screening 3.7 mg/ml pRET-KD + AMPPNP + ALpeptide was mixed 
with well solution at a 1:1 ratio in sitting drops and incubated at 20 °C.  




Figure 5.17 Crystals of pRET-KD with AMPPNP and AL-peptide  
(a) and (b) Images of pRET-KD + AMPPNP + AL-peptide plate crystals grown in 18–
20% (w/v) PEG 3350, 0.2 M sodium citrate tribasic. 
To produce larger crystals than obtained in initial crystallisation screening, screens with 
larger drops based around some of the hit conditions were set up. Plates of up to 120 µm 
were produced on the first round of optimisation (Figure 5.17). Several of these were 
cryoprotected with well solution plus 25% glycerol, harvested, and flash frozen in liquid 
nitrogen. Testing crystals for X-ray diffraction was carried out at Diamond Light Source 
on a microfocus beamline (I-24). Many of the crystals contained multiple lattices, and a 
smeared spot shape was common. The resolution was mostly between 6–8 Å, although 
one crystal diffracted to 4.3 Å, but only in one direction. The crystal that produced the 
best spot shape only diffracted to 8 Å. A dataset from this crystal was collected in order 
to determine the space group and unit cell dimensions. 
Since it was collected using a Pilatus detector the 8 Å dataset was processed using 
D*TREK (Pflugrath, 1999). The space group was found to be C2 with unit cell 
dimensions as detailed in Table 5.8. The Matthews coefficient indicated that there were 
between 3–5 RET-KD molecules in the asymmetric unit. This is a different crystal form 
to those obtained for RET-KD previously (Table 5.8). Therefore if these new 
crystallisation conditions can be optimised to yield single crystals with better diffraction, 
the resulting structure could yield new information about RET-KD’s regulation and 
interaction with substrate. Unfortunately since these crystals were obtained late in the 
course of this thesis, I was not able to perform this further crystal optimisation myself.  

















2 M sodium 
formate,  
0.1 M sodium 
citrate pH 5.5 
2 M sodium 
formate,  
0.1 M sodium 




0.1 M sodium 
citrate pH 5 
14% PEG 
2000mme,  





1.8 Å 2 Å 7.5 Å anisotropic  4.3/8 Å 
Space group  C2 P21 P6322 C2 
Cell lengths 
(Å) 
a 73.1 50.4 96.4 97.2 
b 69.0 80.2 96.4 171.5 
c 78.6 79.7 141.9 85.4 
Cell angles 
α 90° 90° 90° 90° 
β 101.8° 100.9° 90° 113.7° 
γ 90° 90° 120° 90° 
Molecules in the 
asymmetric unit 1 2 1 4 (3–5) 
Cell volume (Å2) 388469 317171 1141372 1304932 
Table 5.8 RET KD crystal forms 
This table details examples of the 4 crystal forms of the RET-KD that have so far been 
obtained. Three of these are examples from this thesis and the non-phosphorylated 
(non-phospho.) RET-KD was crystallised by Phillip Knowles (Knowles et al., 2006). 
All published RET-KD crystal structures are from crystals produced in a very similar 
condition to pRET-KD:adenosine, have C2 symmetry and exhibit very similar unit cell 
dimensions, except the non-phosphorylated RET-KD, which shows the same RET-KD 
dimer despite the slightly different lattice.   
5.7 Conclusions 
In this chapter I have presented a 2.2 Å crystal structure of the RET-KD bound to the 
clinically relevant RET-inhibitor sunitinib. This showed sunitinib binding the active 
DFG-in conformation of the RET-KD, which is unlike sunitinib’s interaction with KIT, 
where it preferentially binds the inactive DFG-out conformation of the KIT-KD.  
I have also presented a high resolution (1.8 Å) crystal structure of the RET-KD bound 
to adenosine, which revealed some previously unseen features of the RET-KD structure, 
including an alternative conformation of the flexible gly-rich loop. A close look at this 
crystal structure also generated a new hypothesis for the mechanism of action of a RET-
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KD oncogenic mutation, which is being tested in mammalian cells in the Structural 
Biology Laboratory.  
Two mutations (P766R/P957R), which together disrupt the formation of the 
crystallographic trans-inhibited dimer, have been presented. This ‘dimer-deficient’ 
double mutant could be used as a tool for testing the trans-inhibited dimer hypothesis in 
cells. Unfortunately crystallisation screening of this mutant was unsuccessful and 
therefore I have not been able to assess the role of the crystallographic dimer in the 
structure of the RET-KD in the crystal. 
Finally I have presented a method for the crystallisation of RET-KD with a substrate 
peptide. These crystals are a new RET-KD crystal form, and if further optimisation 
improved the resolution of the crystals, the resulting structure could reveal new insights 
into RET-KD function and substrate interaction.  
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Chapter 6. Discussion 
Despite well established physiological and pathophysiological roles for RET in 
GFL/GFRα signalling, a molecular description of RET activation and oncogenic 
deregulation is poorly understood. Similarly, an integrated understanding of the 
relationship between the extracellular and intracellular parts of RET during ligand-
dependent activation is completely lacking. In this thesis I have sought to determine the 
architecture of the ligand-binding RET-ECD alone and in complex with ligand/co-
receptor with a view to understanding how RET binds ligand/co-receptor and how this 
engagement might lead to RET intracellular tyrosine kinase activation. I have also 
sought to develop our understanding of the regulation and chemical inhibition of the 
RET-KD by producing new crystal structures of the RET-KD.  In this chapter I will 
discuss the implications of the RET-ECD and GDNF/GFRα1/RET-ECD ternary 
complex architecture presented in this thesis for understanding published functional 
data and for understanding disease-associated RET mutations. I will also briefly discuss 
the limitations of our current understanding of RET regulation and outline some 
possible strategies to develop this going forward.   
6.1 A SAXS-derived model of the RET ECD 
The SAXS-derived model of the subdomain arrangement defining the overall zRET-
ECD architecture shows: a good fit for the clamshell CLD1–CLD2 arrangement, as 
observed in the hRET-CLD(1–2) crystal structure; a near-linear (~150°) calcium-
rigidified CLD2–CLD3 arrangement; a 100° bent CLD3–CLD4 arrangement, which is 
to my knowledge a novel tandem cadherin domain arrangement; and the CRD, at least 
in part, folded back on CLD4. This SAXS-derived model provides a first look at the 
overall RET-ECD architecture and, when combined with other structural and functional 
data, provides some insights into a possible mechanism of RET regulation and how 
RET-ECD Hirschsprung’s mutations may impact on RET folding. 
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6.1.1 The role of calcium in defining the CLD2–CLD3 junction  
The collapse of the near-linear CLD2–CLD3 arrangement in the absence of calcium, as 
observed by SAXS, indicates that like EC–EC junctions in classical cadherins, calcium 
is required for the end-to-end CLD2–CLD3 arrangement (Haussinger et al., 2002; 
Pokutta et al., 1994). Highlighting this in cadherins, a recent crystal structure of a 
calcium-free tandem cadherin domain array from T-cadherin showed its EC(1–2) 
domains adopting a clamshell arrangement with EC1 folded back onto EC2, similar to 
the constitutively calcium-free, disulphide-tethered, RET CLD1–CLD2 arrangement 
(Ciatto et al., 2010; Kjaer et al., 2010). In the T-cadherin case calcium was chelated 
from the EC1–EC2 junction by the citrate present in the crystallisation condition, 
leading to the collapse of the previously characterised near-linear calcium-rigidified 
EC1-EC2 arrangement (Ciatto et al., 2010). In this study my calcium-free zRET-ECD 
samples were purified in the absence of calcium but no attempt was made to chelate 
calcium from the protein. The inability of zRET-ECD prepared in the absence of 
calcium to bind zGFRα1a/zGDNF, unless calcium was added to the buffer, combined 
with the SAXS data showing the collapse of the near-linear CLD2–CLD3 arrangement, 
strongly suggests that there was no calcium associated with the zRET-ECD purified in 
the absence of calcium. Since calcium is required for RET-ECD production (van 
Weering et al., 1998), this indicates that calcium dissociated from the CLD2–CLD3 
junction during purification in the absence of calcium in the purification buffers. zRET-
ECD would therefore require calcium to be present in the extracellular space for 
maintenance of its architecture and functionality. This is consistent with previous data 
showing calcium is required for hRET signalling (Anders et al., 2001; Nozaki et al., 
1998).  The affinity of the three calcium-binding sites at the RET CLD2–CLD3 junction 
has not been measured. In classical cadherins the affinity of the calcium-binding sites 
varies from the micromolar to millimolar range and N-cadherin has been shown to be 
sensitive to the extracellular calcium concentration on a rapid timescale and therefore 
has been proposed to be regulated by calcium (Kim et al., 2011). RET could therefore 
be similarly reversibly regulated by extracellular calcium levels although this has not 
been shown. 
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6.1.2 The CLD3–CLD4 junction, an unusual tandem cadherin domain 
arrangement 
The SAXS-derived zRET-ECD model shows a 100° bend angle between CLD3 and 
CLD4, which was apparently maintained in the absence of calcium. This is distinct 
from the CLD1–CLD2 clamshell arrangement and also from the 80° bend angle 
observed in the first crystal structure of a constitutively calcium-free tandem cadherin 
domain array (EC(2–3)) from non-classical Drosophila N-cadherin (DN-cadherin) (Jin 
et al., 2012). It is also distinct from the calcium-bound EC–EC junctions observed in 
crystal structures of classical cadherins which show interdomain angles of ~140–160° in 
C-cadherin, ~145–155° in N-cadherin and ~130–170° in E-cadherin (Boggon et al., 
2002b; Harrison et al., 2011).  
The structural basis for the observed CLD3–CLD4 arrangement will not be clear until 
the CLD(1–4), or another CLD3–CLD4 containing construct, crystal structure is solved. 
Progress towards such a CLD(1–4) crystal structure was described in Chapter 2. 
Sequence alignment of RET CLDs to classical cadherin ECs identified a long 
hydrophobic 20–30 amino acid linker between predicted CLD3 βG and CLD4 βA, 
which is relatively well conserved amongst vertebrate RETs (Anders et al., 2001) 
(alignment is shown in Figure 1.7). Given that it is predominantly hydrophobic, this 
linker is presumably mostly buried at the CLD3–CLD4 junction. There is another 
plausible interpretation of the arrangement of structural elements at the CLD3–CLD4 
junction however. The CLD3–CLD4 ‘linker’ contains a conserved LXF motif (Figure 
6.1), which defines the start of CLD1 and CLD2, with the CLD3 start defined by the 
cadherin-conserved PXF motif. The phenylalanine from this motif packs into the core 
of the β-barrel fold, stabilising βA at the start of each CLD or EC. Secondary structure 
prediction in PHYRE2 predicts with high confidence (9/9) that a large proportion of the 
CLD3–CLD4 ‘linker’ forms a β-strand. Due to these two features an alternative 
hypothesis is that this ‘linker’ β-strand is actually CLD4 βA, with the previously 
predicted βA actually βB. The previously predicted βB might then form a long, partly 
basic and potentially helical linker between βB and βC at the CLD3–CLD4 junction, in 
line with secondary structure prediction for this region. This linker would contain the 
conserved potentially disulphide-constrained CV/IENC loop (Figure 6.1). All the 
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previously proposed CLD4 β-strands apart from βB are predicted to be β-strands by 
secondary structure prediction, and align well with cadherin consensus motifs. 
Resolution of this awaits a crystal structure, but the CLD3–CLD4 junction is evidently a 
divergent cadherin junction by sequence alignment, resulting in a novel cadherin 
domain arrangement as observed by SAXS. 
 
Figure 6.1 Hirschsprung's mutations at the CLD3–CLD4 and CLD4–CRD junctions 
Vertebrate RET CLD3–CLD4 junction sequence alignment showing the predicted β-
strands based on cadherin alignment (CLD3, magenta; CLD4, grey) and corroborated 
by secondary structure prediction in PHYRE2, except CLD4 βB, which is predicted to 
be helical. The secondary structure predicted β-strand in the proposed CLD3–CLD4 
junction is coloured green. Yellow lines show the predicted disulphide pattern. 
Hirschsprung’s-associated mutations are annotated beneath the alignment. Most of the 
mutations in this region of RET are located at the predicted CLD3–CLD4 junction or 
the base of CLD4, potentially engaging the CRD. The N-termini of the two zRET-
CLD4CRD constructs (long and short) produced in this thesis are annotated above the 
alignment.  
The importance of the CLD3–CLD4 junction in the folding (or function) of the RET-
ECD is highlighted by the presence of a cluster of Hirschsprung’s mutations at the 
predicted junction (Figure 6.1). One of these is an N-linked glycosylation site mutation 
(N394K). D353Y and Δ(379–381)F result in the loss of acidic residues from the 
junction. F393L (from the putative LXF motif), V397M and P399L are at the heart of 
the previously predicted CLD3–CLD4 junction and F393L has been shown to 
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kinetically compromise hRET-ECD folding, but not affect GDNF/GFRα1 binding 
(Kjaer et al., 2010; Kjaer and Ibanez, 2003b).   
6.1.3 Structural characterisation of the CRD 
In both the SAXS-based model of the zRET-ECD and the presented interpretation of 
the mTC 3D reconstruction the CRD is, at least partly, folded back and packed against 
CLD4. Unlike the CLDs the CRD fold cannot be readily predicted based on sequence or 
predicted secondary structure homology and unfortunately I have not been successful at 
obtaining crystals of a zRET-ECD construct containing the CRD. In the absence of X-
ray crystallography data, circular dichroism experiments indicated the CRD largely 
lacks regular secondary structural elements although it may have some proportion of β-
strands. The confidence of β-strand prediction by circular dichroism is poorer than α-
helix prediction however as the circular dichroism signal for β-strands is weak (Martin 
and Schilstra, 2008). The CRD fold is likely dominated by the 7–8 disulphides and a 
number of the CRD cysteine residues are sites of Hirschsprung’s mutations, with 
mutation resulting in impaired folding. The other CRD-associated Hirschsprung’s 
mutations both at the predicted base of CLD4 (Figure 6.1) and within the CRD (Figure 
6.2) commonly result in loss or gain of a charged residue in this largely polar domain. 
 




Figure 6.2 The CRD associated disease mutations and role in ternary complex formation 
Vertebrate RET-CRD sequence alignment with the known Hirschsprung’s and MEN2-
associated mutations indicated beneath the alignment. The epitopes recognised by two 
antibodies that bind RET alone but not in the context of the mTC are marked by green 
boxes.    
6.1.4 A potential interaction between CLD3 and the CRD 
When zRET-CLD4CRD is produced alone around 20% of the protein forms disulphide-
linked dimers. Such covalent species are not observed when the entire zRET-ECD is 
purified and implies the presence of an accessible and unpaired cysteine in the zRET-
CLD4CRD that is either not accessible and/or always paired in the zRET-ECD. The 
zRET-CLD4CRD contains an even number of cysteine residues and CLD3 contains no 
cysteine residues. Therefore the zRET-CLD4CRD construct is unlikely to contain an 
unpaired cysteine due to removal its usual disulphide partner. Unpublished observations 
by Dr. Svend Kjær working with human RET-ECD and CLD4CRD proteins revealed 
that CLD(1–3) influences the arrangement of CLD4CRD. He has found that some 
antibodies, which recognise epitopes in the CRD, only bind in the context of the whole 
ECD and not when only CLD4CRD are present. The arrangement of CLD4CRD when 
they are produced alone is therefore different to their arrangement in the context of the 
whole RET-ECD. One could speculate that the CRD might not be folded back on CLD4 
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in the same way, due to the absence of the CLD3-CRD contact. If true this altered 
CLD4CRD arrangement may be the basis for the observed zRET-CLD4CRD dimers. 
The changed CLD4CRD arrangement could separate two cysteines normally involved 
in formation of an intramolecular disulphide, making formation of this bond less likely 
and resulting in at least a proportion of monomers with unpaired cysteine residues. 
These can then form intermolecular disulphide bonds resulting in the observed 
disulphide-linked dimers. 
An alternative hypothesis is the lack of CLD3 exposes the top of CLD4, which is 
predicted to be the location of a short, conserved, potentially disulphide-constrained 
loop: CV/IENC. It could therefore be these, ordinarily protected, cysteines that are 
involved in the observed intermolecular disulphides.     
The disulphide-linked CLD4CRD dimer is intriguing since some of the oncogenic 
MEN2A mutations in RET occur at cysteine residues in the CLD, resulting in 
constitutive disulphide-linked dimers in the plasma membrane. It is possible I have 
therefore inadvertently trapped a species like one of the MEN2A mutants. Comparative 
mass spectrometry of trypsin-digested monomer versus dimer was attempted to see 
whether the intermolecular disulphide could be identified by the presence of a unique 
disulphide-linked peptide in the dimer. However the C-terminal peptide of the CRD 
derived from trypsin-digestion, where the interesting MEN2A cysteines reside, was too 
large for analysis by mass spectrometry with the available setup. Use of a different 
protease to digest the CLD4CRD monomer and dimer to produce smaller peptides of 
this region could help if this were to be repeated.    
6.2 The architecture of a mammalian RET/ligand/co-receptor 
ternary complex 
In Chapter 3 I presented a 24 Å resolution negative stain EM 3D reconstruction of a 
mammalian RET ternary complex. An interpretation of the arrangement of the RET-
ECD, GFRα1 and GDNF in the RET ternary complex was generated based on fitting of 
the mTC components with known or modelled structure into the EM map. Several 
assumptions were made before fitting as discussed in Chapter 3. The hand of the EM 
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map also had to be assigned and was chosen based on consistency of the resulting 
model with previous RET-GFRα1 interaction site data. The resulting selected 
interpretation has the 2-fold symmetric GDNF/GFRα1 complex at the heart of the mTC, 
with the two RET-ECD molecules wrapped around the outside of the GDNF/GFRα1 
complex making contacts with both GDNF and GFRα1, resulting in an overall two-fold 
symmetric arrangement. Here I will discuss the implications of this current 
interpretation.  
6.2.1 RET activation by ligand/co-receptor engagement 
The current interpretation of the mTC 3D reconstruction reveals a central role for the 
ligand/co-receptor complex in organising and mediating RET dimerisation. Multiple 
interactions between the RET-ECD and ligand/co-receptor result in a ligand/co-
receptor-defined stable arrangement of the two RET-ECDs in the complex, presumably 
positioned to optimally arrange the membrane proximal regions of the RET-ECD for 
activation of the intracellular kinase domain in the full-length receptor.  
In the current interpretation the membrane-proximal CRDs are drawn towards each 
other at the base of the mTC, interacting with opposing faces of GDNF. Part of the 
CRD is potentially also extending down into the base region of the complex towards the 
‘membrane’. Although since the crystal structure of the CRD is unknown and therefore 
cannot be fitted into the EM map this is purely speculative. The central location of the 
CRD in the mTC, packed between CLD4 and GDNF, is consistent with unpublished 
data from Dr. Svend Kjær. He has observed that two antibodies, which recognise 
different epitopes in the CRD, do not bind hRET-ECD when present within the mTC. 
This indicates that these epitopes are buried in the complex (the epitopes are shown in 
Figure 6.2). Juxtaposed CRDs extending towards the membrane in the base region of 
the 3D reconstruction is consistent with the oncogenic activating potential of MEN2A 
cysteine mutations towards the C-terminus of the CRD. The oncogenic disulphide-
linked RET dimers that result from these cysteine mutations presumably recapitulate 
and stabilise the arrangement of the membrane-proximal region of the RET-ECD in the 
wild type ‘active’ RET/ligand/co-receptor complex independent of ligand/co-receptor 
binding, through covalent CRD:CRD interactions.   
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The RET-CLD(1–4) arrangement from the zRET-ECD SAXS analysis has been fitted 
as a rigid body in the EM map and there is no evidence of large conformational changes 
in this portion of the zRET-ECD when bound to ligand/co-receptor. Indeed given that 
CLD(1–2) arrangement is disulphide constrained and the CLD2–CLD3 junction is 
calcium-rigidified, large conformational changes in CLD(1–3) are not expected. The 
rigidity of the CLD(3–4) arrangement is unknown, but it appears to be maintained in 
this current interpretation of the mTC 3D reconstruction. At the current resolution of the 
EM map localised conformational changes may exist within CLD(1–4) but cannot be 
determined with any certainty.  
Allosteric changes such as the movement of part of the CRD away from CLD4 upon 
ligand/co-receptor engagement may conceivably occur. For example, if the CRD does 
extend into the base region of mTC this would contrast with its location against CLD4 
as observed by SAXS of the ECD alone. However greater structural understanding of 
this domain and better resolution EM maps are required to prove this hypothesis. We 
note that precedents have been described previously for the EGFR, where binding of 
EGF ligand leads to a conformational change resulting in the exposure of a dimerising 
arm from the receptor that is otherwise buried in the absence of ligand (Ogiso et al., 
2002).  
6.2.2 Differential signalling by RET in response to different ligands 
The arrangement of the RET-ECD wrapped around the ligand/co-receptor complex is 
consistent with the hypothesis of Goldman and colleagues that RET is able to detect and 
respond to the different bend angles observed in GFL dimers (Parkash and Goldman, 
2009; Parkash et al., 2008). The different bend angles observed in GDNF and Artemin 
result in the Artemin/GFRα3 complex being more linear and longer than the 
GDNF/GFRα1 complex (shown in Figure 1.5). If RET-ECD binds Artemin/GFRα3 in 
the same manner as GDNF/GFRα1 in the current interpretation of the mTC this would 
result in RET-ECDs being flatter with respect to the membrane. This means that 
presumably either the bend angle between the RET transmembrane domain (TM) and 
CLD4 is different—135° for RET bound to GDNF/GFRα1 versus ~115° for RET 
bound to Artemin/GFRα3, based on the TM being perpendicular in the membrane—
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requiring the CRD to be flexible. Or alternatively the CLD4-TM angle is maintained by 
a rigid CRD and the arrangement of the two TMs is changed with respect to each other. 
The latter could result in a changed arrangement of the RET-ICDs, which may be the 
basis of the differential downstream signalling initiated by RET in response to the 
different ligands (Parkash and Goldman, 2009).    
6.2.3 Interactions between RET-ECD and GFRα1/GDNF in the mTC 
Previous published studies looking at the interactions between RET and ligand/co-
receptor, had the following findings: RET-CLD(1–3) are necessary for GFL/GFRα 
binding by human RET-ECD and confer species specificity to the interaction. Elements 
within CLD1 are particularly important, and may influence GFL/GFRα binding 
indirectly, via mediating a RET:RET interaction that stabilises the GFL/GFRα/RET 
interaction. RET-CLD4CRD also has a role in GFL/GFRα binding, and may directly 
interact with GFRα1-D1 and the GDNF N-terminal tail. GFRα-D2D3 contains the 
major RET binding site although it is unknown where this region binds within RET and 
GFRα’s don’t bind RET in the absence of GFLs (these data are summarised in Figure 
1.10). It was previously difficult to rationalise all of these data. However the 
interpretation of the mTC 3D reconstruction presented in this thesis provides a rational 
basis for several of these findings: CLD(1–3) interacts with GFRα1-D3, explaining the 
involvement of these domains in the formation of the ternary complex, although this 
does not explain the species-specificity. The CRD interacts with GDNF and GFRα1-D2 
explaining the requirement for both the CRD and GDNF. Examination of these contact 
regions, predicted by the current interpretation of the 3D reconstruction, revealed 
several potential bona fide RET contact sites on GFRα1 and GDNF, based on the 
conservation of surface-exposed residues. These proposed binding sites are discussed 
below, with reference to published data.    
6.2.3.1 Proposed RET-CLD(1–3) binding sites on GFRα1-D2D3  
In the current interpretation of the 3D reconstruction the major interaction between 
GFRα1 and RET is between the very tip of GFRα1-D3 and CLD1 (Figure 6.3). This 
region of GFRα1-D3, involving the turn between α9 and α10 and the α10 helix, 
Chapter 6. Discussion 
 
 211 
contains an SGNxxE/DE/D motif, which is conserved amongst all four GFRαs in 
vertebrates. The pair of glutamate/aspartate residues have previously been shown by 
mutagenesis studies to be important for the GFRα1/GDNF interaction with RET, with 
the double alanine mutation reducing RET signalling to 37% of the level with wild type 
GFRα1 (Parkash et al., 2008). The asparagine has also been previously proposed to be 
involved in RET binding, since it is surface-exposed and highly conserved; however 
this has not yet been tested (Wang et al., 2006). The hRET-CLD1 surface facing GFRα 
contains a number of mammal-conserved basic residues with the potential to interact 
with these conserved GFRα acidic residues (Figure 6.3). Charge reversal mutations of 
two of these basic residues (R77D/R144E) reduced the affinity of RET-ECD for 
immobilised GFRα1/GDNF by ten-fold without impacting on the RET structure (Kjaer 
et al., 2010).  
The 3D reconstruction current interpretation also predicts a possible minor interaction 
between the loop between α8 and α9 in GFRα1-D3 and the CLD2–CLD3 junction. 
This GFRα1-D3 loop contains charged residues and a surface exposed hydrophobic 
residue. However it is not well conserved amongst GFRαs (Figure 6.3) and therefore 
does not seem a likely to play a major role in the RET:GFRα interaction.  
Based on the crystal structure of the hGDNF/rGFRα1-D2D3 complex, Goldman and 
colleagues identified a number of residues within a charged patch on the surface of the 
co-receptor, including the previously mentioned acidic residues from the SGNxxEE 
motif, which when mutated decreased levels of RET autophosphorylation (Parkash et 
al., 2008). They therefore postulated that these residues were involved in direct RET 
interaction. These residues are shown in Figure 6.3 and other than the previously 
discussed pair of acidics they do not appear to make direct contacts with the RET-ECD 
in this interpretation of the 3D reconstruction. These residues (R190, K194, R197, Q198, 
K202, R257 and R259) form an SOS (heparin mimic)-binding site in the GFRα1/GDNF 
crystal structure. It is therefore possible that their mutation in soluble GFRα1-D2D3 
leads to decreased RET signalling indirectly by decreasing the affinity of GFRα1-D2D3 
for heparin, which may be involved in the capture of GFRα at the membrane. However 
the authors also state that mutation of these residues reduces RET-binding in their 
binding studies, although they do not show these data (Parkash et al., 2008). The 
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involvement of these previously-proposed RET-binding residues within the current 
interpretation presented in this thesis therefore remains uncertain. 
 
Figure 6.3 Proposed RET contact sites on GDNF/GFRα1 
(a) The mTC current interpretation of the 3D reconstruction, with the RET 
GDNF/GFRα1 contact sites circled. The mTC EM map is shown as a transparent blue 
surface, with fitted RET, GFRα1 and GDNF structures shown in surface representation 
at 4 Å. (b) Surface view of the GDNF/GFRα1-D2D3 crystal structure showing the 
proposed RET contact sites from the mTC model. GDNF monomers are coloured 
yellow and orange, GFRα1-D2D3 green. N-linked glycosylation sites are coloured 
white and N-linked glycosylation sites in other GFRα’s, grey. Residues which have 
been shown to be important for RET signalling by mutagenesis experiments (Parkash et 
al., 2008) are coloured red. Surface exposed GFRα/GFL-conserved residues at 
proposed contact sites are coloured blue. Sequence alignments between human GFRα1–
4 for the two proposed GFRα-D3 contact sites are shown, illustrating the conservation 
of the proposed CLD1 interaction site. (c) Surface view of hRET-CLD(1–3) 
highlighting the proposed GFRα1-D3 contact sites. Regions at the contact site shown to 
be important for GFRα1/GDNF binding by homologue scanning mutagenesis (Kjaer 
and Ibanez, 2003a) are coloured green. Mammalian RET conserved basic residues in 
these regions are coloured red. 
6.2.3.2 Proposed RET-CRD binding site on GDNF  
The current interpretation of the mTC 3D reconstruction predicts an interaction between 
the CRD and GDNF ‘finger 1’ and N-terminal tail regions. It also predicts a possible 
interaction of the CRD with GFRα1-D2 close to the GDNF interface. Surface exposed 
GFL-conserved residues and a GFRα-conserved residue in this region that could form 
part of the CRD binding site are shown in Figure 6.3. Residues in these regions have not 
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been previously been tested for their role in mTC complex stability but experiments can 
now be undertaken to explore this putative binding interaction.  
6.2.4 The basis for CLD1 elements conferring species specificity is 
unclear  
The conservation of vertebrate GFRα’s and GFLs makes the basis of human/Xenopus 
species specificity in the RET:GFRα1/GDNF interaction, primarily conferred by CLD1 
elements, difficult to rationalise in the context of an interaction between CLD1 and the 
GFRα-D3. Evidently chimeric approaches are limited by the ability of the chimeric 
proteins to fold properly and such cut-and-paste approaches to protein structure-
function studies do not always work.  
Class averages from negative stain EM of the zTC showed an apparently similar overall 
architecture to the mTC, implying the arrangement of the components in the lower 
vertebrate complex is very similar to the mammalian complex. The absence of the 
mammal-specific CLD1 elements—the βC’–βC” strand and cis-Pro loop—will result in 
a different CLD1 surface topology in lower vertebrate RETs, although there are still a 
few basic residues in lower vertebrate RET-CLD1 at the proposed GFRα1-D3 contact 
site, which could interact with the conserved acidic GFRα1-D3 motif.  
6.3 Regulation and chemical inhibition of RET-KD 
Two new RET-KD crystal structures are presented in Chapter 5 of this thesis. One of 
these structures has the chemical inhibitor sunitinib bound in the nucleotide-binding 
pocket, whilst the second structure has adenosine, derived from the hydrolysis of AMP-
PNP, bound. The sunitinib-bound structure provides an atomic description of sunitinib 
interactions with the nucleotide-binding pocket revealing hydrogen-bonding contacts to 
exclusively mainchain atoms and the disposition of the inhibitor relative to the 
gatekeeper V804. The high-resolution adenosine bound structure identified two distinct 
conformers of the gly-rich loop of the RET-KD. One of the conformers is competent to 
bind ATP (gly-rich loop open), whilst the other appears to be incompatible with ATP 
binding (gly-rich loop closed) since it would sterically clash with the ß and γ phosphate 
moieties. The gly-rich loop open conformation interacts with the oncogenic mutation 
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site E768 suggesting a possible relationship between this conformation and oncogenic 
activation. A method for crystallisation of the RET-KD with AMPPNP and a RET 
activation loop substrate peptide is also described and could be followed up in the future. 
I note that it has not proven possible to capture a DFG-out conformation of the RET-
KD to enable structural characterisation of the interaction of type II inhibitors such as 
sorafenib with RET.  
6.3.1 Towards testing whether the RET-KD is regulated by trans-
inhibition 
All crystal forms of the RET-KD that have been determined within the laboratory show 
the RET-KD adopting a head-to-tail dimeric arrangement. This includes RET-KD 
constructs containing the five N-terminal vector-derived residues that contribute to the 
αN-helix and longer constructs with entirely native juxtamembrane sequences. The 
head-to-tail dimer is incompatible with substrate binding and could therefore form part 
of the RET auto-inhibitory mechanism, perhaps in ligand-free RET dimers. Whether 
physiologically relevant or not this dimer is evidently the favoured RET-KD 
arrangement in RET-KD crystallisation. Perhaps because formation of this compact 
dimer traps a single RET-KD activation loop conformation, whereas the monomeric 
forms of RET-KD may show greater flexibility and sample a number of activation loop 
conformers, leading to the dimer contributing to an ordered crystal lattice comparably 
more readily.  
During this thesis I produced two double mutants of RET-KD, one of which, 
P766R/Q910R, weakens the formation of the head-to-tail dimer. The other, 
P766R/P957R, likely completely prevents head-to-tail dimer formation, as judged by 
the inability of this mutant to crystallise under the same conditions as the wild type 
RET-KD protein. In vitro kinase activity was not altered by either of these double 
mutations when compared with the wild type RET-KD. It would be instructive to obtain 
a crystal structure of the P766R/P957R mutant, since a new crystal lattice may allow us 
to trap other relevant conformations of RET-KD crystallographically. In the absence of 
this however, crystallisation experiments have at least indicated the impact of these 
mutations in perturbing the head-to-tail dimer. Informed by this, these mutations could 
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be useful tools to test the relevance of the crystallographic dimer on RET activity in 
cells.  
6.3.2 Crystal structures of RET with DFG-out inhibitors 
Active arrangements of protein kinase structures are highly similar due to the 
constraints imposed by their shared catalytic mechanism. In contrast, the inactive 
structures of protein kinase are highly variable and there are many distinct and unique 
regulatory mechanisms that operate to inhibit catalytic activity (Noble et al., 2004). All 
crystal forms of RET-KD have an active DFG-in conformation and this feature may 
relate to and indeed be coupled with the observed head-to-tail dimer. This arrangement 
tethers the αC-helix into an active conformation through engagement of the αN helix 
with a hydrophobic patch on the αC-helix. Thus our inability to crystallise known DFG-
out compounds such as sorafenib is perhaps not surprising.  
A new RET-KD crystal form I have been able to obtain contains the RET-KD bound to 
an activation-loop substrate peptide. It is possible that this structure may still capture an 
active conformation of RET-KD, but substrate binding should preclude the head-to-tail 
dimer configuration thus allowing us to finally see a different RET-KD arrangement in 
the crystal. This should therefore be followed up by further optimisation of these 
crystals. 
6.4 Future directions 
6.4.1 Towards an atomic resolution structure of the entire RET-ECD  
The SAXS-derived zRET-ECD model reveals a 100° angle between CLD3 and CLD4, 
however the structural determinants of this unusual cadherin arrangement are unknown. 
Furthermore in the context of a potential RET-CLD1:GFRα-D3 interaction in the RET 
ternary complex, which appears to be conserved between the mTC and zTC, an atomic 
resolution description of a lower vertebrate CLD1 interface for comparison with the 
human CLD1 interface is of significant interest. This is because it may shed light on the 
apparently conserved interaction despite the involvement of divergent structural 
elements between mammalian and lower vertebrate RET. For these reasons optimising 
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the zRET-CLD(1–4)redsug crystals presented in this thesis to allow structure 
determination is an important first step moving forward. Should classical crystal 
optimisation methods including varying the crystallisation condition, protein 
concentration, testing additives to the crystallisation condition and seeding not yield 
crystals with improved diffraction, a further strategy could be to remove more N-linked 
glycosylation sites from the zRET-CLD(1–4) construct. In particular the three N-
glycosylation sites in CLD(1–2) are conserved between human and zebrafish and two 
(N98 and N199, human numbering) were shown to not be essential for hRET-CLD(1–
2) production (Kjaer et al., 2010). These residues may therefore be good future targets 
for mutation since they may not be required for zRET-ECD production, although their 
mutation could still negatively impact overall protein yields.  
The structure of the CRD remains undetermined and this is an outstanding objective for 
future work. A CRD structure would be particularly informative in understanding the 
arrangement of this domain in the mTC and defining any potential for allosteric changes 
arising from ligand/co-receptor binding by fitting the structure into the EM map. It 
would also be a key tool in understanding the Hirschsprung’s and oncogenic mutations 
clustered in this domain. The structure of this domain in the context of the whole ECD 
would be most desirable, given the apparent influence of CLD3 on the CRD 
arrangement and its interaction with CLD4, but even in isolation or with CLD4 the 
crystal structure would be informative. Towards this goal further crystallisation 
screening of the zRET-CLD4CRD constructs presented in this thesis may be fruitful. To 
pursue crystallisation of the entire zRET-ECD further, introducing the N-linked 
glycosylation mutations in the zRET-CLD(1–4)redsug construct to the zRET-ECD 
construct could increase the chances of crystallisation.   
6.4.2 Defining the arrangement of RET-ECD/ligand/co-receptor in the 
mTC and towards atomic resolution of the complex 
The immediate goals of further work on the architecture of the mTC are: to improve the 
resolution of the EM 3D reconstruction to allow components to be fitted in the map 
with greater accuracy; to define the hand of the map; and to validate an interpretation of 
the arrangement of the mTC components in the complex. Recent mTC preparations by 
Dr. Svend Kjær show improved final yields of the complex allowing an additional 
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purification step, which has led to improved sample homogeneity. It is hoped that this 
sample will allow us to improve the resolution of the 3D reconstruction by increasing 
the number of particle images used in the current negative-stain EM 3D reconstruction, 
which may improve resolution or shed light on any conformational variability limiting 
resolution. We could also potentially move to cryo-EM with this significantly improved 
sample, where the obtainable resolution is much higher than negative-stain EM (van 
Heel et al., 2000).   
Following assignment of the hand of the EM map and perhaps improvement in the 
resolution of the map, validation of the interpretation of the 3D reconstruction and the 
identified interaction sites needs to be carried out. Adding a protein tag to the C-
terminus of hRET-ECD should still allow formation of the mTC and EM analysis of 
this tagged complex would confirm the location of the C-terminus of the CRD. The C-
tail of GFRα1 is extended and therefore tagging of this component would probably not 
be particularly informative. Alternatively, Fab fragments (fragment antigen binding) 
from anti-hRET-ECD antibodies with known epitopes could be used as tags. EM 
analysis of a complex of the mTC with a bound Fab fragment could provide 
confirmatory evidence for the location of RET subdomains within the 3D reconstruction. 
Dr. Svend Kjær has identified several such anti-hRET-ECD antibodies well suited to 
forming such complexes and this will be an important future objective. In this chapter I 
have identified potential mTC contact sites between RET-CRD and GDNF and between 
RET-CLD1 and GFRα1-D3. Should the current interpretation of the mTC 3D 
reconstruction hold, mutagenesis studies of these interactions either using a binding 
assay and/or a cell-based RET activity/autophosphorylation assay would help validate 
the relevance of these predicted interactions. Such a cell-based assay for full-length 
RET has recently been established in the Structural Biology Laboratory and going 
forward this assay could be used to assess the functional impact of mutating the 
conserved residues detailed in this chapter at the proposed RET:GFRα1/GDNF contact 
sites. 
The long-term goal in structural characterisation of a RET ternary complex is still to 
obtain a crystal structure of the complex, since this would provide the most detailed 
description of the interactions between the components in the complex. In this thesis I 
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have presented a method for the production of the zTC at sufficient yields for 
crystallisation screening using the well-established Baculovirus system with an insect 
cell host, which is amenable to large-scale cell production (Jarvis et al., 2009). However 
in order to pursue crystallisation of this complex the stability will need to be improved. 
This may simply require buffer screening to identify a buffer in which the complex is 
stable, which could be carried out using a thermal stability assay (Kopec and Schneider, 
2011).   
Beyond this an integrated understanding of the RET receptor tyrosine kinase as a whole, 
combining the RET-ECD and RET-ICD work described in this thesis and by others into 
a single unified model of RET activation would be the target objective. This will likely 
require the production of the full-length RET transmembrane protein purified in 
detergent micelles to mimic the cell membrane environment. If a homogenous sample 
can be produced, this could potentially be well suited to analysis by EM in the presence 
or absence of soluble ligand/coreceptor complexes. Methods for production of such 
ligand/coreceptor complexes from both human/rat (work by Dr. Svend Kjaer) and 
zebrafish species have been described in this thesis. This approach, as recently reported 
for the EGFR (Mi et al., 2011), could allow visualisation of the allosteric changes 
relevant to activation of both wild type and oncogenic forms of RET in the full length 
receptor. Alongside further high resolution structural analysis of RET subdomains and 
complexes this analysis could significantly develop our understanding of this intriguing 
receptor.  
6.5 Concluding remarks 
In this thesis I have sought to develop our understanding of the structure and regulation 
of the RET receptor tyrosine kinase. I have provided the first look at the overall 
architecture of the entire RET-ECD and the RET-ECD/ligand/co-receptor ternary 
complex. These data will inform future studies looking at the activation of RET by 
ligand/co-receptor. I have also presented the crystal structure of the RET-KD with the 
clinically-relevant RET inhibitor sunitinib, revealing the details of the interaction of this 
multi-kinase inhibitor with the RET-KD. 
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Chapter 7. Materials and methods 
7.1 Commonly used materials  
Unless otherwise stated all fine chemicals and oligonucleotide primers were from 
Sigma-Aldrich. All restriction enzymes were from New England Biolabs (NEB).  
7.2 Cloning 
Buffer Composition 
LB medium 5 g Bacto yeast extract, 10 g Bacto-tryptone, 10 g NaCl, volume adjusted to 1 l with water, autoclaved 
LB-agar 6 g agar, 400 ml LB medium, autoclaved  
SOC medium  
20 g Bacto-tryptone, 5 g Bacto yeast extract, 10 mM NaCl, 2.5 mM  
KCl, 10 mM MgCl2, 10 mM MgSO4, 20 mM D-glucose, volume  
adjusted to 1 l with water, autoclaved  
DNA 6× 
sample buffer  0.25% bromophenol blue, 30% (v/v) glycerol 
TAE buffer 40 mM Tris-acetate, 0.1 mM EDTA 
Table 7.1 Buffers used in cloning 
 
7.2.1 Baculovirus transfer vectors 
Derivatives of baculovirus transfer vectors pBacPAK-His3 (Clontech) and pVL1393 
(AB Vector) were used in this thesis. For expression of the extracellular portions of 
zRET and zGFRα1a and their subdomains (detailed in Table 7.2), the cDNA was 
cloned into pBacPAK-LL, a derivative of pBacPAK-His3 that I produced based on the 
expression cassette used in the mammalian cell production of hRET-CLD(1–2) (Kjaer 
et al., 2010). The native signal sequences of zRET and zGFRα1a were used to ensure 
proteins were inserted into the ER and secreted efficiently following expression. At the 
C-terminus of the zRET-ECD or zGFRα1a constructs the pBacPAK-LL vector encodes 
a 3C-protease recognition site and a TEV protease recognition site separated by three 
glycine residues. These are followed by a Protein A tag. Initially the construct only 
contained a TEV protease site, however TEV cleavage of the expressed fusion proteins 
was ineffective. On the assumption that this was due to steric occlusion of the TEV 
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protease site, the linker was extended and a 3C cleavage site was added. The expressed 
fusion proteins could then be efficiently cleaved with TEV or 3C-protease. Cleavage of 
the fusion proteins produced by this expression vector with 3C-protease leaves the 
extraneous residues GSEFLEVLFQ at the C-terminal end; and cleavage with TEV 
protease leaves GSEFLEVLFQGPGGGENLYFQ. The 3C-protease was used 
exclusively in this thesis.  
zGDNF was expressed using a derivative of pVL1393 (AB Vector) obtained from Dr. 
Svend Kjær, which is referred to as pBac, as its baculovirus transfer vector. This 
construct encodes a honeybee melittin signal sequence, which is an effective secretion 
signal sequence for proteins expressed in insect cells (Tessier et al., 1991). This 
construct was used for zGDNF expression since zGDNF is natively expressed as a 
proprotein and subcloning of the mature protein gene sequence would remove the native 
signal sequence as well as the pro-sequence.  
The intracellular hRET-KD was cloned into a pBacPAK-His3 derivative referred to as 
pBacPAK-GST. This vector was obtained from Mr. Phillip Knowles and was used 
previously in the production of hRET-KD in the Structural Biology Laboratory 
(Knowles et al., 2006). However in order to improve the expression levels of hRET-KD, 
a codon optimised gene of hRET-KD for insect cell expression was obtained from 
GeneART and freshly subcloned into this vector. The pBacPAK-GST encodes an N-
terminal glutathione S-transferase (GST) tag followed by a 3C cleavage site. Following 
cleavage of the fusion protein with 3C-protease the extraneous residues GPLSL are left 
at the N-terminus.  
7.2.2 cDNA clones 
The zRET cDNA was a kind gift of Dr. Tiffany Heanue and Dr. Vassilis Pachnis 
(National Institute of Medical Research). The zGFRα1a and zGDNF cDNAs were a 
kind gift of Dr. Iain Shepherd (Emory University, US). zRET-CLD(3–4) containing the 
N-linked glycosylation site mutations N259Q/N308Q/N390Q/N433Q was purchased 
from GeneART and was codon-optimised for insect cell host expression. This was 
subcloned into the zRET-CLD(1–4) construct to produce the zRET-CLD(1–4)redsug 
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construct. The hRET-ICD was also codon-optimised for insect cell expression and was 
purchased from GeneART.  
Construct name Expression cassette details 
pBacPAK-LL-zRET-CLD(1–2)1–249 zRET1–249-3C-TEV-protein A 
pBacPAK-LL-zRET-CLD(1–2)1–253 zRET1–253-3C-TEV-protein A 




pBacPAK-LL-zRET-ECD zRET1–626-3C-TEV-protein A 
pBacPAK-LL-zRET-CLD4CRD373–626 zRET373–626-3C-TEV-protein A 
pBacPAK-LL-zRET-CLD4CRD382–626  zRET382–626-3C-TEV-protein A 
pBac-zGDNF Melittin SS-zGDNF89–235 
pBac-zGDNFΔN Melittin SS-zGDNF135–235 
pBacPAK-LL-zGFRα1aΔC zGFRα1a1–352-3C-TEV-protein A 
pBacPAK-LL-zGFRα1aD2D3 zGFRα1a1–21;143–352-3C-TEV-protein A 
pBacPAK-GST-RET-KD GST-3C-hRET705–826;841–1013 (codon optimised) 
pBacPAK-GST-RET-KDP766R/Q910R 
GST-3C-hRET705–826;841–1013 P766R/Q910R  
(codon optimised) 
pBacPAK-GST-RET-KDP766R/P957R 
GST-3C-hRET705–826;841–1013 P766R/P957R  
(codon optimised) 
Table 7.2 Baculovirus transfer vector constructs 
pBacPAK-LL and pBacPAK-GST = modified pBacPAK-His3 (Clontech) vectors; pBac 
= modified pVL1393 vector (AB Vector); 3C = 3C-protease recognition site; TEV = 
TEV protease recognition site; GST = glutathione S-transferase; Melittin SS = 
honeybee melittin signal sequence. 
7.2.3 Polymerase chain reaction 
Polymerase chain reaction (PCR) amplification of a target gene for cloning into a 
different plasmid vector was carried out in a thermocycler (Peltier). Typically 50 µl 
reaction mixtures contained 1× Thermopol buffer (NEB), 0.4 µM forward primer, 0.4 
µM reverse primer, 2 µM deoxyribonucleic triphosphates (dNTPs), 2 units VENT™ 
polymerase (NEB) and 100 ng template DNA. PCR was carried out with an initial 
denaturation at 94 °C for 1 minute and annealing at 5 °C below the primer melting 
temperature for 1 minute, followed by 30 cycles of the following sequence: extension at 
72 °C for 1 minute per 1 kb of target gene length, denaturation at 94 °C for 30 seconds 
and annealing at 5 °C below the primer melting temperature for 30 seconds. This was 
followed by a final extension step at 72 °C for 10 minutes and storage at 4 °C. Template 
Chapter 7. Materials and Methods 
 
 222 
DNA was then removed from the reaction mix by digestion with 20 units of Dpn1 for at 
least 4 hours.  
7.2.4 Cloning into baculovirus transfer vectors 
PCR products of the target gene, and the target baculovirus transfer vector, were 
digested with restriction enzymes for ligation. Nco1 and BamH1 enzymes were used for 
cloning into the pBacPAK-LL vector; HindIII and XhoI for the pBacPAK-GST vector; 
and XbaI and Not1 for the pBac vector. The target vector DNA was prepared using the 
Qiagen maxi prep kit. Digestion reactions contained 1× NEB reaction buffer, 20 units of 
each enzyme, 1 mg/ml bovine serum albumin and either 45 µl of the PCR reaction mix 
or 50 µl of the desired vector (typically 50 µg DNA) to a final volume of 60 µl. 
Digestion reactions were incubated for at least 4 hours at 37 °C. 10 units of calf 
intestinal alkaline phosphatase was then added to the digested vector and allowed to 
dephosphorylate the cut ends of the vector for one hour at 37 °C. Digestion products of 
the target gene and target vector were purified by gel electrophoresis. 1× DNA loading 
buffer was added to the digest reactions and a DNA ladder, and these were run on a 
0.8% agarose gel containing ethidium bromide in TAE buffer at 120 V for 30–40 
minutes. Bands corresponding to the digested gene and vector were cut out of the gel 
and the agarose removed using Ultrafree DA columns (Millipore). The DNA was 
further purified from the gel extracts using the final steps of the Qiagen mini-prep kit 
protocol: four-fold excess of buffer PB was added to the gel extract; this was applied to 
a mini-prep DNA binding spin column and spun for 1 minute at 1000 × g and 1 minute 
at 16000 × g; the column was then washed with 750 µl buffer PE; digested DNA was 
then eluted in 30 µl buffer EB for the vector and 20 µl for the gene. DNA concentration 
of the purified digested DNA was measured using a Nanodrop 1000 spectrophotometer 
(Thermo Scientific), based on absorbance at 260 nm.  
The purified digested vector and gene were then ligated together. The 20 µl ligation 
reactions contained a 1:6 molar ratio of vector:gene, 1× T4 ligation buffer (NEB) and 
400 cohesive end units of T4 ligase (NEB). A control reaction without gene was also 
carried out in tandem to determine the background level of undigested vector present. 
These were incubated at 16 °C for 3 hours followed by transformation into 250 µl of 
chemically competent NovaBlue cells. Transformation was carried out by a 45 second 
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incubation at 42 °C followed by 2 minutes on ice. The transformed cells were then 
amplified by addition of 500 µl SOC medium and incubation at 37 °C for 1 hour, 
followed by spreading on LB-agar plates with 200 ug/ml carbenicillin (for pBacPAK 
constructs) and incubation at 37 °C overnight.  
If ligation was successful there should be many more colonies on the ligation reaction 
plates compared to the control plate, with the control plate only containing a handful or 
no colonies. If this was the case, plasmids from 10 colonies on the ligation reaction 
plate were typically amplified using the Qiagen mini-prep kit following manufacturers 
instructions. These were then assessed to see whether the ligation had been successful 
by DNA sequencing (section 7.2.7).  
7.2.5 Site-directed mutagenesis 
Site-directed mutagenesis of plasmids, including insertions or deletions of up to 33 
bases pairs, was carried out by QuikChange™ (Stratagene). Typically reaction mixtures 
contained 1× PFU TURBO buffer (Stratagene), 0.4 µM forward primer, 0.4 µM reverse 
primer, 2 µM deoxyribonucleic triphosphates (dNTPs), 2.5 units PFU TURBO 
polymerase (Stratagene), 100 ng template DNA and 2 mM MgSO4. The QuikChange™ 
PCR reactions were carried out with an initial denaturation at 96 °C for 2 minutes and 
annealing at 55 °C for 2 minutes, followed by 17 cycles of the following sequence: 
extension at 68 °C for 1 minute per 1 kb of template DNA plus 1 minute, denaturation 
at 96 °C for 1 minute and annealing at 55 °C for 1 minute. This was followed by a final 
extension step at 68 °C for 20 minutes and storage at 4 °C. Template DNA was then 
removed from the reaction mix by digestion with 20 units of Dpn1 for at least 4 hours at 
37 °C. 250 µl of chemically competent NovaBlue cells were then transformed with 5 µl 
of the reaction mix by incubation at 42 °C for 45 seconds followed by 2 minutes on ice. 
Transformed cells were spread on LB-agar plates containing 200 ug/ml carbenicillin 
(for pBacPAK constructs) and incubated at 37 °C overnight. Plasmids were purified 
using the Qiagen mini-prep kit according to the manufacturers instructions and 
sequenced (section 7.2.7) to determine whether mutagenesis had been successful.  
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7.2.6 Large deletions from plasmid constructs 
To eliminate an intron found in the zRET cDNA a modified QuikChange™ (Stratagene) 
protocol was used, allowing deletion of large portions of DNA. The primers used did 
not span the deletion site, as in standard QuikChangeTM, but were designed for 
amplification of a linear product containing the entire plasmid and gene sequence 
except the sequence to be deleted. The same reaction mix and thermocycler sequence as 
for section 7.2.5 were used for the PCR reaction, which was followed by Dpn1 
digestion of the template with 20 units of Dpn1. To recyclise the linear PCR product, 
the ends were firstly phosphorylated by addition of 1× T4 ligase buffer (NEB) and 10 
units of T4 polynucleotide kinase to the PCR reaction mix for 30 minutes at 37 °C. 
Ligation was then carried out using 2–6 µl reaction mix in 1× T4 ligase buffer (NEB) 
with 1µl T4 ligase at 16 °C for 3 hours with a no ligase control. Ligation products were 
transformed into NovaBlue cells and assessed as described in section 7.2.4.  
7.2.7 DNA sequencing  
The open reading frames of all constructs were verified by DNA sequencing. The 
Cancer Research UK London Research Institute equipment park staff carried out all 
DNA sequencing, using the BigDye™ Terminator Cycle Sequencing kit (PE Applied 
Biosystems) and capillary sequencing on an ABI Prism 3730.  
7.3 Baculovirus method for insect cell expression  
7.3.1 Baculovirus production 
Production of baculoviruses from the baculovirus transfer vector constructs, initial 
amplification of baculoviruses and protein expression testing in insect cells were carried 
out by staff at the Cancer Research UK London Research Institute Protein Production 
Facility. Baculoviruses were produced using the Clontech BacPAK system in Sf9 cells 
(BacPAKTM Expression System User Manual, Clontech). 
Chapter 7. Materials and Methods 
 
 225 
7.3.2 Insect cell culture  
Sf9 cells were cultured in suspension in serum-free SfIII media (Invitrogen) 
supplemented with 10 µg/ml gentamycin. They were grown at 27 °C with shaking (140 
rpm) in 100–500 ml aliquots in 2 l roller bottles. The cells were kept at a cell density of 
between 1.5–6 × 106 cells/ml. Hi5 cells were cultured in suspension in the same way as 
the Sf9 cells, but they were grown in SfII media (Invitrogen) and only switched to SfIII 
media for protein expression. This was because cell doubling rates and viability was 
poor when the Hi5 cells were cultured in SfIII media for long periods, but the yields 
from protein expression by Baculovirus infection were increased by 50–100% when 
carried out in SfIII media.  Cell density and viability was determined using a Vi-CELL 
(Beckman Coulter). Cells that were observed to have an approximate doubling time of 
less than 24 hours or a viability of less than 89 % were not used in baculovirus 
amplification or protein expression.  
7.3.3 Baculovirus amplification 
Baculoviruses were amplified in Sf9 cells. The baculovirus was added at a MOI of 0.1–
0.5 to Sf9 cells at 1 × 106 cells/ml in 250 ml aliquots. The culture was incubated for 6 
days at 27 °C with shaking (140 rpm). The baculovirus containing media was then 
harvested by centrifugation (3000 × g, 20 minutes, 4 °C). This amplification process 
was often repeated: Baculoviruses used in protein expression had been passaged in Sf9 
cells between 3 and 5 times.  
7.3.4 Calculation of viral titre 
The High Pure Viral Nucleic acid Large Volume Kit (Roche) was used to purify 
baculoviruses from serum following manufacturers instructions. RT-PCR was then used 
to determine viral titre following manufacturers instructions. 
7.3.5 Protein expression 
Hi5 cells at 1 × 106 cells/ml in 500 ml aliquots were infected with baculoviruses at a 
MOI of 2 for all proteins except zGFRα1aΔC/zGDNFΔN co-infection. In order to achieve 
similar levels of expression for zGFRα1aΔC and zGDNFΔN when co-expressed, 
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zGFRα1aΔC baculovirus was added with an MOI of 1 and zGDNFΔN baculovirus with 
an MOI of 5. The infected cells were incubated at 27 °C with shaking (140 rpm) for 3.5 
days for intracellular proteins and for 4.5 days for extracellular proteins. The protein 
expression yields following affinity purification (described below) were: 4 mg/l culture 
for zRET-ECD and zRET-CLD(1–4); 1 mg/l culture for zRET-CLD(1–4)redsug; 1.4 mg/l 
for both zRET-CLD4CRD constructs; 1 mg/l culture zGFRα1a/zGDNF coexpression; 4 
mg/l culture hRET-KD wild type and mutants. 
7.4 Protein purification 
7.4.1 Buffers 
Name Composition 
ECD buffer 20 mM Tris pH 7, 200 mM NaCl, (±2 mM CaCl2) 
Anion exchange 
buffer A 
20 mM Tris pH 7, 50 mM NaCl, 5% (v/v) glycerol, (±2 mM CaCl2) 
Anion exchange 
buffer B 
20 mM Tris pH 7, 500 mM NaCl, 5% (v/v) glycerol, (±2 mM CaCl2) 
KD lysis buffer 50 mM Tris pH 8, 100 mM NaCl, 1 mM dithiothreitol (DTT), 10 
mM Benzamidine, 0.2 mM 4-(2-aminoethyl) benzenesulfonyl 
fluoride hydrochloride (AEBSF) 
KD buffer 20 mM Tris pH 8, 100 mM NaCl, 1 mM DTT 
mTC buffer 25 mM Tris, pH 7.5, 150 mM NaCl, 1 mM CaCl2 
GST-Endo-F1 
lysis buffer 
50 mM Tris pH 7.5, 1 × Ethylenediaminetetraacetic acid (EDTA)-
free protease inhibitor cocktail tablet (Roche) 
GST-Endo-F1 size 
exclusion buffer 
50 mM Tris pH 7.5, 200 mM NaCl 
GST-Endo-F1 
storage buffer 
10 mM Sodium acetate pH 5.5, 50 % glycerol 
Table 7.3 Protein purification buffer compositions 
 
7.4.2 Extracellular protein purification 
The following method was used for purification of the zRET-ECD, CLD(1–2), CLD(1–
4) and CLD4–CRD and zGFRα1a (± untagged zGDNF) Protein A tagged proteins. For 
purification of zRET-ECD and CLD(1–4) the buffers contained 2 mM CaCl2.  
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7.4.2.1 Protein A affinity purification 
Following baculovirus infection the media was harvested by centrifugation to remove 
the cells (3000 × g, 20 min, 4 °C). The clarified media was incubated in 2 l batches 
divided into 250 ml aliquots with IgG-sepharose resin (GE Healthcare). 1 ml resin was 
used per litre of media and each 2 l batch was incubated at 4 °C with rotation for 1.5–2 
hours. The resin was then gently spun down (250 rpm, 10 min, 4 °C), the media 
removed and fresh media added. This was repeated until all the media had been 
incubated with the resin. The resin was then placed in a 10 ml syringe with a 0.2 µm 
filter on ice and washed with ice-cold ECD buffer (5 × 10 ml). The resin was 
resuspended in 10 ml ECD buffer and transferred to a 15 ml falcon. GST-tagged human 
rhinovirus 3C-protease (PreScission protease, Amersham Biosciences) was added, 100 
µg per 1 ml resin, and allowed to cleave overnight at 4 °C with rotation. 
Cleaved material was separated from the resin in a 10 ml syringe, and the resin washed 
with at least 2 column volumes of ECD buffer. To remove the GST-tagged protease, 
200 µl of ECD buffer washed glutathione-sepharose resin (GE Healthcare) was added to 
the eluate and incubated for 45 minutes at 4 °C with rotation. Unbound material was 
eluted from the resin in ECD buffer using a 10 ml syringe with a 0.2 µm filter. This 
affinity purified material was then concentrated using Vivaspin centrifugation columns 
and either subjected to further purification by size exclusion chromatography or used 
directly in binding experiments.  
7.4.2.2 Size exclusion chromatography 
Affinity purified protein was concentrated to 5 ml for size exclusion on a 150 ml 
Superdex 200 26/300 column or 0.25 ml for a 24 ml Superdex 200 10/300 or Superose 
6 10/300 GL column (GE Healthcare). Size exclusion was carried out at 4 °C. The 
column was pre-equilibrated with ECD buffer, the sample was then injected and buffer 
flowed at 2 ml/minute for the large column and 0.4 ml/minute for the smaller column, 
using the ÄKTA purifier system (GE Healthcare). 2 ml or 0.4 ml fractions were 
collected. Protein elution was followed using by absorbance at 280 nm (Abs280) 
measurement. Peak fractions were combined and concentrated for anion exchange 
chromatography or used in further experiments directly. 
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7.4.2.3 Anion exchange chromatography 
Protein was concentrated to a volume of 250–500 µl and diluted in 5–10 ml anion 
exchange buffer A.  A 1 ml HiTrap Q HP (GE Healthcare) at 4 °C was equilibrated with 
anion exchange buffer A. The protein was loaded onto the column at a flow rate of 0.4 
ml/minute and unbound protein washed off with anion exchange buffer A. Bound 
protein was then eluted by applying a gradient of 100% anion exchange buffer A to 
100% anion exchange buffer B over 20 column volumes, collecting 0.4 ml fractions. 
Protein elution was followed using the Abs280 measurement. Peak fractions were 
combined and concentrated for use in further experiments. 
7.4.2.4 Deglycosylation with endoglycosidase F1 
Endoglycosidase F1 (Endo-F1) deglycosylation of zRET-ECD proteins was carried out 
using GST-Endo-F1 produced in bacteria using standard protocols from a construct 
kindly donated by Prof. Yvonne Jones (see section 7.4.5). Following affinity 
purification (section 7.4.2.1), GST-Endo-F1 was added to the zRET protein at a ratio of 
1:5 (weight:weight) in ECD buffer and incubated for 20 hours at 4 °C with rotation. The 
GST-Endo-F1 was then removed by addition of 100–200 µl of glutathione-sepharose 
resin and incubation for 30 minutes at 4 °C with rotation; followed by separation of the 
supernatant from the resin using a 10 ml syringe with a 0.2 µm filter. The supernatant 
containing the enzymatically partially-deglycosylated zRET protein was then subject to 
further purification by size exclusion chromatography (section 7.4.2.2). 
7.4.3 Zebrafish ternary complex assembly and purification 
For standard large-scale production of the zTC (zebrafish ternary complex = zRET-
ECD/zGFRα1aΔC/zGDNFΔN) 5.5 l of zGFRα1aΔC-Protein A/zGDNFΔN and 2 l of 
zRET-ECD-Protein A Baculovirus infected cell culture was treated as detailed in 
section 7.4.2.1: The media was clarified by centrifugation and Protein A fusion proteins 
were separately affinity-purified at 4 °C using IgG-sepharose resin (5 ml for 
GFRα1aΔC/GDNFΔN and 2 ml for zRET-ECD). Typically the zRET-ECD was purified 
in this manner the day before the zGFRα1aΔC/zGDNFΔN. The zRET-ECD-Protein A 
bound resin was then washed with ice-cold ECD buffer (5 × 10 ml) and zRET-ECD 
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eluted in 10 ml ECD buffer by addition of 3C-protease overnight as in section 7.4.2.1. 
The zGFRα1aΔC-Protein A/zGDNFΔN bound resin was similarly washed with ice-cold 
ECD buffer (5 × 10 ml), but prior to addition of 3C-protease, the eluted zRET-ECD in 
10–15 ml ECD buffer was added to the washed IgG-sepharose resin with zGFRα1aΔC-
Protein A/zGDNFΔN bound in a 50 ml falcon. zRET-ECD was allowed to bind for one 
hour with rotation at 4 °C. The resin was then placed in a 10 ml syringe on ice and the 
unbound material was eluted. The resin was washed with at least five column volumes 
of ECD buffer, and resuspended in 2–3 column volumes of ECD buffer. As per section 
7.4.2.1–7.4.2.3, 3C-protease was then added to the zGFRα1aΔC-Protein 
A/zGDNFΔN/zRET-ECD resin to elute the complex and purification continued with size 
exclusion chromatography.  
7.4.4 hRET-KD protein purification 
The protocol used for production of GST tagged hRET-KD wild type and mutant 
proteins and is essentially the same as the previously published hRET-KD purification 
protocol (Knowles et al., 2006). 
7.4.4.1 Cell lysis and GST affinity purification 
Cells were harvested following baculovirus infection by centrifugation (2000 × g, 12 
min, 4 °C). Cell pellets from 1 l cell culture were resuspended in 20 ml ice cold KD 
lysis buffer and lysed by sonication for 40–60 seconds on ice. The cell lysate was 
clarified by centrifugation (29220 × g, 30 min, 4 °C).  
0.5 ml glutathione-sepharose resin (GE Healthcare) per l original cell culture was 
washed with KD lysis buffer and added to the clarified lysate. This mixture was 
incubated at 4 °C with rotation for 1.5 hours. The resin was then collected in a 10 ml 
syringe and washed with KD buffer (5 × 10 ml). The resin was subsequently 
resuspended in KD buffer and GST tagged 3C-protease 100 µg per 1 ml resin was 
added. Cleavage was allowed to occur overnight at 4 °C with rotation. Cleaved protein 
was then separated from the resin using a 10 ml syringe, and the resin washed with at 
least 2 column volumes of KD buffer.  
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7.4.4.2 Autophosphorylation and dialysis 
The affinity-purified hRET-KD was phosphorylated by addition of 5 mM ATP (pH 8) 
and 10 mM MgCl2 and incubated on ice for 6 hours. The ATP and magnesium were 
then removed by dialysis of the protein solution against 1 l KD buffer overnight in a 
12.5 kDa molecular weight cut off dialysis membrane at 4 °C.  
Non-phosphorylated hRET-KD was produced by incubation with calf intestinal alkaline 
phosphatase (NEB) for 5 hours at 4 °C whilst protein was still bound to the glutathione-
sepharose resin. The enzyme was then washed off with 2 × 10 ml KD buffer and 3C 
cleavage carried out as in section 7.4.4.1.  
7.4.4.3 Size exclusion chromatography 
Size exclusion chromatography of hRET-KD was carried out as for the extracellular 
proteins (section 7.4.2.2) but using Superdex 75 columns (GE Healthcare) and running 
the column in KD buffer with 400 mM NaCl for the RET-KDP766R/P957R mutant.  
7.4.5 GST-endoglycosidase F1 production 
The pGEX endoglycosidase F1 bacterial expression construct with pRep4 was kindly 
donated by Prof. Yvonne Jones (Oxford University), originally produced by Dr. Yoav 
Peleg (Weismann Institute, Israel). The received plasmids were transformed into 
NovaBlue cells (as section 7.2.4) and the transformed cells were spread on an LB-agar 
plate with 50 µg/ml kanamycin and 100 µg/ml ampicillin, to select for colonies 
containing both plasmids, and incubated at 37 °C overnight. A single colony was 
amplified overnight in 100 ml LB with 50 µg/ml kanamycin and 100 µg/ml ampicillin 
and purified by maxi-prep (Qiagen) following manufacturers instructions.  
7.4.5.1 Protein expression in bacterial cells 
GST-endoglycosidase F1 (GST-Endo-F1) expression and purification was carried out 
based on Grueninger-Leitch et al., 1996. FB810 cells (a RecA- strain of BL21) were 
transformed with maxi-prep prepared plasmids pGEX endoglycosidase F1 and pRep4 
by electroporation in a chilled cuvette. 0.5 ml of SOC media was then added and cells 
were incubated in an eppendorf at 37 °C for 1 hour. 50 µl of the cell culture with 50 µl 
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SOC media were spread on an LB-agar plate with 50 µg/ml kanamycin and 100 µg/ml 
ampicillin and incubated at 37 °C overnight. A single colony from transformation was 
amplified overnight in 100 ml LB with 50 µg/ml kanamycin and 100 µg/ml ampicillin. 
40 ml of this culture was then used to inoculate 2 l of LB containing 50 µg/ml 
kanamycin and 100 µg/ml ampicillin for protein expression. The 2 l culture was grown 
in 1 l aliquots in 2 l flasks at 37 °C until the optical density at 550 nm (OD550) reached 
0.8. Protein expression was then induced by addition of 0.3 mM isopropyl β-D-1-
thiogalactopyranoside (IPTG) and cells were incubated for 4 hours at 37 °C. Cells were 
harvested by centrifugation (4000 × g, 20 minutes, 4 °C). 
7.4.5.2 Cell lysis and protein purification 
GST-Endo-F1 cells were resuspended in 20 ml ice-cold GST-Endo-F1 lysis buffer per 
1 l original cell culture and lysed by sonication on ice (2 minutes, 15 microns). The cell 
lysate was clarified by centrifugation (29220 × g, 30 min, 4 °C). 8 ml of glutathione-
sepharose resin (GE Healthcare) washed with GST-Endo-F1 lysis buffer was added to 
the clarified lysate in a 50 ml falcon and this was incubated at 4 °C for 1 hour with 
rotation. The resin was spun down (500 × g, 5 min, 4 °C) and the supernatant discarded. 
The resin was then washed with 3 × 50 ml GST-Endo-F1 lysis buffer. The GST-Endo-
F1 was eluted from the resin by incubation in 2 × 30 ml GST-Endo-F1 lysis buffer with 
glutathione for 30 minutes at 4 °C with rotation, and the supernatant collected by 
centrifugation (500 × g, 5 min, 4 °C).  
The eluted GST-Endo-F1 was concentrated in a Vivaspin column to 5 ml and loaded on 
a Superdex 75 26/300 column (GE Healthcare) pre-equilibrated with GST-Endo-F1 size 
exclusion buffer. Size exclusion chromatography was carried out using an ÄKTA 
purifier system (GE Healthcare) with a flow rate of 2 ml/minute and 2 ml fractions were 
collected. Fractions from the GST-Endo-F1 peak (as confirmed by SDS-PAGE) were 
combined and dialysed against 1 l GST-Endo-F1 storage buffer overnight at 4 °C.  
The final yield of GST-Endo-F1 following dialysis was 36 mg/l culture. The protein 
was divided into 100 µl aliquots at 4.8 mg/ml, frozen on dry ice and stored at -80 °C. 
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7.5 Mammalian extracellular protein production 
Dr. Svend Kjær produced the human RET-ECD and mammalian ternary complex 
(mTC) used in this thesis. His methods are described below.  
7.5.1 Mammalian cell protein expression  
The hRET-ECD construct used in this thesis contained the cysteine mutations C87R and 
C216R. These mutations remove the two unpaired cysteine residues from the hRET-
ECD and therefore improve expression levels by reducing the tendency of hRET-ECD 
to misfold. These mutations do not affect GFRα1/GDNF binding affinity (Kjaer et al., 
2010). The rGFRα11–425 construct contains the entire rGFRα1 sequence except the C-
terminal GPI-link site and GPI signal sequence. The rGFRα11–425 construct contains the 
mutation N59Q, which removes a partially occupied N-linked glycosylation site.  
hRET-ECD C87R C216R (Kjaer et al., 2010) and rGFRα11–425 N59Q were expressed as 
TEV cleavable Protein A fusion proteins in stably transfected Chinese Hamster Ovary 
(CHO) Lec8 cells (Stanley et al., 1991). The stable cell lines were generated by 
transfecting CHO cells with the pcDNA3 constructs (Table 7.4) using the Effectene 
reagent (Qiagen), followed by selection with 500 µg/ml G418 (Invitrogen). For protein 
production the cells were grown in 2 l roller bottles for 4–5 days in standard DMEM, 
10% (v/v) FBS, 50 µg/ml gentamycin and the supernatant was subsequently harvested 
by centrifugation and filtered with 0.22/0.45 µm filters. 
The mature hGDNF corresponding to residues 77–211 (plus an additional N-terminal 
methionine residue) was kindly provided by Amgen (Thousand Oaks, California) 
produced recombinantly in Escherichia coli. 
Construct name Expression cassette details 
pcDNA3-hRET-ECD C87R C216R hRET-ECD1–635 C87R C216R-TEV-protein A 
pcDNA3-rGFRα11–425 N59Q rGFRα11–425 N59Q-TEV-protein A 
pcDNA3-rGFRα1ΔD1 rGFRα11–20;145–425-TEV-protein A 
Table 7.4 Mammalian expression vectors 
TEV cleavage of the protein A tag from proteins expressed using these constructs 
leaves these extraneous residues at the C-terminus: EFENLYFQ. 
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7.5.2 Mammalian ternary complex assembly and purification 
For a standard preparation of ternary complex, 2 l of supernatant containing either 
hRET-ECD-TEV-Protein A or rGFRα1-TEV-Protein A was incubated overnight at 4 °C 
with 0.5 ml IgG-sepharose resin (GE Healthcare). The resin was subsequently isolated 
by slow-speed centrifugation and washed 3 times with mTC buffer (25 mM Tris, pH 7.5, 
150 mM NaCl, 1 mM CaCl2) in a 50 ml falcon. For production of the hRET-ECD, 100 
µg of TEV protease was added to the resin overnight at 4 °C in 5 ml of mTC buffer and 
the supernatant containing hRET-ECD kept. For assembly of the mTC, washed IgG-
sepharose resin with bound rGFRα1-TEV-Protein A was incubated with 200 µg of 
recombinant human GDNF (kindly provided by Amgen) for 1 hour and then washed 
with mTC buffer. Finally, the supernatant containing hRET-ECD was added to the 
rGFRα1/hGDNF resin for 1 hour, the resin was washed 3 times with mTC buffer in a 
50 ml falcon and the hRET-ECD/rGFRα1/hGDNF ternary complex eluted from the 
resin by addition of 100 µg of TEV overnight at 4°C. The complex was subsequently 
purified by size exclusion chromatography in mTC buffer using a Superose 6 10/300 
GL column (GE Healthcare) connected to an ÄKTA Explorer system (GE Healthcare). 
7.5.3 Human RET-ECD purification 
For SAXS analysis the hRET-ECD was produced as described above and further 
purified following TEV cleavage from the IgG-sepharose resin by size exclusion 
chromatography in mTC buffer using a Superdex 200 10/300 column (GE Healthcare). 
7.6 Protein analysis 
7.6.1 Measurement of protein concentrations 
Protein concentrations were calculated based on the Abs280, measured using a 
Nanodrop 1000 spectrophotometer (Thermo Scientific), using the protein molecular 
weights and extinction coefficients as detailed in Table 7.5.  














(*103 M-1 cm-1) 
zRET-ECD 614 69.34 5.07 66.25 
zRET-CLD(1–2)1–249 237 27.00 5.52 24.79 
zRET-CLD(1–2)1–253 241 27.48 5.09 24.79 
zRET-CLD(1–4) 490 55.65 5.08 52.43 
zRET-CLD(1–4)redsug 490 55.70 5.08 52.43 
zRET-CLD4CRD373–626 264 29.54 4.99 28.52 
zRET-CLD4CRD382–626 255 28.51 4.91 28.52 
zGFRα1aΔC 344 38.74 8.44 31.09 
zGFRα1aD2D3 222 24.75 8.06 14.66 
zGDNF 149 17.06 9.32 6.34 
zGDNFΔN 104 11.92 7.15 6.34 
zTC (2 zGDNFΔN/2 zGFRα1aΔC/ 
2 zRET-ECD) 2124 239.90 5.89 207.48 
hRET-ECD 616 68.84 5.52 75.55 
mTC (2 hGDNF/2 rGFRα1a/ 
2 hRET-ECD) 2378 264.34 7.65 236.53 
hRET-KD 300 34.30 9.04 49.39 
Table 7.5 Protein parameters 
Theoretical biophysical parameters of expressed proteins following cleavage of the 
signal sequences and affinity tags. Th extinction coefficient assuming all cysteines form 
disulphide bonds is given for extracellular proteins and assuming all cysteines are 
reduced for intracellular proteins. Parameters calculated by ProtParam tool in ExPASY 
(http://web.expasy.org/protparam). 
7.6.2 SDS-PAGE 
Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) was carried 
out using either 4–12 % NuPAGE gels (Invitrogen) with MOPs running buffer 
(Invitrogen) or 4–20 % NuSep gels (NuSep) with SDS running buffer. Protein samples 
were prepared by addition of 5× SDS loading buffer and incubation at 95 °C for 5 
minutes. Samples were loaded in the wells of the gel and a voltage of 100–150 V was 
applied until the SDS loading buffer dye had migrated to the bottom of the gel. Gels 
were stained with PhastGel™ Blue R-350 Coomassie staining solution (GE Healthcare) 
for 15 minutes and destained with a 10% acetic acid, 40% methanol solution for 1–1.5 
hours.  




5× SDS loading 
buffer 
5% (w/v) SDS, 0.2 M Tris pH 6.8, 33% Glycerol, 2 mg/ml 
bromophenol blue (+ β-mercaptoethanol for reducing gels) 
10× SDS running 
buffer 




One PhastGel™ Blue R-350 tablet (GE Healthcare) was dissolved 
in 80 ml water, 120 ml methanol added and solution was stored 
at 4 °C. Before use 50 ml of this solution was added to 50 ml 
20% acetic acid. 
Destain solution 10% acetic acid, 40% methanol solution 
Cathode buffer 1× NativePAGE™ running buffer, 1× NativePAGE™ cathode 
buffer additive (includes 0.02 % Coomassie G-250)  
Anode buffer 1× NativePAGE™ running buffer 
Table 7.6 SDS-PAGE and Native PAGE buffers 
7.6.3 Native PAGE 
Native PAGE was carried out at 4 °C using the NativePAGE™ reagents from 
Invitrogen. Protein samples were prepared by addition of 4× NativePAGE™ sample 
buffer, and loaded in the wells of a 4–16 % NativePAGE™ Novex® Bis-Tris gel. 
Chilled Coomassie-containing cathode buffer (Table 7.6) was added to the inner buffer 
chamber of the gel tank and chilled anode buffer was added to outer chamber. A voltage 
of 150 V was applied to the gel for 105–120 minutes. The gel was then destained with 
destain solution. 
7.6.4 Dynamic light scattering  
DLS measurements were carried out in a Zetasizer Nano ZS (Malvern Instruments) and 
analysis was performed using the manufacturer-supplied software. 12 µl protein 
samples of > 0.5 mg/ml were placed in a quartz cuvette for measurement. This analysis 
provides an imperfect estimate of particle diameter and molecular weight of proteins in 
solution, but is particularly helpful in assessing whether a protein sample is aggregated.  
7.6.5 Size exclusion chromatography coupled with multi-angle light 
scattering  
SEC-MALS was used to determine the molecular weight of proteins as they elute from 
a size exclusion chromatography column. The SEC-MALS system used was an ÄKTA 
purifier system (GE Healthcare), with a Superose 6 10/300 GL column (GE Healthcare), 
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coupled to a Optilab®T-rEX (Wyatt Technology), which measures differential refractive 
index and is used to determine protein concentration, and a DAWN® HELEOS® II 
(Wyatt Technology) MALS unit. The system was equilibrated in ECD buffer (for 
analysis of zRET and zTC samples) at a flow rate of 0.1–0.5 ml/min until the 
differential refractive index had stabilised. 100 µl of protein sample at ~3 mg/ml was 
loaded onto the Superose 6 column and the SEC-MALS system was run at a 0.5 ml/min 
flow rate for 60 minutes. The SEC-MALS data was analysed using the manufacturer-
supplied software to determine the molecular weight of the protein across the size 
exclusion peak.  
7.6.6 Circular dichroism 
Dr. Stephen Martin at the National Institute of Medical Research, London, carried out 
circular dichroism experiments. Protein samples at ~0.15 mg/ml in ECD buffer were 
placed in a 200 µl fused silica cuvette (Hellma, Jena) with 1 mm path length. Far-UV 
circular dichroism measurements were recorded on a Jasco J-715 spectropolarimeter 
thermostatted by a PTC 348-WI Peltier unit. Spectra were recorded with 0.2 nm 
resolution and the spectrum of buffer alone was subtracted from the protein spectra. 
Circular dichroism data processing was carried out using Dr. Stephen Martin’s software 
(unpublished). Secondary structure prediction from circular dichroism data was carried 
out using SELCON, CONTIN and CDSSTR programs, which use different algorithms 
to compare the experimental circular dichroism spectrum to circular dichroism spectra 
of a number of reference proteins with known secondary structure content (Sreerama 
and Woody, 2000).  
7.6.7 Ellmans assay for detecting free thiols 
Mr. Phillip Knowles carried out the Ellmans assay on monomeric and dimeric zRET-
CLD4CRD373–626. The reagent mixture contained 100 mM Tris pH 8, 5.4 M Guanidium 
chloride, 0.5 mM Ellman’s reagent (from 1 M stock dissolved in DMSO). 900 µl of the 
reagent mixture was added to 100 µl of protein in ECD buffer or ECD buffer alone. A 
positive control of 900 µl reagent mixture with 100 µl 0.25 mM reduced glutathione 
was also carried out. The absorbance at 412 nm (Abs412) was taken for each sample, 
the Abs412 of the buffer only sample was deducted, and the concentration of free thiols 
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calculated using the extinction coefficient of the Ellman’s reagent derivative 2-nitro-5-
thiobenzoate, produced in the presence of free thiols, at high salt (13700 M-1cm-1).  
7.6.8 Zebrafish ternary complex assembly assay 
The zTC assembly assay was carried out using affinity purified zRET-ECD, purified in 
ECD buffer with no added calcium, and affinity purified zRET-CLD(1–4) in ECD 
buffer with 2 mM CaCl2.  
zGFRα1aΔC-proteinA expressed alone or with zGDNFΔN in Hi5 cells was purified from 
the media using 0.5 ml IgG-sepharose resin per l culture and washed with ECD buffer 
with no added calcium (as described in section 7.4.2.1). Samples of washed IgG-
sepharose resin bound zGFRα1aΔC-proteinA and zGDNFΔN/zGFRα1aΔC-proteinA were 
run on SDS-PAGE to confirm similar levels of zGFRα1aΔC-proteinA were present in 
both samples and that the zGDNFΔN and zGFRα1aΔC-proteinA levels were 
approximately stoichiometric. The IgG-sepharose resin bound zGFRα1aΔC-proteinA 
and zGDNFΔN/zGFRα1aΔC-proteinA were each divided into three aliquots containing 
0.15 ml resin. 2× excess zRET-ECD ± 2 mM CaCl2 or zRET-CLD(1–4) + 2 mM CaCl2 
were added to these aliquots and incubated at 4 °C for 1 hour with rotation. Unbound 
protein was then removed and the resin washed with 10 ml ECD buffer ± 2 mM CaCl2. 
Bound protein was then eluted from the resin in ECD buffer ± 2 mM CaCl2 by cleavage 
of the zGFRα1aΔC Protein A tag with GST tagged 3C-protease 100 µg per 1 ml resin. 
Eluted protein samples were run on SDS-PAGE to determine whether zRET-ECD or 
zRET-CLD(1–4) had bound.  
7.6.9 Testing glycosidases assay 
The protein glycosidase enzymes endoglycosidase F1 (Endo-F1; Calbiochem), 
endoglycosidase H (Endo-H; Sigma Aldrich) and peptide N-glycosidase F (PNGase F; 
produced by the Structural Biology Laboratory) were tested for their ability to 
deglycosylate zRET-ECD at 4 °C, 20 °C and 37 °C over 20 hours. The 50 µl assay 
mixture contained 24 µg zRET-ECD and >2 units of glycosidase in ECD buffer with 
calcium supplemented with the glycosidase buffer (1× final concentration; Table 7.7). A 
control reaction without glycosidase was also carried out at each temperature. 12 µl gel 
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samples were removed from each assay mixture after 1, 3 and 20 hours. Gel samples 
were run on non-reducing SDS-PAGE for analysis.  
10 × Buffer Components 
Endo-F1 500 mM Sodium phosphate buffer pH 5.5 
Endo-H 500 mM Sodium citrate buffer pH 5.5 
PNGase F  500 mM Sodium phosphate buffer pH 7.5 
Table 7.7 Glycosidase enzyme buffers  
7.6.10 RET tyrosine kinase activity assay 
pRET-KD wild type and mutant kinase activity was measured using a continuous ADP-
coupled assay, where ATP consumption is coupled to NADH oxidation (Knowles et al., 
2006). The reaction mix is detailed in Table 7.8. A poly(E4Y) peptide of random length 
(Sigma Aldrich) was used as a substrate and its concentration was varied from 0.25–8 
mg/ml, which allowed calculation of the kcat and the Km for the peptide since both 
wild type and mutant RET-KDs in these conditions reached saturation at < 8 mg/ml 
peptide substrate. Each substrate concentration was tested in triplicate for each of the 
RET-KD proteins. RET-KD and poly(E4Y) peptide were pre-incubated for 10 minutes. 
The reaction was then started by addition of ATP with the other assay components. 100 
µl reactions were carried out in triplicate in a 96 well format. Loss of NADH was 
followed by measurement of the Abs343 every minute for 40 minutes in a Tecan plate 
reader. Addition of ADP to the reaction mix was used as a positive control to ensure 
assay components were functional. Peptide was left out of the mix to measure 
background ATP consumption, which was very low. The initial rate of reaction for each 
peptide concentration was calculated from the linear portion of the Abs343 curve, and 
the background ATP consumption reaction rate was deducted. Kinetic constants were 
calculated by fitting the data to the Michaelis-Menten equation using Prism® software 
(GraphPad).  
The IC50 for sunitinib malate (Toronto Research Chemicals) was calculated for 
phosphorylated and non-phosphorylated RET-KD using this assay with 1 mg/ml 
poly(E4Y) peptide and varying the final sunitinib malate concentration in the assay mix 
from 0–100 µM. Each sunitinib concentration was tested in triplicate for both proteins. 
RET-KD was pre-incubated with sunitinib malate for 30 minutes prior to addition of 
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peptide and then other assay components. Otherwise reactions were carried out and data 
analysed as detailed above. 
Final concentration Component 
25 μg/ml (740 nM) RET-KD 
0.25–8 mg/ml poly(E4Y) peptide 
100 mM  Tris pH 7.5 
10 mM MgSO4 
2 mM Phosphoenolpyruvate 
1 mM Reduced nicotinamide adenine dinucleotide (NADH) 
1 mM ATP pH 8 
2 units Pyruvate kinase (Calbiochem) 
1.4 units Lactate dehydrogenase (Calbiochem) 
Table 7.8 Kinase activity assay reaction mix 
 
7.7 Homology models of RET and GFRα  subdomains 
To generate accurate homology models for individual zRET CLDs (for SAXS) and 
hGFRα1-D1 (for EM) the closest structural homologues from the PDB were identified 
and structure prediction based on these homologues was carried out using PHYRE2 
(Kelley and Sternberg, 2009). From the input amino acid sequence PHYRE2 runs the 
secondary structure prediction programs Psi-Pred (McGuffin et al., 2000), SSPro 
(Pollastri et al., 2002) and JPred (Cole et al., 2008), and generates a consensus 
secondary structure prediction, from which structural homologues of the input protein 
are identified and a tertiary structure prediction is made. The ‘normal’ mode of 
PHYRE2 was used for zRET-CLD3 and hGFRα-D1 structure prediction. In this mode 
PHYRE2 identifies structural homologues from the PDB of the input and produces a 
tertiary structure prediction model of the input for each identified PDB entry. This 
model is generated based primarily on secondary structure alignment, and regions of the 
input that do not align are left out of the model.  
For hGFRα1-D1, the GFRα3-D3 from PDB 2GH0 was the best identified homologue 
(92.7 % confidence) and was therefore chosen as the template for the hGFRα1-D1 
structure prediction model. zRET-CLD3 was more difficult to model. The best 
homologue was a cadherin domain from C-cadherin (PDB 1L3W) with 69.4% 
confidence. However, the structure prediction model using 1L3W as a template placed 
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some of the calcium-binding residues that contribute to the CLD2–CLD3 junction at the 
wrong end of the CLD3 model. After looking through the other PHYRE2 identified 
homologues, the model based on human protocadherin 9 (PDB 2EE0) had a better beta 
strand topology for the second half of CLD3. These two models were therefore 
combined using COOT (Emsley and Cowtan, 2004), basing the arrangement of 
calcium-binding residues on C-cadherin (PDB 1L3W; alignment of C-cadherin to RET 
CLDs is shown in Figure 1.7). 
The ‘intensive’ mode was used for the zRET-CLD(1–2) and zRET-CLD4 models. This 
mode builds a model for the entire input amino acid sequence. As in the ‘normal’ mode 
structural homologues from PDB are identified; but in the ‘intensive’ mode if a number 
of structures with high probability that the input and identified structure are homologues, 
these structures used jointly as templates for tertiary structure modelling of the input. 
For zRET-CLD(1–2) the hRET-CLD(1–2) (PBD 2X2U) was the sole template used for 
structure prediction. In this manner 96% of zRET-CLD(1–2) could be modelled with 
>90% confidence. zRET-CLD4 was modelled based on four templates: two different 
cadherin domains from 1NCI (N-cadherin) and individual domains from 2X2U (hRET-
CLD(1–2)) and 1OP4 (N-cadherin prodomain). The probability that these templates 
were homologues was between 87 and 89%. This generated a zRET-CLD4 model 
where ~90% was modelled with >80% confidence. Any regions of the input that could 
not be modelled by alignment were modelled ab initio using POING (Kelley and 
Sternberg, 2009).  
The ‘intensive’ mode did not generate satisfactory models of zRET-CLD3 and 
hGFRα1-D1 since a larger proportion of these structures were modelled ab initio in this 
mode.  
7.7.1 Glycosylating structure prediction models 
The GLYCAM web server (Woods Group, 2005-2012) was used to add N-linked 
glycans to the structure prediction models (Kirschner et al., 2008). Paucimannose 
moieties (A-D-Manp-(1-6)-[A-D-Manp-(1-3)]-B-D-Manp-(1-4)-B-D-GlcpNAc-(1-4)-
[A-L-Fucp-(1-6)]-B-D-GlcpNAc) were added to the predicted N-linked glycosylation 
sites, followed by energy minimisation with AMBER (Case et al., 2012). 
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7.8 Small angle X-ray scattering (SAXS) 
7.8.1 Sample preparation and data collection at the ESRF 
Size exclusion purified zRET-ECD and hRET-ECD were used in SAXS experiments at 
the European Synchrotron Radiation Facility (ESRF). SAXS data was collected on the 
bioSAXS beamline ID14-3 with a Pilatus 1M detector (Dectris Ltd.) and a sample-
detector distance of 2.5 m. Samples were passed through a 1.8 mm diameter quartz 
capillary (mounted in vacuum) for data collection. Data was collected for a range of 
concentrations between 2–7 mg/ml for each protein to assess whether interparticle 
effects such as aggregation were present. 10 frames of 2 second exposures were 
collected for each sample whilst the sample was continually moving through the 
capillary. The SAXS data measured on a 2D detector for each frame was converted to a 
1D SAXS profile of intensity of the scattered beam (I) as a function of the modulus of 
the scattering vector (s = (4π/λ)sin θ, where λ is the wavelength (Å) and 2θ the 
scattering angle). Comparison between the 1D SAXS profile of each frame allowed any 
radiation damage that occurred over the course of data collection to be detected. The 
frames showing the same SAXS profile were merged in order to improve the signal to 
noise ratio. Data was also collected for the buffers and this was subtracted from the 
protein sample data to remove the contribution from background scatter from the buffer 
and experimental setup.  
7.8.2 Sample preparation and data collection at SOLEIL 
SAXS data collection at Synchrotron SOLEIL at the SWING beamline was carried out 
using their online High Performance Liquid Chromatography (HPLC) setup (David and 
Pérez, 2009), which allows separation of any aggregates/oligomers present in the 
sample from the monomer peak directly before SAXS data collection. The beamline is 
equipped with a PCCD170170 detector (AVIEX) and a sample-detector distance of 1.8 
m was used. Data was collected from samples passing through a thermostated 1.5 mm 
diameter quartz capillary within the vacuum chamber. Each frame of data collected 
corresponded to a 1.5 or 2 second exposure, which was followed by 1 second dead time.  
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Size-exclusion purified zRET and zTC samples at 12–24 mg/ml were injected onto a 5 
ml SHODEX KW403-4F column size exclusion column connected to a HPLC system 
(Agilent) and eluted directly into the data collection capillary. Size exclusion was 
carried out in ECD buffer at a flow rate of 150 µl/min. Around 60 frames of SAXS data 
was collected for the size exclusion buffer, after the void volume of the column (5 ml) 
but before protein elution. SAXS data was collected for the protein sample across the 
entire size exclusion elution peak, often corresponding to 100 frames of SAXS data (as 
determined by the Abs280 trace).  
7.8.2.1 HPLC coupled SAXS initial data processing 
Raw image SAXS data collected at SOLEIL was processed using Foxtrot (SOLEIL in-
house software) to generate the 1D SAXS profiles for each data collection frame. The 
frames of data from the buffer were then merged and subtracted from each individual 
frame of data from the HPLC protein elution peak. The most intense SAXS profile 
(corresponding to the data collected at the centre of the HPLC peak) was then analysed 
in Foxtrot to determine the Rg using the Guiner approximation (I(s) = I(0)exp(-s2Rg2/3) 
where s is the modulus of the scattering vector, I(0) is the intensity extrapolated to s = 0, 
and Rg is the radius of gyration) (Guinier and Fournet, 1955). Using the same limits for 
the Guiner approximation the Rg was then calculated for every data collection SAXS 
profile across the HPLC peak. This analysis allowed any changes in the Rg across the 
peak to be detected. Several frames (7–10) corresponding to the centre of the HPLC 
peak, which were determined to have the same Rg, were then merged and the resulting 
SAXS profile was used for subsequent analysis.  
7.8.3 SAXS data processing  
The final averaged experimental SAXS profiles from ERSF and SOLEIL data 
collections were processed using the ATSAS suite (Konarev et al., 2006). Firstly 
PRIMUS was used to determine the Rg using the Guiner approximation (Guinier and 
Fournet, 1955) and generate Kratky plots (Kratky and Porod, 1949) to confirm the 
proteins were folded (Putnam et al., 2007). GNOM (Svergun, 1992) was then used to fit 
the data and generate the pair distance distribution function (P(r)). GNOM uses a 
number of criteria to assess the quality of the output fit and P(r). These are the chi-
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square value (or discrepancy between the experimental data (Iexp) and the fit (Icalc)), the 
smoothness of the solution, the stability of the solution, the presence of systematic 
deviations between the experimental data and the fit, the validity of the chosen real 
space interval and the positive part of the P(r) equalling 1 (Svergun, 1992). These five 
criteria are weighted and combined to give a score for the GNOM solution of between 0 
and 1. The maximum vector length (Dmax) in the sample was determined iteratively in 
GNOM, using 3× Rg as the initial estimate. The Dmax was chosen based on the score 
of the GNOM solution and whether the P(r) equalled zero at 0 Å and the Dmax. The 
final scores for the GNOM solutions are detailed in Table 7.9.  
Protein GNOM solution score Quality of solution 
ERSF SAXS data   
hRET-ECD 0.724 Reasonable 
zRET-ECD 0.601 Reasonable 
   
Soleil HPLC-coupled SAXS data   
zRET-CLD(1–4) 0.704 Reasonable 
Partially-deglycosylated zRET-CLD(1–4) 0.799 Good 
zRET-ECD  0.724 Reasonable 
Partially-deglycosylated zRET-ECD 0.840 Good 
Calcium-free zRET-ECD 0.663 Reasonable 
Calcium-free zRET-CLD(1–4) 0.666 Reasonable 
zTC 0.700 Reasonable 
Table 7.9 Quality of GNOM pair distance distribution function solutions 
The GNOM solution score is a composite score based on five criteria, as described in 
the text. The quality of the solution is defined by GNOM as reasonable where the score 
is > 0.5 and good when it is > 0.75.  
The SAXS MoW web server (Fischer et al., 2009) was used on the GNOM output file 
to estimate the molecular weight of the sample from the Kratky plot of the SAXS data. 
This analysis confirmed the oligomeric state of the protein in the X-ray beam. The 
molecular weight of the sample can also be calculated from the I(0) if the sample 
concentration is known. However the exact concentration of the sample in the beam 
when using the online HPLC is unknown. 
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7.8.4 Ab-initio shape determination from SAXS data 
DAMMIF (Franke and Svergun, 2009) was used to generate ab-initio models of the 
shape of the protein from the GNOM output file. DAMMIF was run multiple times (10–
50) and the resulting models were aligned and an averaged model generated using 
DAMAVER (Volkov and Svergun, 2003) in batch mode.  
7.8.5 Building domain arrangement models based on SAXS data 
Interpretation of the SAXS data was carried out primarily in CHIMERA (Goddard et al., 
2007). The structure prediction models of zRET-CLD(1–3) and zRET-CLD4 were 
docked into the average SAXS ab initio models using CHIMERA’s ‘fit-in-map’ tool. 
Since SAXS data does not determine the handedness of the protein the mirror image of 
each ab initio model was generated in IMAGIC (van Heel et al., 1996). The zRET-CLD 
models were also docked into the enantiomorph ab initio models and the final ab initio 
model chosen based on the fit of the zRET-CLD(1–3) model.  
Since structure prediction models for the entire glycosylated zRET-CLD(1–4)—except 
the linker between CLD3 and CLD4—could be generated, the arrangement of the 
domains as determined by fitting into the ab initio envelope could then be compared to 
the experimental SAXS profile. The theoretical SAXS curve of the fitted glycosylated 
zRET-CLD(1–4) was generated and compared to the experimental data using the FoXS 
server (Schneidman-Duhovny et al., 2010) implemented in CHIMERA. Different 
CLD(1–4) models were compared on the basis of the discrepancy between the 
theoretical SAXS curve of the model to the experimental data, as determined by the chi-
square value (χ2 = Σ((Iexp(s) − Imodel(s))/σexp(s)) calculated over s from 0–0.5 A-1).   
7.8.6 Rigid-body modelling against SAXS data  
Preliminary rigid body modelling of CLD(1-4) against the glycosylated zRET-CLD(1-
4) data was carried out by Dr. Andrew Purkiss-Trew using SASREF (Petoukhov and 
Svergun, 2005). This analysis was carried out using the hRET-CLD(1-2) structure and 
individual C-cadherin EC domains as CLD3 and CLD4 representatives. The best-fit 
arrangement of the input domains to the SAXS data, as measured by the chi-square 
value, was carried out by SASREF with the following imposed constraints on the 
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relationship between the three structural models. These constraints were designed to 
ensure the correct ends of the CLD models were contacting in the final model. Residues 
at the base of CLD(1-2) and the top of the CLD3 model were limited to being no more 
than 10 Å apart, and residues at the base of the CLD3 model and the top of CLD4 were 
limited to being no more than 7 Å apart. The final model from this simulated annealing 
procedure using these unglycosylated models had a chi-square value of 11.4 and 
showed a ~150° angle between CLD2 and CLD3 and a ~100° angle between CLD3 and 
CLD4, consistent with the arrangement of the CLDs from fitting in the deglycosylated 
zRET-ECD ab initio envelope.  
7.9 X-ray crystallography 
7.9.1 Co-crystallisation with inhibitor and peptide 
The pRET-KD was co-crystallised with inhibitors (sunitinib and AMPPNP) and a 
peptide (RET activation loop peptide (ALpep): SRDVYEEDSYVKRSQG; produced by 
the Cancer Research UK London Research Institute Peptide Synthesis Laboratory). This 
was carried out by incubating the affinity or size exclusion purified pRET-KD with 
inhibitor at a 1:3 protein:inhibitor molar ratio on ice for 1 hour prior to concentration of 
the protein for crystallisation screening. The ALpep was added to pRET-KD:AMPPNP 
following concentration to 3–4 mg/ml. The ALpep was added at an approximate 1:3 
pRET-KD:peptide molar ratio and allowed to bind for 1 hour on ice, prior to setting up 
the crystallisation screens.  
7.9.2 Initial crystallisation screening 
Initial crystallisation screening was carried out using 96 well format kits from Hampton 
Research, Molecular Dimensions, Qiagen, Emerald Biosciences and Jena Biosciences, 
using the vapour diffusion method. Screening was carried out in 2-drop 96 well MRC 
plates at either 4 °C or 20 °C. 100 µl of kit solutions were transferred to the MRC plate 
using a Hydra robot (Thermo Scientific). Sitting drops of typically 100 nl of the purified 
protein at 3–30 mg/ml plus 100 nl of the well solution were aliquoted using a Mosquito 
robot (TTP Labtech). Screens were then incubated in a temperature controlled incubator 
or a robotic crystal hotel and imager (Rock Imager, Formulatrix). The concentration of 
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the protein used in crystallisation screening was varied based on the relative levels of 
precipitated versus clear drops observed in the previously setup screens, with the 
protein concentration reduced if drops were predominantly precipitated and increased if 
they were predominantly clear.  
If no crystals were observed in a range of crystal screens and the protein concentration 
had been optimised, the protein buffer was then varied and optimised. Low (50 mM) 
and high (400 mM) NaCl were typically tried. A thermal stability shift assay was also 
conducted for zRET-ECD (Ericsson et al., 2006): Different buffers with varying pH (6–
8) and NaCl concentration (25–500 mM) and ± 5% glycerol were tested for their effect 
on the thermal stability of zRET-ECD. Sypro Orange dye (Thermofluor) was added to 5 
µg zRET-ECD in these buffers in transparent PCR tubes with a total reaction volume of 
100 µl. The temperature was raised from 20–90 °C in a real-time PCR machine (iQ5, 
Biorad) and the Sypro Orange fluorescence followed. Protein denaturation was 
associated with an increased Sypro Orange fluorescence and therefore the melting 
temperature (Tm) could be determined from the inflection point of the Sypro Orange 
fluorescence curve. The buffer in which zRET-ECD had the highest Tm was 20 mM 
Tris pH7, 200 mM NaCl, 1 mM CaCl2, 5% glycerol. The presence of glycerol was 
therefore also tried in crystallisation screening of zRET-ECD. 
7.9.3 Crystal optimisation 
If crystals were observed in the crystallisation screens and were confirmed to be protein 
either by UV absorption (Rock Imager) or X-ray diffraction, the crystallisation 
condition was reproduced and optimised manually using a larger sitting drop size (1–5 
µl) in a 24 well format tray. Typically this involved varying the pH, salt concentration, 
precipitant concentration and protein concentration around that of the initial condition 
from the screening kit. The aim was to produce three-dimensional single crystals that 
were as large as possible. In the case of pRET-KD:sunitinib an additive screen was also 
carried out using the additive screen kit from Hampton Research.  
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7.9.4 Cryo-protection and crystal mounting 
In preparation for X-ray data collection crystals were cryoprotected, mounted in 
litholoops (Molecular Dimensions) and flash-frozen in liquid nitrogen. The 
cryoprotectant solution typically contained the crystallisation condition with additional 
glycerol or PEG400. The cryoprotectant used was based on McFerrin and Snell, 2002 
and tested by applying to a larger litholoop than intended for the crystal, freezing in the 
cryo-stream and taking a test diffraction image with 5 minute exposure time on the in-
house X-ray system (Rigaku). If no ice rings were observed in the diffraction pattern, 
the cryoprotectant was used for crystal cryoprotection.  
7.9.5 Diffraction data collection  
X-ray diffraction data were collected at Diamond Light Source or ESRF. Details of the 
beamline used are given in the results section where the X-ray data is presented. X-ray 
diffraction data collection was carried out as follows. The loop was mounted on the 
goniometer and the crystal was centred in the X-ray beam. The data collection strategy 
was determined using MOSFLM (Powell, 1999) or EDNA (Diamond Light Source) 
based on test shots at commonly 0°, 45° and 90° rotation angles of the goniometer.  
7.9.6 Diffraction data processing 
Diffraction data were processed using MOSFLM (Battye et al., 2011; Powell, 1999), 
XDS (Kabsch, 2010) or D*TREK (Pflugrath, 1999). D*TREK was used for data 
collected on a Pilatus detector, since it worked better than MOSFLM with low intensity 
spots. These programs were used following the standard workflow as defined in their 
graphical user interfaces. The diffraction spots on the collected images were found, 
indexed and integrated based on refined unit cell parameters and crystal orientation, and 
the Laue and space group predicted. The integrated spot intensity data was then scaled 
and merged either in SCALA (Evans, 2006), with the Laue and space group determined 
using POINTLESS (Evans, 2006), or directly in XDS or D*TREK (SCALA and 
POINTLESS are part of the CCP4 suite (Collaborative Computational Project, 1994)). 
The output files generated by these scale and merge programs detailing data quality 
metrics against resolution and image number were analysed to determine the resolution 
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limit, and to identify any poor images to be discarded. The data were then commonly 
scaled and merged again at the determined resolution with the poor images removed.  
7.9.7 Molecular replacement 
The pRET-KD:sunitinib and pRET-KD:adenosine structures were solved by molecular 
replacement using the published pRET-KD:PP1 structure (PDB 2IVV). The number of 
molecules in the asymmetric unit was determined using the ‘Cell Content Analysis’ tool, 
which determines the Matthew’s Coefficient, in the CCP4 suite. For both pRET-
KD:sunitinib and pRET-KD:adenosine there was found to be one pRET-KD molecule 
in the asymmetric unit. Molecular replacement was carried out using the maximum-
likelihood program PHASER (McCoy et al., 2007) with just the protein chain 
coordinates from the pRET-KD:PP1 structure. This process yielded one good solution 
for both pRET-KD:sunitinib and pRET-KD:adenosine. 
7.9.7.1 Determination of the pRET-KDP766R/Q910R arrangement in the 
crystal 
The pRET-KDP766R/Q910R structure could not be solved by molecular replacement, as the 
resolution of the dataset was too low (~7 Å). Since an unpublished structure of the 
RET-KD at 3.3 Å resolution had been solved in the lab with the same space group and 
very similar unit cell dimensions, we reasoned that the arrangement of the RET-KD 
molecules in the pRET-KDP766R/Q910R crystal might be the same as in this structure. To 
test this we used the protein coordinates of the 3.3 Å structure with cell dimensions 
altered to match those of pRET-KDP766R/Q910R. These coordinates were subjected to 10 
rounds of restrained refinement against the scaled and merged pRET-KDP766R/Q910R 
dataset in REFMAC (Murshudov et al., 1997). This generated a very low-resolution but 
connected electron density map with the model having an Rfree of 43 %.  
7.9.8 Refinement and model building  
Alternate rounds of refinement and model building were carried out to the molecular 
replacement solution electron density map and protein coordinates. This process was 
conducted to improve the phases of the data and thereby improve the electron density 
map. The pRET-KD:sunitinib structure was refined in REFMAC (Murshudov et al., 
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1997) and the pRET-KD:adenosine structure was refined in PHENIX (Adams et al., 
2010) and BUSTER-TNT (Global Phasing Ltd.) (Blanc et al., 2004). In this case 
BUSTER-TNT was successful, and improved the connectivity of the electron density 
map for the unmodelled loop, allowing it to be built confidently. Model building for 
both structures was carried out in COOT (Emsley and Cowtan, 2004). TLS groups were 
used in refinement of the structures, allowing individual rigid body refinement of the 
RET-KD N and C-lobes. The refinement and model building cycle was continued until 
the Rfree ceased to improve and the electron density map was as well interpreted by the 
structural model as possible whilst maintaining a difference between the Rwork and Rfree 
of less than 7%. BUSTER-TNT was used in the latter stages of pRET-KD:adenosine 
refinement to improve the density for the split conformation of the gly-rich loop, since 
it was designed to show less bias towards the partial model in refining the phases, 
thereby improving the electron density for the unmodelled parts of the structure. 
Structure validation was carried out using the tools in COOT.  
7.10 Negative stain electron microscopy 
7.10.1 Preparation of the EM grids and data collection 
Size exclusion purified mTC and zTC were used for negative stain EM. Sample purity 
and complex stoichiometry was assessed by SDS-PAGE and, for the mTC, a 
TapeStation (Agilent), which allows quantification of the relative levels of the complex 
components. In the case of the zTC crosslinking was required for complex integrity. 
Crosslinking was carried out by addition of 0.05% glutaldehyde to the sample and 
incubation on ice for 3 minutes prior to placing the sample on the EM grid.  
The samples were applied to glow-discharged (PELCO EasiGlow) quantifoil (R1.2/1.3, 
Quantifoil Microtool GmBH) grids coated with a thin carbon layer and stained with 2% 
(w/v) uranyl acetate.  The grids were screened on a Tecnai T12 Spirit (FEI) operating at 
120kV, and the grids with satisfactory sample quality and staining were stored. The 
images for analysis were collected with a FEI Tecnai F20 electron microscope operating 
at 200kV on a Tietz 4000×4000 CCD detector at a nominal magnification of 80000× 
corresponding to 2.17 Å/pixel.  
Chapter 7. Materials and Methods 
 
 250 
7.10.2 Particle picking 
Particle images were picked manually from the collected EM grid images using Boxer, 
part of the EMAN suite (Ludtke et al., 1999). A box size of 192 × 192 pixels was used 
equating to 416.64 Å2, between 2–3× the size of the particles. Particles were only 
picked from images of well-stained areas of the grid, where particles were well defined 
and lighter than the background. Particles were selected on the basis of their size—very 
large or very small particles compared to the intact complex were ignored. In total 
~11000 particles were picked. Initial attempts at a 3D reconstruction from this stack of 
particle images were unsuccessful. Since it was observed that there was a wide range of 
staining levels in the particle image stack, particle picking was repeated with more 
stringent criteria for particle selection, with only the very well defined particles being 
selected. ~2000 particles were picked in this process. This approach did bias the particle 
image stack towards certain views, which were generally better defined. However, 
coverage of the range of possible views, as determined by the coverage of the Euler 
sphere during the subsequent 3D reconstruction process, was maintained.  
The particle images were coarsened to 4.34 Å/pixel to increase the speed of subsequent 
computational processing steps. These raw images were then band-pass filtered, 
normalised and the unwanted background removed by masking. The high-pass filtering 
(200 Å), to suppress disturbing low spatial frequencies that can interfere with particle 
alignment procedures (van Heel et al., 2000), was carried out in IMAGIC (van Heel et 
al., 1996). Normalisation and application of a circular mask with soft edges was also 
carried out in IMAGIC. Low-pass filtering (30 Å) in SPIDER (Frank et al., 1996) was 
then carried out to suppress the noisy high frequency data.  
7.10.3 Alignment and classification 
In order to improve the signal to noise ratio particle images are aligned, classified and 
class members combined and averaged. Initial characterisation of the data was carried 
out by ‘reference-free’ particle alignment and classification in EMAN (Ludtke et al., 
1999). During the 3D reconstruction process particle alignment was carried out in 
SPIDER (Frank et al., 1996) using forward projections of the latest 3D reconstruction 
as references. Early in the 3D reconstruction process, forward projections corresponding 
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to 12° steps were generated and those with clear features were used as references for 
alignment. Once the 3D reconstruction had improved, a larger number of forward 
projections from a finer sampling of the Euler sphere were used as references for 
alignment to improve the detail in the resulting class averages. Classification and 
generation of class averages from the SPIDER aligned particle image stack was carried 
out in IMAGIC (van Heel et al., 1996) using a multi-variate statistical analysis (MSA) 
method (van Heel, 1984).  
7.10.4 3D reconstruction  
7.10.4.1 Angular reconstitution 
3D reconstruction was carried out using the angular reconstitution method (van Heel, 
1987) as implemented in IMAGIC (van Heel et al., 1996). This is a ‘common-lines’ 
based method. The common lines projection theorem states that any two 2D projections 
of the same 3D object will share a common 1D line projection. Since the particle 
images (and class averages) are 2D projections of the 3D molecule, this theorem applies, 
and the relative Euler-angle orientations between class averages can therefore be 
determined by identifying the common lines (van Heel et al., 2000).  
MSA of the centred particle stack in IMAGIC involves the generation of eigenimages, 
from which any symmetry present in the particle can be identified (van Heel et al., 
2000). The mTC was determined to have two-fold symmetry in this manner, which was 
consistent with the apparent two-fold evident in some of the particle images. Therefore 
the 3D reconstruction process was carried out with C2 symmetry imposed. In the 
absence of symmetry, at least three 2D projections are required to solve the orientation 
problem using the common lines method. In the presence of two-fold symmetry only 
two approximately orthogonal 2D projections (class averages) are required to solve the 
orientation problem. The 3D reconstruction of the mTC was therefore initiated using 
two representative class averages: One possessing two-fold symmetry, and therefore 
perpendicular to the two-fold axis, and the other apparently orthogonal to the first. 
Upon assignment of the relative Euler angles of these two class averages, these classes 
were then used as references to assign the Euler angles of the full range of class 
averages.  
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Whether the Euler angle assignment of each class average was correct was determined 
by generating a 3D reconstruction from the Euler angle assigned class averages, and 
then generating re-projections of this 3D corresponding to each class average in 
IMAGIC. Euler angle assignment was determined to be correct if the class average and 
the corresponding 3D re-projection matched. The correctly assigned class averages were 
then used as references for reassigning the Euler angles of the full range of class 
averages. This approach was carried out iteratively until no additional class averages 
could be correctly assigned.  
At this stage, a 3D reconstruction was generated from the correctly Euler angle assigned 
class averages, and forward projections of this 3D reconstruction were used to realign 
and classify the particle image stack (section 7.10.3). The new class averages were then 
assigned Euler angles using the correctly assigned class averages from the previous 
round as references, and the iterative process of expanding the number of correctly 
assigned class averages repeated.  
This cycle of iterative Euler angle assignment followed by realignment and 
classification of the particle image stack to the resulting 3D reconstruction was repeated. 
The aim was to improve the 3D reconstruction in each round by increasing the coverage 
of the Euler sphere with correctly assigned class averages and improving the detail in 
the class averages, by alignment of the particles to a better set of references.  
Once no further improvement in either Euler sphere coverage or class average detail 
could be observed using this angular reconstitution method with the small (~2000 
particle images) stringently selected particle image stack, the 3D reconstruction was 
refined by the projection matching procedure using the ~11000 particle image stack. 
7.10.4.2 Projection matching 
Projection matching was carried out in IMAGIC (van Heel et al., 1996). In this method, 
matching the class averages to forward projections of the current 3D reconstruction is 
used for Euler angle assignment of the class averages. Otherwise the iterative procedure 
of 3D reconstruction from the correctly assigned classes, followed by generation of new 
class averages by alignment of the particle image stack to the 3D reconstruction and 
subsequent classification, is the same as the angular reconstitution method described 
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above. The goal of improving the Euler sphere coverage and detail in the class averages 
to produce a better 3D reconstruction is also the same.  
7.10.5 Interpretation of the 3D reconstruction 
The graphical program CHIMERA (Goddard et al., 2007) was used for visualisation 
and interpretation of the final 3D reconstruction (EM map). The crystal structures and 
structure prediction models of the components of the complex were docked into the EM 
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